@ARTICLE{Grossman2016-sk,
  title    = "Toward a Shared Vision for Cancer Genomic Data",
  author   = "Grossman, Robert L and Heath, Allison P and Ferretti, Vincent and
              Varmus, Harold E and Lowy, Douglas R and Kibbe, Warren A and
              Staudt, Louis M",
  abstract = "The Genomic Data Commons will initially house raw genomic data
              and diagnostic, histologic, and clinical outcome data from
              National Cancer Institute--funded projects. A harmonization
              process will align sequencing data to the genome and identify
              mutations and alterations.",
  journal  = "N. Engl. J. Med.",
  volume   =  375,
  number   =  12,
  pages    = "1109--1112",
  month    =  "22~" # sep,
  year     =  2016
}

@ARTICLE{Tan2015-dv,
  title       = "Unified representation of genetic variants",
  author      = "Tan, Adrian and Abecasis, Gon{\c c}alo R and Kang, Hyun Min",
  affiliation = "Department of Biostatistics and Center for Statistical
                 Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
                 Department of Biostatistics and Center for Statistical
                 Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
                 Department of Biostatistics and Center for Statistical
                 Genetics, University of Michigan, Ann Arbor, MI 48109, USA.",
  abstract    = "UNLABELLED: A genetic variant can be represented in the
                 Variant Call Format (VCF) in multiple different ways.
                 Inconsistent representation of variants between variant
                 callers and analyses will magnify discrepancies between them
                 and complicate variant filtering and duplicate removal. We
                 present a software tool vt normalize that normalizes
                 representation of genetic variants in the VCF. We formally
                 define variant normalization as the consistent representation
                 of genetic variants in an unambiguous and concise way and
                 derive a simple general algorithm to enforce it. We
                 demonstrate the inconsistent representation of variants across
                 existing sequence analysis tools and show that our tool
                 facilitates integration of diverse variant types and call
                 sets. AVAILABILITY AND IMPLEMENTATION: The source code is
                 available for download at http://github.com/atks/vt. More
                 detailed documentation is available at
                 http://genome.sph.umich.edu/wiki/Variant\_Normalization.
                 CONTACT: hmkang@umich.edu SUPPLEMENTARY INFORMATION:
                 Supplementary data are available at Bioinformatics online.",
  journal     = "Bioinformatics",
  volume      =  31,
  number      =  13,
  pages       = "2202--2204",
  month       =  "1~" # jul,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Zhang2011-bl,
  title     = "International Cancer Genome Consortium Data Portal---a one-stop
               shop for cancer genomics data",
  author    = "Zhang, Junjun and Baran, Joachim and Cros, A and Guberman,
               Jonathan M and Haider, Syed and Hsu, Jack and Liang, Yong and
               Rivkin, Elena and Wang, Jianxin and Whitty, Brett and
               Wong-Erasmus, Marie and Yao, Long and Kasprzyk, Arek",
  abstract  = "The International Cancer Genome Consortium (ICGC) is a
               collaborative effort to characterize genomic abnormalities in 50
               different cancer types. To make this data available, the ICGC
               has created the ICGC Data Portal. Powered by the BioMart
               software, the Data Portal allows each ICGC member institution to
               manage and maintain its own databases locally, while seamlessly
               presenting all the data in a single access point for users. The
               Data Portal currently contains data from 24 cancer projects,
               including ICGC, The Cancer Genome Atlas (TCGA), Johns Hopkins
               University, and the Tumor Sequencing Project. It consists of
               3478 genomes and 13 cancer types and subtypes. Available open
               access data types include simple somatic mutations, copy number
               alterations, structural rearrangements, gene expression,
               microRNAs, DNA methylation and exon junctions. Additionally,
               simple germline variations are available as controlled access
               data. The Data Portal uses a web-based graphical user interface
               (GUI) to offer researchers multiple ways to quickly and easily
               search and analyze the available data. The web interface can
               assist in constructing complicated queries across multiple data
               sets. Several application programming interfaces are also
               available for programmatic access. Here we describe the
               organization, functionality, and capabilities of the ICGC Data
               Portal.Database URL:http://dcc.icgc.org",
  journal   = "Database",
  publisher = "Oxford University Press",
  volume    =  2011,
  month     =  "1~" # jan,
  year      =  2011
}

@ARTICLE{Hecht2015-ti,
  title    = "Better prediction of functional effects for sequence variants",
  author   = "Hecht, Maximilian and Bromberg, Yana and Rost, Burkhard",
  abstract = "Elucidating the effects of naturally occurring genetic variation
              is one of the major challenges for personalized health and
              personalized medicine. Here, we introduce SNAP2, a novel neural
              network based classifier that improves over the state-of-the-art
              in distinguishing between effect and neutral variants. Our
              method's improved performance results from screening many
              potentially relevant protein features and from refining our
              development data sets. Cross-validated on >100k experimentally
              annotated variants, SNAP2 significantly outperformed other
              methods, attaining a two-state accuracy (effect/neutral) of 83\%.
              SNAP2 also outperformed combinations of other methods.
              Performance increased for human variants but much more so for
              other organisms. Our method's carefully calibrated reliability
              index informs selection of variants for experimental follow up,
              with the most strongly predicted half of all effect variants
              predicted at over 96\% accuracy. As expected, the evolutionary
              information from automatically generated multiple sequence
              alignments gave the strongest signal for the prediction. However,
              we also optimized our new method to perform surprisingly well
              even without alignments. This feature reduces prediction runtime
              by over two orders of magnitude, enables cross-genome
              comparisons, and renders our new method as the best solution for
              the 10-20\% of sequence orphans. SNAP2 is available at:
              https://rostlab.org/services/snap2web.",
  journal  = "BMC Genomics",
  volume   = "16 Suppl 8",
  pages    = "S1",
  month    =  "18~" # jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{De_Coronado2004-px,
  title   = "{NCI} Thesaurus: using science-based terminology to integrate
             cancer research results",
  author  = "De Coronado, Sherri and Haber, Margaret W and Sioutos, Nicholas
             and Tuttle, Mark S and Wright, Lawrence W and {Others}",
  journal = "Medinfo",
  volume  =  11,
  number  = "Pt 1",
  pages   = "33--37",
  year    =  2004
}

@ARTICLE{Gao2013-li,
  title       = "Integrative analysis of complex cancer genomics and clinical
                 profiles using the {cBioPortal}",
  author      = "Gao, Jianjiong and Aksoy, B{\"u}lent Arman and Dogrusoz, Ugur
                 and Dresdner, Gideon and Gross, Benjamin and Sumer, S Onur and
                 Sun, Yichao and Jacobsen, Anders and Sinha, Rileen and
                 Larsson, Erik and Cerami, Ethan and Sander, Chris and Schultz,
                 Nikolaus",
  affiliation = "Computational Biology Center, Memorial Sloan-Kettering Cancer
                 Center, New York, NY 10065, USA.",
  abstract    = "The cBioPortal for Cancer Genomics (http://cbioportal.org)
                 provides a Web resource for exploring, visualizing, and
                 analyzing multidimensional cancer genomics data. The portal
                 reduces molecular profiling data from cancer tissues and cell
                 lines into readily understandable genetic, epigenetic, gene
                 expression, and proteomic events. The query interface combined
                 with customized data storage enables researchers to
                 interactively explore genetic alterations across samples,
                 genes, and pathways and, when available in the underlying
                 data, to link these to clinical outcomes. The portal provides
                 graphical summaries of gene-level data from multiple
                 platforms, network visualization and analysis, survival
                 analysis, patient-centric queries, and software programmatic
                 access. The intuitive Web interface of the portal makes
                 complex cancer genomics profiles accessible to researchers and
                 clinicians without requiring bioinformatics expertise, thus
                 facilitating biological discoveries. Here, we provide a
                 practical guide to the analysis and visualization features of
                 the cBioPortal for Cancer Genomics.",
  journal     = "Sci. Signal.",
  volume      =  6,
  number      =  269,
  pages       = "l1",
  month       =  "2~" # apr,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Shaw2013-wl,
  title       = "Crizotinib versus chemotherapy in advanced {ALK-positive} lung
                 cancer",
  author      = "Shaw, Alice T and Kim, Dong-Wan and Nakagawa, Kazuhiko and
                 Seto, Takashi and Crin{\'o}, Lucio and Ahn, Myung-Ju and De
                 Pas, Tommaso and Besse, Benjamin and Solomon, Benjamin J and
                 Blackhall, Fiona and Wu, Yi-Long and Thomas, Michael and
                 O'Byrne, Kenneth J and Moro-Sibilot, Denis and Camidge, D Ross
                 and Mok, Tony and Hirsh, Vera and Riely, Gregory J and Iyer,
                 Shrividya and Tassell, Vanessa and Polli, Anna and Wilner,
                 Keith D and J{\"a}nne, Pasi A",
  affiliation = "Massachusetts General Hospital, Boston, MA 02114, USA.
                 ashaw1@partners.org",
  abstract    = "BACKGROUND: In single-group studies, chromosomal
                 rearrangements of the anaplastic lymphoma kinase gene (ALK)
                 have been associated with marked clinical responses to
                 crizotinib, an oral tyrosine kinase inhibitor targeting ALK.
                 Whether crizotinib is superior to standard chemotherapy with
                 respect to efficacy is unknown. METHODS: We conducted a phase
                 3, open-label trial comparing crizotinib with chemotherapy in
                 347 patients with locally advanced or metastatic ALK-positive
                 lung cancer who had received one prior platinum-based regimen.
                 Patients were randomly assigned to receive oral treatment with
                 crizotinib (250 mg) twice daily or intravenous chemotherapy
                 with either pemetrexed (500 mg per square meter of
                 body-surface area) or docetaxel (75 mg per square meter) every
                 3 weeks. Patients in the chemotherapy group who had disease
                 progression were permitted to cross over to crizotinib as part
                 of a separate study. The primary end point was
                 progression-free survival. RESULTS: The median
                 progression-free survival was 7.7 months in the crizotinib
                 group and 3.0 months in the chemotherapy group (hazard ratio
                 for progression or death with crizotinib, 0.49; 95\%
                 confidence interval [CI], 0.37 to 0.64; P<0.001). The response
                 rates were 65\% (95\% CI, 58 to 72) with crizotinib, as
                 compared with 20\% (95\% CI, 14 to 26) with chemotherapy
                 (P<0.001). An interim analysis of overall survival showed no
                 significant improvement with crizotinib as compared with
                 chemotherapy (hazard ratio for death in the crizotinib group,
                 1.02; 95\% CI, 0.68 to 1.54; P=0.54). Common adverse events
                 associated with crizotinib were visual disorder,
                 gastrointestinal side effects, and elevated liver
                 aminotransferase levels, whereas common adverse events with
                 chemotherapy were fatigue, alopecia, and dyspnea. Patients
                 reported greater reductions in symptoms of lung cancer and
                 greater improvement in global quality of life with crizotinib
                 than with chemotherapy. CONCLUSIONS: Crizotinib is superior to
                 standard chemotherapy in patients with previously treated,
                 advanced non-small-cell lung cancer with ALK rearrangement.
                 (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).",
  journal     = "N. Engl. J. Med.",
  volume      =  368,
  number      =  25,
  pages       = "2385--2394",
  month       =  "20~" # jun,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Danecek2011-du,
  title       = "The variant call format and {VCFtools}",
  author      = "Danecek, Petr and Auton, Adam and Abecasis, Goncalo and
                 Albers, Cornelis A and Banks, Eric and DePristo, Mark A and
                 Handsaker, Robert E and Lunter, Gerton and Marth, Gabor T and
                 Sherry, Stephen T and McVean, Gilean and Durbin, Richard and
                 {1000 Genomes Project Analysis Group}",
  affiliation = "Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
                 Cambridge CB10 1SA, UK.",
  abstract    = "SUMMARY: The variant call format (VCF) is a generic format for
                 storing DNA polymorphism data such as SNPs, insertions,
                 deletions and structural variants, together with rich
                 annotations. VCF is usually stored in a compressed manner and
                 can be indexed for fast data retrieval of variants from a
                 range of positions on the reference genome. The format was
                 developed for the 1000 Genomes Project, and has also been
                 adopted by other projects such as UK10K, dbSNP and the NHLBI
                 Exome Project. VCFtools is a software suite that implements
                 various utilities for processing VCF files, including
                 validation, merging, comparing and also provides a general
                 Perl API. AVAILABILITY: http://vcftools.sourceforge.net",
  journal     = "Bioinformatics",
  volume      =  27,
  number      =  15,
  pages       = "2156--2158",
  month       =  "1~" # aug,
  year        =  2011,
  language    = "en"
}

@ARTICLE{Faltas2016-yz,
  title    = "Generating a neoantigen map of advanced urothelial carcinoma by
              whole exome sequencing",
  author   = "Faltas, Bishoy and Bhinder, Bhavneet and Beltran, Himisha and
              Tagawa, Scott T and Molina, Ana M and Nanus, David M and
              Elemento, Olivier and Rubin, Mark A",
  abstract = "354 Background: immune-checkpoint blockade is a promising
              treatment of advanced urothelial carcinoma (UC) that unleashes
              pre-existing immune responses against recognized tumor antigens.
              Somatic mutations lead to the formation of neoantigens, which are
              highly antigenic mutant proteins. Methods: Our objective was to
              generate a neoantigen map through analysis of whole exome
              sequencing data of our cohort of patients (pts) with
              platinum-resistant UC. Whole exome sequencing (WES) data from 73
              prospectively collected UC samples from 34 patients were analyzed
              using our neoantigen prediction pipeline. We defined neoantigens
              as mutant nonamers with high affinity binding to predicted class
              I MHC molecules for each patient. HLA haplotypes were inferred
              from WES of matched germline DNA. Results: A significant
              correlation between global somatic mutation rates, and
              neo-epitope burden was observed (R2 = 0.93), a similar
              correlation was observed between single nucleotide variants (SNV)
              and neo-epitope burdens (R2 = 0.94). We identified a strong
              positive correlation between the numbers of pack-years of smoking
              and neoepitope burden in patients with advanced UC (p = 0.0004).
              No correlation between global somatic mutational and predicted
              neoepitope burdens with overall survival was identified.
              Metastatic samples had a trend of harboring more SNVs (median 49
              vs. 22, P = 0.13), and neoepitopes (median 17 vs 12, P = 0.22)
              compared to primary samples. Interestingly, only 32\% of total
              SNVs and 8 \% of neoepitopes (with binding affinities of [$\leq$]
              50nM) that were initially identified, reappeared in metastatic
              samples from the same patients obtained at a later time point. A
              significant selection against strong binding neo-epitopes was
              observed in subsequent samples from metastatic tumors (p-value <
              0.005). Conclusions: A strong correlation between mutational
              burden and predicted neoantigenic load was observed in UC.
              Neoantigenic signatures were shaped by environmental exposures
              such as smoking. The significant heterogeneity in primary and
              metastatic neoantigens was possibly due to immunoediting as the
              tumor evolved. These findings may have important implications for
              selecting patients for immunotherapeutic approaches.",
  journal  = "J. Clin. Oncol.",
  volume   =  34,
  number   = "2\_suppl",
  pages    = "354",
  month    =  "10~" # jan,
  year     =  2016
}

@ARTICLE{Garraway2013-zo,
  title   = "{Genomics-Driven} Oncology: Framework for an Emerging Paradigm",
  author  = "Garraway, Levi A",
  journal = "J. Clin. Orthod.",
  volume  =  31,
  number  =  15,
  pages   = "1806--1814",
  month   =  "20~" # may,
  year    =  2013
}

@ARTICLE{Lopez-Chavez2015-cg,
  title       = "Molecular profiling and targeted therapy for advanced thoracic
                 malignancies: a biomarker-derived, multiarm, multihistology
                 phase {II} basket trial",
  author      = "Lopez-Chavez, Ariel and Thomas, Anish and Rajan, Arun and
                 Raffeld, Mark and Morrow, Betsy and Kelly, Ronan and Carter,
                 Corey Allan and Guha, Udayan and Killian, Keith and Lau,
                 Christopher C and Abdullaev, Zied and Xi, Liqiang and Pack,
                 Svetlana and Meltzer, Paul S and Corless, Christopher L and
                 Sandler, Alan and Beadling, Carol and Warrick, Andrea and
                 Liewehr, David J and Steinberg, Seth M and Berman, Arlene and
                 Doyle, Austin and Szabo, Eva and Wang, Yisong and Giaccone,
                 Giuseppe",
  affiliation = "Ariel Lopez-Chavez, Anish Thomas, Arun Rajan, Mark Raffeld,
                 Betsy Morrow, Ronan Kelly, Corey Allan Carter, Udayan Guha,
                 Keith Killian, Christopher C. Lau, Zied Abdullaev, Liqiang Xi,
                 Svetlana Pack, Paul S. Meltzer, David J. Liewehr, Seth M.
                 Steinberg, Arlene Berman, Eva Szabo, Yisong Wang, and Giuseppe
                 Giaccone, National Cancer Institute; Austin Doyle, Cancer
                 Therapy Evaluation Program, Bethesda, MD; Ariel Lopez-Chavez,
                 Christopher L. Corless, Alan Sandler, Carol Beadling, and
                 Andrea Warrick, Knight Cancer Institute, Oregon Health and
                 Science University, Portland, OR; Ariel Lopez-Chavez,
                 Sylvester Comprehensive Cancer Center, University of Miami,
                 Miami, FL; and Yisong Wang and Giuseppe Giaccone, Lombardi
                 Comprehensive Cancer Center, Georgetown University,
                 Washington, DC. Ariel Lopez-Chavez, Anish Thomas, Arun Rajan,
                 Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey Allan Carter,
                 Udayan Guha, Keith Killian, Christopher C. Lau, Zied
                 Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer, David
                 J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. Ariel Lopez-Chavez, Anish Thomas,
                 Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey
                 Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau,
                 Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer,
                 David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo,
                 Yisong Wang, and Giuseppe Giaccone, National Cancer Institute;
                 Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD;
                 Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler,
                 Carol Beadling, and Andrea Warrick, Knight Cancer Institute,
                 Oregon Health and Science University, Portland, OR; Ariel
                 Lopez-Chavez, Sylvester Comprehensive Cancer Center,
                 University of Miami, Miami, FL; and Yisong Wang and Giuseppe
                 Giaccone, Lombardi Comprehensive Cancer Center, Georgetown
                 University, Washington, DC. gg496@georgetown.edu.",
  abstract    = "PURPOSE: We conducted a basket clinical trial to assess the
                 feasibility of such a design strategy and to independently
                 evaluate the effects of multiple targeted agents against
                 specific molecular aberrations in multiple histologic subtypes
                 concurrently. PATIENTS AND METHODS: We enrolled patients with
                 advanced non-small-cell lung cancer (NSCLC), small-cell lung
                 cancer, and thymic malignancies who underwent genomic
                 characterization of oncogenic drivers. Patients were enrolled
                 onto a not-otherwise-specified arm and treated with
                 standard-of-care therapies or one of the following five
                 biomarker-matched treatment groups: erlotinib for EGFR
                 mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF
                 mutations; MK2206 for PIK3CA, AKT, or PTEN mutations;
                 lapatinib for ERBB2 mutations or amplifications; and sunitinib
                 for KIT or PDGFRA mutations or amplification. RESULTS: Six
                 hundred forty-seven patients were enrolled, and 88\% had their
                 tumors tested for at least one gene. EGFR mutation frequency
                 was 22.1\% in NSCLC, and erlotinib achieved a response rate of
                 60\% (95\% CI, 32.3\% to 83.7\%). KRAS mutation frequency was
                 24.9\% in NSCLC, and selumetinib failed to achieve its primary
                 end point, with a response rate of 11\% (95\% CI, 0\% to
                 48\%). Completion of accrual to all other arms was not
                 feasible. In NSCLC, patients with EGFR mutations had the
                 longest median survival (3.51 years; 95\% CI, 2.89 to 5.5
                 years), followed by those with ALK rearrangements (2.94 years;
                 95\% CI, 1.66 to 4.61 years), those with KRAS mutations (2.3
                 years; 95\% CI, 2.3 to 2.17 years), those with other genetic
                 abnormalities (2.17 years; 95\% CI, 1.3 to 2.74 years), and
                 those without an actionable mutation (1.85 years; 95\% CI,
                 1.61 to 2.13 years). CONCLUSION: This basket trial design was
                 not feasible for many of the arms with rare mutations, but it
                 allowed the study of the genetics of less common malignancies.",
  journal     = "J. Clin. Oncol.",
  volume      =  33,
  number      =  9,
  pages       = "1000--1007",
  month       =  "20~" # mar,
  year        =  2015,
  language    = "en"
}

@MISC{noauthor_undated-vq,
  title        = "International Cancer Genome Consortium",
  abstract     = "International Cancer Genome Consortium...",
  howpublished = "\url{http://icgc.org}",
  note         = "Accessed: 2017-5-15"
}

@UNPUBLISHED{Tamborero2017-ay,
  title    = "Cancer Genome Interpreter Annotates The Biological And Clinical
              Relevance Of Tumor Alterations",
  author   = "Tamborero, David and Rubio-Perez, Carlota and Deu-Pons, Jordi and
              Schroeder, Michael P and Vivancos, Ana and Rovira, Ana and
              Tusquets, Ignasi and Albanell, Joan and Rodon, Jordi and
              Tabernero, Josep and de Torres, Carmen and Dienstmann, Rodrigo
              and Gonzalez-Perez, Abel and Lopez-Bigas, Nuria",
  abstract = "While tumor genome sequencing has become widely available in
              clinical and research settings, the interpretation of tumor
              somatic variants remains an important bottleneck. Most of the
              alterations observed in tumors, including those in well-known
              cancer genes, are of uncertain significance. Moreover, the
              information on tumor genomic alterations shaping the response to
              existing therapies is fragmented across the literature and
              several specialized resources. Here we present the Cancer Genome
              Interpreter (http://www.cancergenomeinterpreter.org), an open
              access tool that we have implemented to annotate genomic
              alterations and interpret their possible role in tumorigenesis
              and in the response to anti-cancer therapies.",
  journal  = "bioRxiv",
  pages    = "140475",
  month    =  "20~" # may,
  year     =  2017,
  language = "en"
}

@MISC{noauthor_undated-vx,
  title        = "International Cancer Genome Consortium",
  abstract     = "International Cancer Genome Consortium...",
  howpublished = "\url{http://icgc.org}",
  note         = "Accessed: 2017-5-15"
}

@ARTICLE{Maemondo2010-dj,
  title     = "Gefitinib or Chemotherapy for {Non--Small-Cell} Lung Cancer with
               Mutated {EGFR}",
  author    = "Maemondo, Makoto and Inoue, Akira and Kobayashi, Kunihiko and
               Sugawara, Shunichi and Oizumi, Satoshi and Isobe, Hiroshi and
               Gemma, Akihiko and Harada, Masao and Yoshizawa, Hirohisa and
               Kinoshita, Ichiro and Fujita, Yuka and Okinaga, Shoji and
               Hirano, Haruto and Yoshimori, Kozo and Harada, Toshiyuki and
               Ogura, Takashi and Ando, Masahiro and Miyazawa, Hitoshi and
               Tanaka, Tomoaki and Saijo, Yasuo and Hagiwara, Koichi and
               Morita, Satoshi and Nukiwa, Toshihiro",
  abstract  = "Previously untreated patients with non?small-cell lung cancer
               expressing mutated epidermal growth factor receptors (EGFRs)
               were randomly assigned to receive either the EGFR kinase
               inhibitor gefitinib or carboplatin plus paclitaxel. The
               gefitinib group had a significantly higher rate of complete
               response (73.7\%, vs. 30.7\% in the standard-chemotherapy group)
               and significantly longer survival (median, 30.5 months, vs. 23.6
               months). Thus, defining the small subgroup of patients with EGFR
               mutations prospectively has important treatment implications.",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  362,
  number    =  25,
  pages     = "2380--2388",
  month     =  "24~" # jun,
  year      =  2010
}

@ARTICLE{Lopes2012-je,
  title       = "A combined functional annotation score for non-synonymous
                 variants",
  author      = "Lopes, Margarida C and Joyce, Chris and Ritchie, Graham R S
                 and John, Sally L and Cunningham, Fiona and Asimit, Jennifer
                 and Zeggini, Eleftheria",
  affiliation = "Wellcome Trust Sanger Institute, Hinxton, Hinxton, UK.
                 ml10@sanger.ac.uk",
  abstract    = "AIMS: Next-generation sequencing has opened the possibility of
                 large-scale sequence-based disease association studies. A
                 major challenge in interpreting whole-exome data is predicting
                 which of the discovered variants are deleterious or neutral.
                 To address this question in silico, we have developed a score
                 called Combined Annotation scoRing toOL (CAROL), which
                 combines information from 2 bioinformatics tools: PolyPhen-2
                 and SIFT, in order to improve the prediction of the effect of
                 non-synonymous coding variants. METHODS: We used a weighted Z
                 method that combines the probabilistic scores of PolyPhen-2
                 and SIFT. We defined 2 dataset pairs to train and test CAROL
                 using information from the dbSNP: 'HGMD-PUBLIC' and 1000
                 Genomes Project databases. The training pair comprises a total
                 of 980 positive control (disease-causing) and 4,845 negative
                 control (non-disease-causing) variants. The test pair consists
                 of 1,959 positive and 9,691 negative controls. RESULTS: CAROL
                 has higher predictive power and accuracy for the effect of
                 non-synonymous variants than each individual annotation tool
                 (PolyPhen-2 and SIFT) and benefits from higher coverage.
                 CONCLUSION: The combination of annotation tools can help
                 improve automated prediction of whole-genome/exome
                 non-synonymous variant functional consequences.",
  journal     = "Hum. Hered.",
  volume      =  73,
  number      =  1,
  pages       = "47--51",
  month       =  "18~" # jan,
  year        =  2012,
  language    = "en"
}

@ARTICLE{Gonzalez-Perez2011-gc,
  title       = "Improving the assessment of the outcome of nonsynonymous
                 {SNVs} with a consensus deleteriousness score, Condel",
  author      = "Gonz{\'a}lez-P{\'e}rez, Abel and L{\'o}pez-Bigas, Nuria",
  affiliation = "Research Programme on Biomedical Informatics, Universitat
                 Pompeu Fabra, Parc de Recerca Biom{\`e}dica de Barcelona,
                 Barcelona. abel.gonzalez@upf.edu",
  abstract    = "Several large ongoing initiatives that profit from
                 next-generation sequencing technologies have driven--and in
                 coming years will continue to drive--the emergence of long
                 catalogs of missense single-nucleotide variants (SNVs) in the
                 human genome. As a consequence, researchers have developed
                 various methods and their related computational tools to
                 classify these missense SNVs as probably deleterious or
                 probably neutral polymorphisms. The outputs produced by each
                 of these computational tools are of different natures and thus
                 difficult to compare and integrate. Taking advantage of the
                 possible complementarity between different tools might allow
                 more accurate classifications. Here we propose an effective
                 approach to integrating the output of some of these tools into
                 a unified classification; this approach is based on a weighted
                 average of the normalized scores of the individual methods
                 (WAS). (In this paper, the approach is illustrated for the
                 integration of five tools.) We show that this WAS outperforms
                 each individual method in the task of classifying missense
                 SNVs as deleterious or neutral. Furthermore, we demonstrate
                 that this WAS can be used not only for classification purposes
                 (deleterious versus neutral mutation) but also as an indicator
                 of the impact of the mutation on the functionality of the
                 mutant protein. In other words, it may be used as a
                 deleteriousness score of missense SNVs. Therefore, we
                 recommend the use of this WAS as a consensus deleteriousness
                 score of missense mutations (Condel).",
  journal     = "Am. J. Hum. Genet.",
  volume      =  88,
  number      =  4,
  pages       = "440--449",
  month       =  "8~" # apr,
  year        =  2011,
  language    = "en"
}

@ARTICLE{Cancer_Genome_Atlas_Network2012-nz,
  title    = "Comprehensive molecular portraits of human breast tumours",
  author   = "{Cancer Genome Atlas Network}",
  abstract = "We analysed primary breast cancers by genomic DNA copy number
              arrays, DNA methylation, exome sequencing, messenger RNA arrays,
              microRNA sequencing and reverse-phase protein arrays. Our ability
              to integrate information across platforms provided key insights
              into previously defined gene expression subtypes and demonstrated
              the existence of four main breast cancer classes when combining
              data from five platforms, each of which shows significant
              molecular heterogeneity. Somatic mutations in only three genes
              (TP53, PIK3CA and GATA3) occurred at >10\% incidence across all
              breast cancers; however, there were numerous subtype-associated
              and novel gene mutations including the enrichment of specific
              mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype.
              We identified two novel protein-expression-defined subgroups,
              possibly produced by stromal/microenvironmental elements, and
              integrated analyses identified specific signalling pathways
              dominant in each molecular subtype including a
              HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature
              within the HER2-enriched expression subtype. Comparison of
              basal-like breast tumours with high-grade serous ovarian tumours
              showed many molecular commonalities, indicating a related
              aetiology and similar therapeutic opportunities. The biological
              finding of the four main breast cancer subtypes caused by
              different subsets of genetic and epigenetic abnormalities raises
              the hypothesis that much of the clinically observable plasticity
              and heterogeneity occurs within, and not across, these major
              biological subtypes of breast cancer.",
  journal  = "Nature",
  volume   =  490,
  number   =  7418,
  pages    = "61--70",
  month    =  "4~" # oct,
  year     =  2012,
  language = "en"
}

@ARTICLE{Blumenthal2016-fb,
  title       = "{Next-Generation} Sequencing in Oncology in the Era of
                 Precision Medicine",
  author      = "Blumenthal, Gideon M and Mansfield, Elizabeth and Pazdur,
                 Richard",
  affiliation = "Center for Drug Evaluation and Research, US Food and Drug
                 Administration, Silver Spring, Maryland. Center for Devices
                 and Radiologic Health, US Food and Drug Administration, Silver
                 Spring, Maryland. Center for Drug Evaluation and Research, US
                 Food and Drug Administration, Silver Spring, Maryland.",
  journal     = "JAMA Oncol",
  volume      =  2,
  number      =  1,
  pages       = "13--14",
  month       =  jan,
  year        =  2016,
  language    = "en"
}

@MISC{noauthor_undated-of,
  title        = "{gnomAD} browser",
  howpublished = "\url{http://gnomad.broadinstitute.org/}",
  note         = "Accessed: 2017-5-31"
}

@ARTICLE{Bethune2017-ns,
  title       = "Personalized {T} cell-mediated cancer immunotherapy: progress
                 and challenges",
  author      = "Bethune, Michael T and Joglekar, Alok V",
  affiliation = "Division of Biology and Biological Engineering, California
                 Institute of Technology, Pasadena, CA 91125, USA. Electronic
                 address: mbethune@caltech.edu. Division of Biology and
                 Biological Engineering, California Institute of Technology,
                 Pasadena, CA 91125, USA. Electronic address:
                 alokvj@caltech.edu.",
  abstract    = "Immunotherapies are yielding effective treatments for several
                 previously untreatable cancers. Until recently, vaccines and
                 adoptive cell therapies have been designed to target public
                 tumor antigens common to multiple patients rather than private
                 antigens specific to a single patient. Due to the difficulty
                 of identifying public antigens that are expressed exclusively
                 on tumor cells, these studies have yielded both clinical
                 successes and serious immune-related adverse events. Multiple
                 avenues of research now underscore the centrality of
                 tumor-specific mutated private antigens to endogenous
                 anti-tumor immunity. Immunotherapies that target these
                 neoantigens may enable safer and more durable tumor
                 regression, but personalized targeting presents a number of
                 challenges. Foremost among these is to develop processes that
                 accelerate advancement from neoantigen discovery to use of
                 these neoantigens as vaccines or as targets for adoptive cell
                 therapies. Exome sequencing has facilitated discovery of
                 neoantigens for melanoma and other highly mutated cancers. New
                 technologies - possibly proceeding from T cell receptor
                 repertoire sequencing - are needed to identify antigens for
                 cancers with low mutational burden and few neoantigens. In
                 this review, we discuss progress toward personalizing T
                 cell-mediated immunotherapy for cancer as well as challenges
                 going forward.",
  journal     = "Curr. Opin. Biotechnol.",
  volume      =  48,
  pages       = "142--152",
  month       =  "8~" # may,
  year        =  2017,
  language    = "en"
}

@ARTICLE{Uzilov2016-ct,
  title       = "Development and clinical application of an integrative genomic
                 approach to personalized cancer therapy",
  author      = "Uzilov, Andrew V and Ding, Wei and Fink, Marc Y and Antipin,
                 Yevgeniy and Brohl, Andrew S and Davis, Claire and Lau, Chun
                 Yee and Pandya, Chetanya and Shah, Hardik and Kasai, Yumi and
                 Powell, James and Micchelli, Mark and Castellanos, Rafael and
                 Zhang, Zhongyang and Linderman, Michael and Kinoshita, Yayoi
                 and Zweig, Micol and Raustad, Katie and Cheung, Kakit and
                 Castillo, Diane and Wooten, Melissa and Bourzgui, Imane and
                 Newman, Leah C and Deikus, Gintaras and Mathew, Bino and Zhu,
                 Jun and Glicksberg, Benjamin S and Moe, Aye S and Liao, Jun
                 and Edelmann, Lisa and Dudley, Joel T and Maki, Robert G and
                 Kasarskis, Andrew and Holcombe, Randall F and Mahajan, Milind
                 and Hao, Ke and Reva, Boris and Longtine, Janina and
                 Starcevic, Daniela and Sebra, Robert and Donovan, Michael J
                 and Li, Shuyu and Schadt, Eric E and Chen, Rong",
  affiliation = "Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Biomedical Sciences, Long Island
                 University Post, Brookville, NY, 11548, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Sarcoma Department, Moffitt Cancer Center,
                 Tampa, FL, 33612, USA. Department of Genetics and Genomic
                 Sciences, Icahn Institute for Genomics and Multiscale Biology,
                 Icahn School of Medicine at Mount Sinai, New York, NY, 10029,
                 USA. Department of Genetics and Genomic Sciences, Icahn
                 Institute for Genomics and Multiscale Biology, Icahn School of
                 Medicine at Mount Sinai, New York, NY, 10029, USA. Department
                 of Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Pathology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Genetics and Genomic Sciences, Icahn Institute
                 for Genomics and Multiscale Biology, Icahn School of Medicine
                 at Mount Sinai, New York, NY, 10029, USA. Department of
                 Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Division of Hematology and
                 Medical Oncology, Tisch Cancer Institute, Icahn School of
                 Medicine at Mount Sinai, New York, NY, 10029, USA. Department
                 of Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Division of Hematology and
                 Medical Oncology, Tisch Cancer Institute, Icahn School of
                 Medicine at Mount Sinai, New York, NY, 10029, USA. Department
                 of Genetics and Genomic Sciences, Icahn Institute for Genomics
                 and Multiscale Biology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Pathology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 Department of Pathology, Icahn School of Medicine at Mount
                 Sinai, New York, NY, 10029, USA. Department of Genetics and
                 Genomic Sciences, Icahn Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 NY, 10029, USA. Department of Genetics and Genomic Sciences,
                 Icahn Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, NY, 10029, USA.
                 eric.schadt@mssm.edu. Department of Genetics and Genomic
                 Sciences, Icahn Institute for Genomics and Multiscale Biology,
                 Icahn School of Medicine at Mount Sinai, New York, NY, 10029,
                 USA. rong.chen@mssm.edu.",
  abstract    = "BACKGROUND: Personalized therapy provides the best outcome of
                 cancer care and its implementation in the clinic has been
                 greatly facilitated by recent convergence of enormous progress
                 in basic cancer research, rapid advancement of new tumor
                 profiling technologies, and an expanding compendium of
                 targeted cancer therapeutics. METHODS: We developed a
                 personalized cancer therapy (PCT) program in a clinical
                 setting, using an integrative genomics approach to fully
                 characterize the complexity of each tumor. We carried out
                 whole exome sequencing (WES) and single-nucleotide
                 polymorphism (SNP) microarray genotyping on DNA from tumor and
                 patient-matched normal specimens, as well as RNA sequencing
                 (RNA-Seq) on available frozen specimens, to identify somatic
                 (tumor-specific) mutations, copy number alterations (CNAs),
                 gene expression changes, gene fusions, and also germline
                 variants. To provide high sensitivity in known cancer mutation
                 hotspots, Ion AmpliSeq Cancer Hotspot Panel v2 (CHPv2) was
                 also employed. We integrated the resulting data with cancer
                 knowledge bases and developed a specific workflow for each
                 cancer type to improve interpretation of genomic data.
                 RESULTS: We returned genomics findings to 46 patients and
                 their physicians describing somatic alterations and predicting
                 drug response, toxicity, and prognosis. Mean 17.3
                 cancer-relevant somatic mutations per patient were identified,
                 13.3-fold, 6.9-fold, and 4.7-fold more than could have been
                 detected using CHPv2, Oncomine Cancer Panel (OCP), and
                 FoundationOne, respectively. Our approach delineated the
                 underlying genetic drivers at the pathway level and provided
                 meaningful predictions of therapeutic efficacy and toxicity.
                 Actionable alterations were found in 91 \% of patients (mean
                 4.9 per patient, including somatic mutations, copy number
                 alterations, gene expression alterations, and germline
                 variants), a 7.5-fold, 2.0-fold, and 1.9-fold increase over
                 what could have been uncovered by CHPv2, OCP, and
                 FoundationOne, respectively. The findings altered the course
                 of treatment in four cases. CONCLUSIONS: These results show
                 that a comprehensive, integrative genomic approach as outlined
                 above significantly enhanced genomics-based PCT strategies.",
  journal     = "Genome Med.",
  volume      =  8,
  number      =  1,
  pages       = "62",
  month       =  "1~" # jun,
  year        =  2016,
  keywords    = "Cancer; Clinical application; Genomics; Personalized medicine",
  language    = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Druker2006-qk,
  title     = "Long-term benefits of imatinib ({IM}) for patients newly
               diagnosed with chronic myelogenous leukemia in chronic phase
               ({CML-CP)}: the 5-year update from the {IRIS} study",
  author    = "Druker, B J and Guilhot, F and OBrien, S and Larson, R A",
  journal   = "J. Clin. Oncol.",
  publisher = "American Society of Clinical Oncology",
  volume    =  24,
  number    =  90180,
  pages     = "6506--6506",
  year      =  2006
}

@ARTICLE{Mao2013-ie,
  title       = "{CanDrA}: cancer-specific driver missense mutation annotation
                 with optimized features",
  author      = "Mao, Yong and Chen, Han and Liang, Han and Meric-Bernstam,
                 Funda and Mills, Gordon B and Chen, Ken",
  affiliation = "Department of Bioinformatics and Computational Biology, The
                 University of Texas M.D. Anderson Cancer Center, Houston,
                 Texas, United States of America.",
  abstract    = "Driver mutations are somatic mutations that provide growth
                 advantage to tumor cells, while passenger mutations are those
                 not functionally related to oncogenesis. Distinguishing
                 drivers from passengers is challenging because drivers occur
                 much less frequently than passengers, they tend to have low
                 prevalence, their functions are multifactorial and not
                 intuitively obvious. Missense mutations are excellent
                 candidates as drivers, as they occur more frequently and are
                 potentially easier to identify than other types of mutations.
                 Although several methods have been developed for predicting
                 the functional impact of missense mutations, only a few have
                 been specifically designed for identifying driver mutations.
                 As more mutations are being discovered, more accurate
                 predictive models can be developed using machine learning
                 approaches that systematically characterize the commonality
                 and peculiarity of missense mutations under the background of
                 specific cancer types. Here, we present a cancer driver
                 annotation (CanDrA) tool that predicts missense driver
                 mutations based on a set of 95 structural and evolutionary
                 features computed by over 10 functional prediction algorithms
                 such as CHASM, SIFT, and MutationAssessor. Through feature
                 optimization and supervised training, CanDrA outperforms
                 existing tools in analyzing the glioblastoma multiforme and
                 ovarian carcinoma data sets in The Cancer Genome Atlas and the
                 Cancer Cell Line Encyclopedia project.",
  journal     = "PLoS One",
  volume      =  8,
  number      =  10,
  pages       = "e77945",
  month       =  "30~" # oct,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Yue2006-kj,
  title    = "{SNPs3D}: Candidate gene and {SNP} selection for association
              studies",
  author   = "Yue, Peng and Melamud, Eugene and Moult, John",
  abstract = "The relationship between disease susceptibility and genetic
              variation is complex, and many different types of data are
              relevant. We describe a web resource and database that provides
              and integrates as much information as possible on disease/gene
              relationships at the molecular level.",
  journal  = "BMC Bioinformatics",
  volume   =  7,
  number   =  1,
  pages    = "166",
  year     =  2006
}

@ARTICLE{Choi2015-dd,
  title       = "{PROVEAN} web server: a tool to predict the functional effect
                 of amino acid substitutions and indels",
  author      = "Choi, Yongwook and Chan, Agnes P",
  affiliation = "The J. Craig Venter Institute, Rockville, MD 20850, USA. The
                 J. Craig Venter Institute, Rockville, MD 20850, USA.",
  abstract    = "UNLABELLED: We present a web server to predict the functional
                 effect of single or multiple amino acid substitutions,
                 insertions and deletions using the prediction tool PROVEAN.
                 The server provides rapid analysis of protein variants from
                 any organisms, and also supports high-throughput analysis for
                 human and mouse variants at both the genomic and protein
                 levels. AVAILABILITY AND IMPLEMENTATION: The web server is
                 freely available and open to all users with no login
                 requirements at http://provean.jcvi.org. CONTACT:
                 achan@jcvi.org SUPPLEMENTARY INFORMATION: Supplementary data
                 are available at Bioinformatics online.",
  journal     = "Bioinformatics",
  volume      =  31,
  number      =  16,
  pages       = "2745--2747",
  month       =  "15~" # aug,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Siepel2005-ke,
  title       = "Evolutionarily conserved elements in vertebrate, insect, worm,
                 and yeast genomes",
  author      = "Siepel, Adam and Bejerano, Gill and Pedersen, Jakob S and
                 Hinrichs, Angie S and Hou, Minmei and Rosenbloom, Kate and
                 Clawson, Hiram and Spieth, John and Hillier, Ladeana W and
                 Richards, Stephen and Weinstock, George M and Wilson, Richard
                 K and Gibbs, Richard A and Kent, W James and Miller, Webb and
                 Haussler, David",
  affiliation = "Center for Biomolecular Science and Engineering, University of
                 California, Santa Cruz, Santa Cruz, California 95064, USA.
                 acs@soe.ucsc.edu",
  abstract    = "We have conducted a comprehensive search for conserved
                 elements in vertebrate genomes, using genome-wide multiple
                 alignments of five vertebrate species (human, mouse, rat,
                 chicken, and Fugu rubripes). Parallel searches have been
                 performed with multiple alignments of four insect species
                 (three species of Drosophila and Anopheles gambiae), two
                 species of Caenorhabditis, and seven species of Saccharomyces.
                 Conserved elements were identified with a computer program
                 called phastCons, which is based on a two-state phylogenetic
                 hidden Markov model (phylo-HMM). PhastCons works by fitting a
                 phylo-HMM to the data by maximum likelihood, subject to
                 constraints designed to calibrate the model across species
                 groups, and then predicting conserved elements based on this
                 model. The predicted elements cover roughly 3\%-8\% of the
                 human genome (depending on the details of the calibration
                 procedure) and substantially higher fractions of the more
                 compact Drosophila melanogaster (37\%-53\%), Caenorhabditis
                 elegans (18\%-37\%), and Saccharaomyces cerevisiae (47\%-68\%)
                 genomes. From yeasts to vertebrates, in order of increasing
                 genome size and general biological complexity, increasing
                 fractions of conserved bases are found to lie outside of the
                 exons of known protein-coding genes. In all groups, the most
                 highly conserved elements (HCEs), by log-odds score, are
                 hundreds or thousands of bases long. These elements share
                 certain properties with ultraconserved elements, but they tend
                 to be longer and less perfectly conserved, and they overlap
                 genes of somewhat different functional categories. In
                 vertebrates, HCEs are associated with the 3' UTRs of
                 regulatory genes, stable gene deserts, and megabase-sized
                 regions rich in moderately conserved noncoding sequences.
                 Noncoding HCEs also show strong statistical evidence of an
                 enrichment for RNA secondary structure.",
  journal     = "Genome Res.",
  volume      =  15,
  number      =  8,
  pages       = "1034--1050",
  month       =  aug,
  year        =  2005,
  language    = "en"
}

@ARTICLE{Nickerson2003-wt,
  title   = "{SeattleSNPs}",
  author  = "Nickerson, D A and Rieder, M J",
  journal = "NHLBI Program for Genomic Applications HL66682",
  year    =  2003
}

@ARTICLE{Flaherty2012-dq,
  title       = "Combined {BRAF} and {MEK} inhibition in melanoma with {BRAF}
                 {V600} mutations",
  author      = "Flaherty, Keith T and Infante, Jeffery R and Daud, Adil and
                 Gonzalez, Rene and Kefford, Richard F and Sosman, Jeffrey and
                 Hamid, Omid and Schuchter, Lynn and Cebon, Jonathan and
                 Ibrahim, Nageatte and Kudchadkar, Ragini and Burris, 3rd,
                 Howard A and Falchook, Gerald and Algazi, Alain and Lewis,
                 Karl and Long, Georgina V and Puzanov, Igor and Lebowitz,
                 Peter and Singh, Ajay and Little, Shonda and Sun, Peng and
                 Allred, Alicia and Ouellet, Daniele and Kim, Kevin B and
                 Patel, Kiran and Weber, Jeffrey",
  affiliation = "Massachusetts General Hospital Cancer Center, Boston, USA.",
  abstract    = "BACKGROUND: Resistance to therapy with BRAF kinase inhibitors
                 is associated with reactivation of the mitogen-activated
                 protein kinase (MAPK) pathway. To address this problem, we
                 conducted a phase 1 and 2 trial of combined treatment with
                 dabrafenib, a selective BRAF inhibitor, and trametinib, a
                 selective MAPK kinase (MEK) inhibitor. METHODS: In this
                 open-label study involving 247 patients with metastatic
                 melanoma and BRAF V600 mutations, we evaluated the
                 pharmacokinetic activity and safety of oral dabrafenib (75 or
                 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in
                 85 patients and then randomly assigned 162 patients to receive
                 combination therapy with dabrafenib (150 mg) plus trametinib
                 (1 or 2 mg) or dabrafenib monotherapy. The primary end points
                 were the incidence of cutaneous squamous-cell carcinoma,
                 survival free of melanoma progression, and response. Secondary
                 end points were overall survival and pharmacokinetic activity.
                 RESULTS: Dose-limiting toxic effects were infrequently
                 observed in patients receiving combination therapy with 150 mg
                 of dabrafenib and 2 mg of trametinib (combination 150/2).
                 Cutaneous squamous-cell carcinoma was seen in 7\% of patients
                 receiving combination 150/2 and in 19\% receiving monotherapy
                 (P=0.09), whereas pyrexia was more common in the combination
                 150/2 group than in the monotherapy group (71\% vs. 26\%).
                 Median progression-free survival in the combination 150/2
                 group was 9.4 months, as compared with 5.8 months in the
                 monotherapy group (hazard ratio for progression or death,
                 0.39; 95\% confidence interval, 0.25 to 0.62; P<0.001). The
                 rate of complete or partial response with combination 150/2
                 therapy was 76\%, as compared with 54\% with monotherapy
                 (P=0.03). CONCLUSIONS: Dabrafenib and trametinib were safely
                 combined at full monotherapy doses. The rate of pyrexia was
                 increased with combination therapy, whereas the rate of
                 proliferative skin lesions was nonsignificantly reduced.
                 Progression-free survival was significantly improved. (Funded
                 by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.).",
  journal     = "N. Engl. J. Med.",
  volume      =  367,
  number      =  18,
  pages       = "1694--1703",
  month       =  "1~" # nov,
  year        =  2012,
  language    = "en"
}

@ARTICLE{Glusman2011-ls,
  title    = "Kaviar: an accessible system for testing {SNV} novelty",
  author   = "Glusman, Gustavo and Caballero, Juan and Mauldin, Denise E and
              Hood, Leroy and Roach, Jared C",
  abstract = "SUMMARY: With the rapidly expanding availability of data from
              personal genomes, exomes and transcriptomes, medical researchers
              will frequently need to test whether observed genomic variants
              are novel or known. This task requires downloading and handling
              large and diverse datasets from a variety of sources, and
              processing them with bioinformatics tools and pipelines.
              Alternatively, researchers can upload data to online tools, which
              may conflict with privacy requirements. We present here Kaviar, a
              tool that greatly simplifies the assessment of novel variants.
              Kaviar includes: (i) an integrated and growing database of
              genomic variation from diverse sources, including over 55 million
              variants from personal genomes, family genomes, transcriptomes,
              SNV databases and population surveys; and (ii) software for
              querying the database efficiently.",
  journal  = "Bioinformatics",
  volume   =  27,
  number   =  22,
  pages    = "3216--3217",
  month    =  "15~" # nov,
  year     =  2011,
  keywords = "Databases, Nucleic Acid; Genetic Variation; Genomics; Humans;
              Software; Transcriptome"
}

@ARTICLE{Church2005-lr,
  title    = "The personal genome project",
  author   = "Church, G M",
  journal  = "Mol. Syst. Biol.",
  volume   =  1,
  pages    = "2005.0030",
  month    =  "13~" # dec,
  year     =  2005,
  language = "en"
}

@ARTICLE{Carter2009-ci,
  title       = "Cancer-specific high-throughput annotation of somatic
                 mutations: computational prediction of driver missense
                 mutations",
  author      = "Carter, Hannah and Chen, Sining and Isik, Leyla and
                 Tyekucheva, Svitlana and Velculescu, Victor E and Kinzler,
                 Kenneth W and Vogelstein, Bert and Karchin, Rachel",
  affiliation = "Department of Biomedical Engineering and Institute for
                 Computational Medicine, Johns Hopkins University, Baltimore,
                 Maryland 21218, USA.",
  abstract    = "Large-scale sequencing of cancer genomes has uncovered
                 thousands of DNA alterations, but the functional relevance of
                 the majority of these mutations to tumorigenesis is unknown.
                 We have developed a computational method, called
                 Cancer-specific High-throughput Annotation of Somatic
                 Mutations (CHASM), to identify and prioritize those missense
                 mutations most likely to generate functional changes that
                 enhance tumor cell proliferation. The method has high
                 sensitivity and specificity when discriminating between known
                 driver missense mutations and randomly generated missense
                 mutations (area under receiver operating characteristic curve,
                 >0.91; area under Precision-Recall curve, >0.79). CHASM
                 substantially outperformed previously described missense
                 mutation function prediction methods at discriminating known
                 oncogenic mutations in P53 and the tyrosine kinase epidermal
                 growth factor receptor. We applied the method to 607 missense
                 mutations found in a recent glioblastoma multiforme sequencing
                 study. Based on a model that assumed the glioblastoma
                 multiforme mutations are a mixture of drivers and passengers,
                 we estimate that 8\% of these mutations are drivers, causally
                 contributing to tumorigenesis.",
  journal     = "Cancer Res.",
  volume      =  69,
  number      =  16,
  pages       = "6660--6667",
  month       =  "15~" # aug,
  year        =  2009,
  language    = "en"
}

@ARTICLE{noauthor_2008-wg,
  title     = "Comprehensive genomic characterization defines human
               glioblastoma genes and core pathways",
  abstract  = "Human cancer cells typically harbour multiple chromosomal
               aberrations, nucleotide substitutions and epigenetic
               modifications that drive malignant transformation. The Cancer
               Genome Atlas (TCGA) pilot project aims to assess the value of
               large-scale multi-dimensional analysis of these molecular
               characteristics in human cancer and to provide the data rapidly
               to the research community. Here we report the interim
               integrative analysis of DNA copy number, gene expression and DNA
               methylation aberrations in 206 glioblastomas--the most common
               type of adult brain cancer--and nucleotide sequence aberrations
               in 91 of the 206 glioblastomas. This analysis provides new
               insights into the roles of ERBB2, NF1 and TP53, uncovers
               frequent mutations of the phosphatidylinositol-3-OH kinase
               regulatory subunit gene PIK3R1, and provides a network view of
               the pathways altered in the development of glioblastoma.
               Furthermore, integration of mutation, DNA methylation and
               clinical treatment data reveals a link between MGMT promoter
               methylation and a hypermutator phenotype consequent to mismatch
               repair deficiency in treated glioblastomas, an observation with
               potential clinical implications. Together, these findings
               establish the feasibility and power of TCGA, demonstrating that
               it can rapidly expand knowledge of the molecular basis of
               cancer.",
  journal   = "Nature",
  publisher = "Macmillan Publishers Limited. All rights reserved",
  volume    =  455,
  number    =  7216,
  pages     = "1061--1068",
  month     =  "23~" # oct,
  year      =  2008,
  keywords  = "Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms;
               Brain Neoplasms: genetics; DNA Methylation; DNA Modification
               Methylases; DNA Modification Methylases: genetics; DNA Repair;
               DNA Repair Enzymes; DNA Repair Enzymes: genetics; DNA Repair:
               genetics; Female; Gene Dosage; Gene Expression Regulation,
               Neoplastic; Genes, Tumor Suppressor; Genes, erbB-1; Genes,
               erbB-1: genetics; Genome, Human; Genome, Human: genetics;
               Genomics; Glioblastoma; Glioblastoma: genetics; Humans; Male;
               Middle Aged; Models, Molecular; Mutation; Mutation: genetics;
               Neurofibromin 1; Neurofibromin 1: genetics; Phosphatidylinositol
               3-Kinases; Phosphatidylinositol 3-Kinases: genetics; Protein
               Structure, Tertiary; Retrospective Studies; Signal Transduction;
               Signal Transduction: genetics; Tumor Suppressor Proteins; Tumor
               Suppressor Proteins: genetics"
}

@ARTICLE{Adzhubei2013-nj,
  title       = "Predicting functional effect of human missense mutations using
                 {PolyPhen-2}",
  author      = "Adzhubei, Ivan and Jordan, Daniel M and Sunyaev, Shamil R",
  affiliation = "Division of Genetics, Brigham \& Women's Hospital, Harvard
                 Medical School, Boston, Massachusetts, USA.",
  abstract    = "PolyPhen-2 (Polymorphism Phenotyping v2), available as
                 software and via a Web server, predicts the possible impact of
                 amino acid substitutions on the stability and function of
                 human proteins using structural and comparative evolutionary
                 considerations. It performs functional annotation of
                 single-nucleotide polymorphisms (SNPs), maps coding SNPs to
                 gene transcripts, extracts protein sequence annotations and
                 structural attributes, and builds conservation profiles. It
                 then estimates the probability of the missense mutation being
                 damaging based on a combination of all these properties.
                 PolyPhen-2 features include a high-quality multiple protein
                 sequence alignment pipeline and a prediction method employing
                 machine-learning classification. The software also integrates
                 the UCSC Genome Browser's human genome annotations and MultiZ
                 multiple alignments of vertebrate genomes with the human
                 genome. PolyPhen-2 is capable of analyzing large volumes of
                 data produced by next-generation sequencing projects, thanks
                 to built-in support for high-performance computing
                 environments like Grid Engine and Platform LSF.",
  journal     = "Curr. Protoc. Hum. Genet.",
  volume      = "Chapter 7",
  pages       = "Unit7.20",
  month       =  jan,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Barretina2012-yz,
  title    = "The Cancer Cell Line Encyclopedia enables predictive modelling of
              anticancer drug sensitivity",
  author   = "Barretina, Jordi and Caponigro, Giordano and Stransky, Nicolas
              and Venkatesan, Kavitha and Margolin, Adam A and Kim, Sungjoon
              and Wilson, Christopher J and Leh{\'a}r, Joseph and Kryukov,
              Gregory V and Sonkin, Dmitriy and Reddy, Anupama and Liu, Manway
              and Murray, Lauren and Berger, Michael F and Monahan, John E and
              Morais, Paula and Meltzer, Jodi and Korejwa, Adam and
              Jan{\'e}-Valbuena, Judit and Mapa, Felipa A and Thibault, Joseph
              and Bric-Furlong, Eva and Raman, Pichai and Shipway, Aaron and
              Engels, Ingo H and Cheng, Jill and Yu, Guoying K and Yu, Jianjun
              and Aspesi, Peter and de Silva, Melanie and Jagtap, Kalpana and
              Jones, Michael D and Wang, Li and Hatton, Charles and
              Palescandolo, Emanuele and Gupta, Supriya and Mahan, Scott and
              Sougnez, Carrie and Onofrio, Robert C and Liefeld, Ted and
              MacConaill, Laura and Winckler, Wendy and Reich, Michael and Li,
              Nanxin and Mesirov, Jill P and Gabriel, Stacey B and Getz, Gad
              and Ardlie, Kristin and Chan, Vivien and Myer, Vic E and Weber,
              Barbara L and Porter, Jeff and Warmuth, Markus and Finan, Peter
              and Harris, Jennifer L and Meyerson, Matthew and Golub, Todd R
              and Morrissey, Michael P and Sellers, William R and Schlegel,
              Robert and Garraway, Levi A",
  abstract = "The systematic translation of cancer genomic data into knowledge
              of tumour biology and therapeutic possibilities remains
              challenging. Such efforts should be greatly aided by robust
              preclinical model systems that reflect the genomic diversity of
              human cancers and for which detailed genetic and pharmacological
              annotation is available. Here we describe the Cancer Cell Line
              Encyclopedia (CCLE): a compilation of gene expression,
              chromosomal copy number and massively parallel sequencing data
              from 947 human cancer cell lines. When coupled with
              pharmacological profiles for 24 anticancer drugs across 479 of
              the cell lines, this collection allowed identification of
              genetic, lineage, and gene-expression-based predictors of drug
              sensitivity. In addition to known predictors, we found that
              plasma cell lineage correlated with sensitivity to IGF1 receptor
              inhibitors; AHR expression was associated with MEK inhibitor
              efficacy in NRAS-mutant lines; and SLFN11 expression predicted
              sensitivity to topoisomerase inhibitors. Together, our results
              indicate that large, annotated cell-line collections may help to
              enable preclinical stratification schemata for anticancer agents.
              The generation of genetic predictions of drug response in the
              preclinical setting and their incorporation into cancer clinical
              trial design could speed the emergence of 'personalized'
              therapeutic regimens.",
  journal  = "Nature",
  volume   =  483,
  number   =  7391,
  pages    = "603--607",
  month    =  "29~" # mar,
  year     =  2012
}

@MISC{Fda2015-kv,
  title  = "Optimizing {FDA's} Regulatory Oversight of Next Generation
            Sequencing Diagnostic {Tests---Preliminary} Discussion Paper",
  author = "{FDA}",
  month  =  "20~" # feb,
  year   =  2015
}

@ARTICLE{Li2009-du,
  title       = "The Sequence {Alignment/Map} format and {SAMtools}",
  author      = "Li, Heng and Handsaker, Bob and Wysoker, Alec and Fennell, Tim
                 and Ruan, Jue and Homer, Nils and Marth, Gabor and Abecasis,
                 Goncalo and Durbin, Richard and {1000 Genome Project Data
                 Processing Subgroup}",
  affiliation = "Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
                 Cambridge, CB10 1SA, UK, Broad Institute of MIT and Harvard,
                 Cambridge, MA 02141, USA.",
  abstract    = "SUMMARY: The Sequence Alignment/Map (SAM) format is a generic
                 alignment format for storing read alignments against reference
                 sequences, supporting short and long reads (up to 128 Mbp)
                 produced by different sequencing platforms. It is flexible in
                 style, compact in size, efficient in random access and is the
                 format in which alignments from the 1000 Genomes Project are
                 released. SAMtools implements various utilities for
                 post-processing alignments in the SAM format, such as
                 indexing, variant caller and alignment viewer, and thus
                 provides universal tools for processing read alignments.
                 AVAILABILITY: http://samtools.sourceforge.net.",
  journal     = "Bioinformatics",
  volume      =  25,
  number      =  16,
  pages       = "2078--2079",
  month       =  "15~" # aug,
  year        =  2009,
  language    = "en"
}

@ARTICLE{Zarin2008-la,
  title       = "Medicine. Moving toward transparency of clinical trials",
  author      = "Zarin, Deborah A and Tse, Tony",
  affiliation = "National Library of Medicine, National Institutes of Health,
                 U.S. Department of Health and Human Services, Bethesda, MD
                 20894, USA. dzarin@mail.nih.gov",
  journal     = "Science",
  volume      =  319,
  number      =  5868,
  pages       = "1340--1342",
  month       =  "7~" # mar,
  year        =  2008,
  language    = "en"
}

@ARTICLE{Lawrence2014-ss,
  title       = "Discovery and saturation analysis of cancer genes across 21
                 tumour types",
  author      = "Lawrence, Michael S and Stojanov, Petar and Mermel, Craig H
                 and Robinson, James T and Garraway, Levi A and Golub, Todd R
                 and Meyerson, Matthew and Gabriel, Stacey B and Lander, Eric S
                 and Getz, Gad",
  affiliation = "Broad Institute of MIT and Harvard, 7 Cambridge Center,
                 Cambridge, Massachusetts 02142, USA. 1] Broad Institute of MIT
                 and Harvard, 7 Cambridge Center, Cambridge, Massachusetts
                 02142, USA [2] Dana-Farber Cancer Institute, 450 Brookline
                 Avenue, Boston, Massachusetts 02215, USA. 1] Broad Institute
                 of MIT and Harvard, 7 Cambridge Center, Cambridge,
                 Massachusetts 02142, USA [2] Massachusetts General Hospital,
                 Cancer Center and Department of Pathology, 55 Fruit Street,
                 Boston, Massachusetts 02114, USA. Broad Institute of MIT and
                 Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
                 USA. 1] Broad Institute of MIT and Harvard, 7 Cambridge
                 Center, Cambridge, Massachusetts 02142, USA [2] Dana-Farber
                 Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts
                 02215, USA [3] Harvard Medical School, 25 Shattuck Street,
                 Boston, Massachusetts 02115, USA. 1] Broad Institute of MIT
                 and Harvard, 7 Cambridge Center, Cambridge, Massachusetts
                 02142, USA [2] Dana-Farber Cancer Institute, 450 Brookline
                 Avenue, Boston, Massachusetts 02215, USA [3] Harvard Medical
                 School, 25 Shattuck Street, Boston, Massachusetts 02115, USA
                 [4] Howard Hughes Medical Institute, 4000 Jones Bridge Road,
                 Chevy Chase, Maryland 20815, USA. 1] Broad Institute of MIT
                 and Harvard, 7 Cambridge Center, Cambridge, Massachusetts
                 02142, USA [2] Dana-Farber Cancer Institute, 450 Brookline
                 Avenue, Boston, Massachusetts 02215, USA [3] Harvard Medical
                 School, 25 Shattuck Street, Boston, Massachusetts 02115, USA.
                 Broad Institute of MIT and Harvard, 7 Cambridge Center,
                 Cambridge, Massachusetts 02142, USA. 1] Broad Institute of MIT
                 and Harvard, 7 Cambridge Center, Cambridge, Massachusetts
                 02142, USA [2] Harvard Medical School, 25 Shattuck Street,
                 Boston, Massachusetts 02115, USA [3] Massachusetts Institute
                 of Technology, 77 Massachusetts Avenue, Cambridge,
                 Massachusetts 02139, USA [4]. 1] Broad Institute of MIT and
                 Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
                 USA [2] Massachusetts General Hospital, Cancer Center and
                 Department of Pathology, 55 Fruit Street, Boston,
                 Massachusetts 02114, USA [3] Harvard Medical School, 25
                 Shattuck Street, Boston, Massachusetts 02115, USA [4].",
  abstract    = "Although a few cancer genes are mutated in a high proportion
                 of tumours of a given type (>20\%), most are mutated at
                 intermediate frequencies (2-20\%). To explore the feasibility
                 of creating a comprehensive catalogue of cancer genes, we
                 analysed somatic point mutations in exome sequences from 4,742
                 human cancers and their matched normal-tissue samples across
                 21 cancer types. We found that large-scale genomic analysis
                 can identify nearly all known cancer genes in these tumour
                 types. Our analysis also identified 33 genes that were not
                 previously known to be significantly mutated in cancer,
                 including genes related to proliferation, apoptosis, genome
                 stability, chromatin regulation, immune evasion, RNA
                 processing and protein homeostasis. Down-sampling analysis
                 indicates that larger sample sizes will reveal many more genes
                 mutated at clinically important frequencies. We estimate that
                 near-saturation may be achieved with 600-5,000 samples per
                 tumour type, depending on background mutation frequency. The
                 results may help to guide the next stage of cancer genomics.",
  journal     = "Nature",
  volume      =  505,
  number      =  7484,
  pages       = "495--501",
  month       =  "23~" # jan,
  year        =  2014,
  language    = "en"
}

@ARTICLE{Gao2017-vl,
  title       = "{3D} clusters of somatic mutations in cancer reveal numerous
                 rare mutations as functional targets",
  author      = "Gao, Jianjiong and Chang, Matthew T and Johnsen, Hannah C and
                 Gao, Sizhi Paul and Sylvester, Brooke E and Sumer, Selcuk Onur
                 and Zhang, Hongxin and Solit, David B and Taylor, Barry S and
                 Schultz, Nikolaus and Sander, Chris",
  affiliation = "Marie-Jos{\'e}e and Henry R. Kravis Center for Molecular
                 Oncology, Memorial Sloan Kettering Cancer Center, New York,
                 NY, USA. jgao@cbio.mskcc.org. Human Oncology and Pathogenesis
                 Program, Memorial Sloan Kettering Cancer Center, New York, NY,
                 USA. Department of Epidemiology and Biostatistics, Memorial
                 Sloan Kettering Cancer Center, New York, NY, USA. Departments
                 of Bioengineering and Therapeutic Sciences, University of
                 California, San Francisco, CA, USA. Human Oncology and
                 Pathogenesis Program, Memorial Sloan Kettering Cancer Center,
                 New York, NY, USA. Louis V. Gerstner Jr. Graduate School of
                 Biomedical Sciences, Memorial Sloan Kettering Cancer Center,
                 New York, NY, USA. Human Oncology and Pathogenesis Program,
                 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
                 Human Oncology and Pathogenesis Program, Memorial Sloan
                 Kettering Cancer Center, New York, NY, USA. Marie-Jos{\'e}e
                 and Henry R. Kravis Center for Molecular Oncology, Memorial
                 Sloan Kettering Cancer Center, New York, NY, USA.
                 Marie-Jos{\'e}e and Henry R. Kravis Center for Molecular
                 Oncology, Memorial Sloan Kettering Cancer Center, New York,
                 NY, USA. Marie-Jos{\'e}e and Henry R. Kravis Center for
                 Molecular Oncology, Memorial Sloan Kettering Cancer Center,
                 New York, NY, USA. Human Oncology and Pathogenesis Program,
                 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
                 Department of Medicine, Memorial Sloan Kettering Cancer
                 Center, New York, NY, USA. Weill Cornell Medical College,
                 Cornell University, New York, NY, USA. Marie-Jos{\'e}e and
                 Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
                 Kettering Cancer Center, New York, NY, USA. Human Oncology and
                 Pathogenesis Program, Memorial Sloan Kettering Cancer Center,
                 New York, NY, USA. Department of Epidemiology and
                 Biostatistics, Memorial Sloan Kettering Cancer Center, New
                 York, NY, USA. Marie-Jos{\'e}e and Henry R. Kravis Center for
                 Molecular Oncology, Memorial Sloan Kettering Cancer Center,
                 New York, NY, USA. Department of Epidemiology and
                 Biostatistics, Memorial Sloan Kettering Cancer Center, New
                 York, NY, USA. Department of Cell Biology, Harvard Medical
                 School, Boston, MA, USA. cBio Center, Dana-Farber Cancer
                 Institute, Boston, MA, USA. Computational Biology Program,
                 Memorial Sloan Kettering Cancer Center, New York, NY, USA.",
  abstract    = "Many mutations in cancer are of unknown functional
                 significance. Standard methods use statistically significant
                 recurrence of mutations in tumor samples as an indicator of
                 functional impact. We extend such analyses into the long tail
                 of rare mutations by considering recurrence of mutations in
                 clusters of spatially close residues in protein structures.
                 Analyzing 10,000 tumor exomes, we identify more than 3000
                 rarely mutated residues in proteins as potentially functional
                 and experimentally validate several in RAC1 and MAP2K1. These
                 potential driver mutations (web resources: 3dhotspots.org and
                 cBioPortal.org) can extend the scope of genomically informed
                 clinical trials and of personalized choice of therapy.",
  journal     = "Genome Med.",
  volume      =  9,
  number      =  1,
  pages       = "4",
  month       =  "23~" # jan,
  year        =  2017,
  keywords    = "Cancer genomics; Driver mutations; Precision medicine; Protein
                 structures",
  language    = "en"
}

@ARTICLE{Chalmers2017-ya,
  title       = "Analysis of 100,000 human cancer genomes reveals the landscape
                 of tumor mutational burden",
  author      = "Chalmers, Zachary R and Connelly, Caitlin F and Fabrizio,
                 David and Gay, Laurie and Ali, Siraj M and Ennis, Riley and
                 Schrock, Alexa and Campbell, Brittany and Shlien, Adam and
                 Chmielecki, Juliann and Huang, Franklin and He, Yuting and
                 Sun, James and Tabori, Uri and Kennedy, Mark and Lieber,
                 Daniel S and Roels, Steven and White, Jared and Otto, Geoffrey
                 A and Ross, Jeffrey S and Garraway, Levi and Miller, Vincent A
                 and Stephens, Phillip J and Frampton, Garrett M",
  affiliation = "Foundation Medicine Inc., 150 Second St., Cambridge, MA,
                 02141, USA. Foundation Medicine Inc., 150 Second St.,
                 Cambridge, MA, 02141, USA. Foundation Medicine Inc., 150
                 Second St., Cambridge, MA, 02141, USA. Foundation Medicine
                 Inc., 150 Second St., Cambridge, MA, 02141, USA. Foundation
                 Medicine Inc., 150 Second St., Cambridge, MA, 02141, USA.
                 Foundation Medicine Inc., 150 Second St., Cambridge, MA,
                 02141, USA. Foundation Medicine Inc., 150 Second St.,
                 Cambridge, MA, 02141, USA. The Hospital for Sick Children,
                 Toronto, Ontario, Canada. The Hospital for Sick Children,
                 Toronto, Ontario, Canada. Foundation Medicine Inc., 150 Second
                 St., Cambridge, MA, 02141, USA. Dana-Farber Cancer Institute,
                 Harvard Medical School, Boston, Massachusetts, USA. Foundation
                 Medicine Inc., 150 Second St., Cambridge, MA, 02141, USA.
                 Foundation Medicine Inc., 150 Second St., Cambridge, MA,
                 02141, USA. The Hospital for Sick Children, Toronto, Ontario,
                 Canada. Foundation Medicine Inc., 150 Second St., Cambridge,
                 MA, 02141, USA. Foundation Medicine Inc., 150 Second St.,
                 Cambridge, MA, 02141, USA. Foundation Medicine Inc., 150
                 Second St., Cambridge, MA, 02141, USA. Foundation Medicine
                 Inc., 150 Second St., Cambridge, MA, 02141, USA. Foundation
                 Medicine Inc., 150 Second St., Cambridge, MA, 02141, USA.
                 Foundation Medicine Inc., 150 Second St., Cambridge, MA,
                 02141, USA. Dana-Farber Cancer Institute, Harvard Medical
                 School, Boston, Massachusetts, USA. Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts, USA. Foundation Medicine
                 Inc., 150 Second St., Cambridge, MA, 02141, USA. Foundation
                 Medicine Inc., 150 Second St., Cambridge, MA, 02141, USA.
                 Foundation Medicine Inc., 150 Second St., Cambridge, MA,
                 02141, USA. gframpton@foundationmedicine.com.",
  abstract    = "BACKGROUND: High tumor mutational burden (TMB) is an emerging
                 biomarker of sensitivity to immune checkpoint inhibitors and
                 has been shown to be more significantly associated with
                 response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or
                 PD-L1 expression, as measured by immunohistochemistry (IHC).
                 The distribution of TMB and the subset of patients with high
                 TMB has not been well characterized in the majority of cancer
                 types. METHODS: In this study, we compare TMB measured by a
                 targeted comprehensive genomic profiling (CGP) assay to TMB
                 measured by exome sequencing and simulate the expected
                 variance in TMB when sequencing less than the whole exome. We
                 then describe the distribution of TMB across a diverse cohort
                 of 100,000 cancer cases and test for association between
                 somatic alterations and TMB in over 100 tumor types. RESULTS:
                 We demonstrate that measurements of TMB from comprehensive
                 genomic profiling are strongly reflective of measurements from
                 whole exome sequencing and model that below 0.5 Mb the
                 variance in measurement increases significantly. We find that
                 a subset of patients exhibits high TMB across almost all types
                 of cancer, including many rare tumor types, and characterize
                 the relationship between high TMB and microsatellite
                 instability status. We find that TMB increases significantly
                 with age, showing a 2.4-fold difference between age 10 and age
                 90 years. Finally, we investigate the molecular basis of TMB
                 and identify genes and mutations associated with TMB level. We
                 identify a cluster of somatic mutations in the promoter of the
                 gene PMS2, which occur in 10\% of skin cancers and are highly
                 associated with increased TMB. CONCLUSIONS: These results show
                 that a CGP assay targeting ~1.1 Mb of coding genome can
                 accurately assess TMB compared with sequencing the whole
                 exome. Using this method, we find that many disease types have
                 a substantial portion of patients with high TMB who might
                 benefit from immunotherapy. Finally, we identify novel,
                 recurrent promoter mutations in PMS2, which may be another
                 example of regulatory mutations contributing to tumorigenesis.",
  journal     = "Genome Med.",
  volume      =  9,
  number      =  1,
  pages       = "34",
  month       =  "19~" # apr,
  year        =  2017,
  keywords    = "Cancer genomics; Mismatch repair; PMS2; Tumor mutational
                 burden",
  language    = "en"
}

@ARTICLE{Schwarz2014-ep,
  title       = "{MutationTaster2}: mutation prediction for the deep-sequencing
                 age",
  author      = "Schwarz, Jana Marie and Cooper, David N and Schuelke, Markus
                 and Seelow, Dominik",
  affiliation = "1] Department of Neuropediatrics, Charit{\'e} -
                 Universit{\"a}tsmedizin Berlin, Berlin, Germany. [2] NeuroCure
                 Clinical Research Center, Charit{\'e} -
                 Universit{\"a}tsmedizin Berlin, Berlin, Germany. Institute of
                 Medical Genetics, Cardiff University, Cardiff, UK. 1]
                 Department of Neuropediatrics, Charit{\'e} -
                 Universit{\"a}tsmedizin Berlin, Berlin, Germany. [2] NeuroCure
                 Clinical Research Center, Charit{\'e} -
                 Universit{\"a}tsmedizin Berlin, Berlin, Germany. 1] Department
                 of Neuropediatrics, Charit{\'e} - Universit{\"a}tsmedizin
                 Berlin, Berlin, Germany. [2] NeuroCure Clinical Research
                 Center, Charit{\'e} - Universit{\"a}tsmedizin Berlin, Berlin,
                 Germany.",
  journal     = "Nat. Methods",
  volume      =  11,
  number      =  4,
  pages       = "361--362",
  month       =  apr,
  year        =  2014,
  language    = "en"
}

@ARTICLE{Tomczak2015-da,
  title       = "The Cancer Genome Atlas ({TCGA)}: an immeasurable source of
                 knowledge",
  author      = "Tomczak, Katarzyna and Czerwi{\'n}ska, Patrycja and
                 Wiznerowicz, Maciej",
  affiliation = "Postgraduate School of Molecular Medicine, Medical University
                 of Warsaw, Warsaw, Poland ; Laboratory of Gene Therapy,
                 Department of Cancer Immunology, The Greater Poland Cancer
                 Centre, Poznan, Poland. Postgraduate School of Molecular
                 Medicine, Medical University of Warsaw, Warsaw, Poland ;
                 Laboratory of Gene Therapy, Department of Cancer Immunology,
                 The Greater Poland Cancer Centre, Poznan, Poland. Laboratory
                 of Gene Therapy, Department of Cancer Immunology, The Greater
                 Poland Cancer Centre, Poznan, Poland ; Department of Cancer
                 Immunology and Diagnostics, Chair of Medical Biotechnology,
                 Poznan University of Medical Sciences, Poznan, Poland.",
  abstract    = "The Cancer Genome Atlas (TCGA) is a public funded project that
                 aims to catalogue and discover major cancer-causing genomic
                 alterations to create a comprehensive ``atlas'' of cancer
                 genomic profiles. So far, TCGA researchers have analysed large
                 cohorts of over 30 human tumours through large-scale genome
                 sequencing and integrated multi-dimensional analyses. Studies
                 of individual cancer types, as well as comprehensive
                 pan-cancer analyses have extended current knowledge of
                 tumorigenesis. A major goal of the project was to provide
                 publicly available datasets to help improve diagnostic
                 methods, treatment standards, and finally to prevent cancer.
                 This review discusses the current status of TCGA Research
                 Network structure, purpose, and achievements.",
  journal     = "Contemp. Oncol.",
  volume      =  19,
  number      = "1A",
  pages       = "A68--77",
  year        =  2015,
  keywords    = "The Cancer Genome Atlas (TCGA); big data analysis; cancer
                 genomics",
  language    = "en"
}

@ARTICLE{Uzun2007-bk,
  title       = "Structure {SNP} ({StSNP)}: a web server for mapping and
                 modeling {nsSNPs} on protein structures with linkage to
                 metabolic pathways",
  author      = "Uzun, Alper and Leslin, Chesley M and Abyzov, Alexej and
                 Ilyin, Valentin",
  affiliation = "Department of Biology, Northeastern University, 360 Huntington
                 Ave., Boston, MA 02115, USA.",
  abstract    = "SNPs located within the open reading frame of a gene that
                 result in an alteration in the amino acid sequence of the
                 encoded protein [nonsynonymous SNPs (nsSNPs)] might directly
                 or indirectly affect functionality of the protein, alone or in
                 the interactions in a multi-protein complex, by
                 increasing/decreasing the activity of the metabolic pathway.
                 Understanding the functional consequences of such changes and
                 drawing conclusions about the molecular basis of diseases,
                 involves integrating information from multiple heterogeneous
                 sources including sequence, structure data and pathway
                 relations between proteins. The data from NCBI's SNP database
                 (dbSNP), gene and protein databases from Entrez, protein
                 structures from the PDB and pathway information from KEGG have
                 all been cross referenced into the StSNP web server, in an
                 effort to provide combined integrated, reports about nsSNPs.
                 StSNP provides 'on the fly' comparative modeling of nsSNPs
                 with links to metabolic pathway information, along with
                 real-time visual comparative analysis of the modeled
                 structures using the Friend software application. The use of
                 metabolic pathways in StSNP allows a researcher to examine
                 possible disease-related pathways associated with a particular
                 nsSNP(s), and link the diseases with the current available
                 molecular structure data. The server is publicly available at
                 http://glinka.bio.neu.edu/StSNP/.",
  journal     = "Nucleic Acids Res.",
  volume      =  35,
  number      = "Web Server issue",
  pages       = "W384--92",
  month       =  jul,
  year        =  2007,
  language    = "en"
}

@ARTICLE{Cerami2012-el,
  title       = "The cBio cancer genomics portal: an open platform for
                 exploring multidimensional cancer genomics data",
  author      = "Cerami, Ethan and Gao, Jianjiong and Dogrusoz, Ugur and Gross,
                 Benjamin E and Sumer, Selcuk Onur and Aksoy, B{\"u}lent Arman
                 and Jacobsen, Anders and Byrne, Caitlin J and Heuer, Michael L
                 and Larsson, Erik and Antipin, Yevgeniy and Reva, Boris and
                 Goldberg, Arthur P and Sander, Chris and Schultz, Nikolaus",
  affiliation = "Computational Biology Center, Memorial Sloan-Kettering Cancer
                 Center, New York, New York 10021, USA.
                 cancergenomics@cbio.mskcc.org",
  abstract    = "The cBio Cancer Genomics Portal (http://cbioportal.org) is an
                 open-access resource for interactive exploration of
                 multidimensional cancer genomics data sets, currently
                 providing access to data from more than 5,000 tumor samples
                 from 20 cancer studies. The cBio Cancer Genomics Portal
                 significantly lowers the barriers between complex genomic data
                 and cancer researchers who want rapid, intuitive, and
                 high-quality access to molecular profiles and clinical
                 attributes from large-scale cancer genomics projects and
                 empowers researchers to translate these rich data sets into
                 biologic insights and clinical applications.",
  journal     = "Cancer Discov.",
  volume      =  2,
  number      =  5,
  pages       = "401--404",
  month       =  may,
  year        =  2012,
  language    = "en"
}

@ARTICLE{Pedersen2016-pu,
  title       = "Vcfanno: fast, flexible annotation of genetic variants",
  author      = "Pedersen, Brent S and Layer, Ryan M and Quinlan, Aaron R",
  affiliation = "Department of Human Genetics, University of Utah, Salt Lake
                 City, UT, 84105, USA. bpederse@gmail.com. USTAR Center for
                 Genetic Discovery, University of Utah, Salt Lake City, UT,
                 84105, USA. bpederse@gmail.com. Department of Biomedical
                 Informatics, University of Utah, Salt Lake City, UT, 84105,
                 USA. bpederse@gmail.com. Department of Human Genetics,
                 University of Utah, Salt Lake City, UT, 84105, USA. USTAR
                 Center for Genetic Discovery, University of Utah, Salt Lake
                 City, UT, 84105, USA. Department of Biomedical Informatics,
                 University of Utah, Salt Lake City, UT, 84105, USA. Department
                 of Human Genetics, University of Utah, Salt Lake City, UT,
                 84105, USA. aquinlan@genetics.utah.edu. USTAR Center for
                 Genetic Discovery, University of Utah, Salt Lake City, UT,
                 84105, USA. aquinlan@genetics.utah.edu. Department of
                 Biomedical Informatics, University of Utah, Salt Lake City,
                 UT, 84105, USA. aquinlan@genetics.utah.edu.",
  abstract    = "The integration of genome annotations is critical to the
                 identification of genetic variants that are relevant to
                 studies of disease or other traits. However, comprehensive
                 variant annotation with diverse file formats is difficult with
                 existing methods. Here we describe vcfanno, which flexibly
                 extracts and summarizes attributes from multiple annotation
                 files and integrates the annotations within the INFO column of
                 the original VCF file. By leveraging a parallel ``chromosome
                 sweeping'' algorithm, we demonstrate substantial performance
                 gains by annotating ~85,000 variants per second with 50
                 attributes from 17 commonly used genome annotation resources.
                 Vcfanno is available at https://github.com/brentp/vcfanno
                 under the MIT license.",
  journal     = "Genome Biol.",
  volume      =  17,
  number      =  1,
  pages       = "118",
  month       =  "1~" # jun,
  year        =  2016,
  keywords    = "Annotation; Genetic variation; Genome analysis; SNP; VCF;
                 Variant; Variant prioritization",
  language    = "en"
}

@ARTICLE{Damodaran2015-so,
  title       = "Cancer Driver Log ({CanDL)}: Catalog of Potentially Actionable
                 Cancer Mutations",
  author      = "Damodaran, Senthilkumar and Miya, Jharna and Kautto, Esko and
                 Zhu, Eliot and Samorodnitsky, Eric and Datta, Jharna and
                 Reeser, Julie W and Roychowdhury, Sameek",
  affiliation = "Division of Medical Oncology, Department of Internal Medicine,
                 The Ohio State University, Columbus, Ohio. Comprehensive
                 Cancer Center, The Ohio State University, Columbus, Ohio.
                 Comprehensive Cancer Center, The Ohio State University,
                 Columbus, Ohio. Comprehensive Cancer Center, The Ohio State
                 University, Columbus, Ohio. Comprehensive Cancer Center, The
                 Ohio State University, Columbus, Ohio. Comprehensive Cancer
                 Center, The Ohio State University, Columbus, Ohio.
                 Comprehensive Cancer Center, The Ohio State University,
                 Columbus, Ohio. Division of Medical Oncology, Department of
                 Internal Medicine, The Ohio State University, Columbus, Ohio;
                 Comprehensive Cancer Center, The Ohio State University,
                 Columbus, Ohio; Department of Pharmacology, The Ohio State
                 University, Columbus, Ohio. Electronic address:
                 sameek.roychowdhury@osumc.edu.",
  abstract    = "Massively parallel sequencing technologies have enabled
                 characterization of genomic alterations across multiple tumor
                 types. Efforts have focused on identifying driver mutations
                 because they represent potential targets for therapy. However,
                 because of the presence of driver and passenger mutations, it
                 is often challenging to assign the clinical relevance of
                 specific mutations observed in patients. Currently, there are
                 multiple databases and tools that provide in silico assessment
                 for potential drivers; however, there is no comprehensive
                 resource for mutations with functional characterization.
                 Therefore, we created an expert-curated database of
                 potentially actionable driver mutations for molecular
                 pathologists to facilitate annotation of cancer genomic
                 testing. We reviewed scientific literature to identify
                 variants that have been functionally characterized in vitro or
                 in vivo as driver mutations. We obtained the chromosome
                 location and all possible nucleotide positions for each amino
                 acid change and uploaded them to the Cancer Driver Log (CanDL)
                 database with associated literature reference indicating
                 functional driver evidence. In addition to a simple interface,
                 the database allows users to download all or selected genes as
                 a comma-separated values file for incorporation into their own
                 analysis pipeline. Furthermore, the database includes a
                 mechanism for third-party contributions to support updates for
                 novel driver mutations. Overall, this freely available
                 database will facilitate rapid annotation of cancer genomic
                 testing in molecular pathology laboratories for mutations.",
  journal     = "J. Mol. Diagn.",
  volume      =  17,
  number      =  5,
  pages       = "554--559",
  month       =  sep,
  year        =  2015,
  language    = "en"
}

@MISC{noauthor_undated-ax,
  title        = "Therapeutically Applicable Research to Generate Effective
                  Treatments ({TARGET})",
  abstract     = "Therapeutically Applicable Research to Generate Effective
                  Treatments (TARGET) initiative studies the biology of
                  childhood cancers through comprehensive molecular
                  characterization.",
  howpublished = "\url{https://ocg.cancer.gov/programs/target}",
  note         = "Accessed: 2017-5-31"
}

@ARTICLE{Ruffalo2011-qb,
  title    = "Comparative analysis of algorithms for next-generation sequencing
              read alignment",
  author   = "Ruffalo, M and LaFramboise, T and Koyuturk, M",
  abstract = "MOTIVATION: The advent of next-generation sequencing (NGS)
              techniques presents many novel opportunities for many
              applications in life sciences. The vast number of short reads
              produced by these techniques, however, pose significant
              computational challenges. The first step in many types of genomic
              analysis is the mapping of short reads to a reference genome, and
              several groups have developed dedicated algorithms and software
              packages to perform this function. As the developers of these
              packages optimize their algorithms with respect to various
              considerations, the relative merits of different software
              packages remain unclear. However, for scientists who generate and
              use NGS data for their specific research projects, an important
              consideration is choosing the software that is most suitable for
              their application. RESULTS: With a view to comparing existing
              short read alignment software, we develop a simulation and
              evaluation suite, Seal, which simulates NGS runs for different
              configurations of various factors, including sequencing error,
              indels, and coverage. We also develop criteria to compare the
              performances of software with disparate output structure (e.g.,
              some packages return a single alignment while some return
              multiple possible alignments). Using these criteria, we
              comprehensively evaluate the performances of Bowtie, BWA, mr- and
              mrsFAST, Novoalign, SHRiMP and SOAPv2, with regard to accuracy
              and runtime. Conclusion: We expect that the results presented
              here will be useful to investigators in choosing the alignment
              software that is most suitable for their specific research aims.
              Our results also provide insights into the factors that should be
              considered to use alignment results effectively. Seal can also be
              used to evaluate the performance of algorithms that use deep
              sequencing data for various purposes (e.g., identification of
              genomic variants). AVAILABILITY: Seal is available as open-source
              at http://compbio.case.edu/seal/.",
  journal  = "Bioinformatics",
  month    =  "19~" # aug,
  year     =  2011
}

@ARTICLE{Simon2016-ik,
  title    = "Genomic {Alteration-Driven} Clinical Trial Designs in Oncology",
  author   = "Simon, Richard",
  abstract = "The established molecular heterogeneity of human cancers
              necessitates the development of new paradigms to serve as a
              reliable basis for precision medicine. The assumptions underlying
              some of the conventional approaches to clinical trial design and
              analysis are no longer appropriate because of the molecular
              heterogeneity of tumors of a given primary site. This article
              reviews some clinical trial designs that have been actively
              applied in the codevelopment of therapeutics and predictive
              biomarkers to inform their use in oncology. These include the
              enrichment design, the basket design, and the umbrella design.
              Oncology leads most other therapeutic areas in development of
              personalized or precision medicine. Personalized or precision
              medicine is practiced daily in oncology on the basis of tumor
              genomics and may evolve in other therapeutic areas as it has in
              oncology, rather than according to inherited polymorphisms as so
              often imagined. Consequently, some of the clinical trial designs
              described here may serve as a possible blueprint for therapeutic
              development in fields other than oncology.",
  journal  = "Ann. Intern. Med.",
  volume   =  165,
  number   =  4,
  pages    = "270--278",
  month    =  "16~" # aug,
  year     =  2016,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Reva2011-en,
  title       = "Predicting the functional impact of protein mutations:
                 application to cancer genomics",
  author      = "Reva, Boris and Antipin, Yevgeniy and Sander, Chris",
  affiliation = "Computational Biology Center, Memorial Sloan-Kettering Cancer
                 Center, NY 10065, USA.",
  abstract    = "As large-scale re-sequencing of genomes reveals many protein
                 mutations, especially in human cancer tissues, prediction of
                 their likely functional impact becomes important practical
                 goal. Here, we introduce a new functional impact score (FIS)
                 for amino acid residue changes using evolutionary conservation
                 patterns. The information in these patterns is derived from
                 aligned families and sub-families of sequence homologs within
                 and between species using combinatorial entropy formalism. The
                 score performs well on a large set of human protein mutations
                 in separating disease-associated variants (19 200), assumed
                 to be strongly functional, from common polymorphisms (35
                 600), assumed to be weakly functional (area under the receiver
                 operating characteristic curve of 0.86). In cancer, using
                 recurrence, multiplicity and annotation for 10 000 mutations
                 in the COSMIC database, the method does well in assigning
                 higher scores to more likely functional mutations ('drivers').
                 To guide experimental prioritization, we report a list of
                 about 1000 top human cancer genes frequently mutated in one or
                 more cancer types ranked by likely functional impact; and, an
                 additional 1000 candidate cancer genes with rare but likely
                 functional mutations. In addition, we estimate that at least
                 5\% of cancer-relevant mutations involve switch of function,
                 rather than simply loss or gain of function.",
  journal     = "Nucleic Acids Res.",
  volume      =  39,
  number      =  17,
  pages       = "e118",
  month       =  "1~" # sep,
  year        =  2011,
  language    = "en"
}

@ARTICLE{Wheeler2013-dn,
  title       = "Cancer pharmacogenomics: strategies and challenges",
  author      = "Wheeler, Heather E and Maitland, Michael L and Dolan, M Eileen
                 and Cox, Nancy J and Ratain, Mark J",
  affiliation = "Committee on Clinical Pharmacology and Pharmacogenomics,
                 University of Chicago, 900 East 57th Street, Chicago, Illinois
                 60637, USA.",
  abstract    = "Genetic variation influences the response of an individual to
                 drug treatments. Understanding this variation has the
                 potential to make therapy safer and more effective by
                 determining selection and dosing of drugs for an individual
                 patient. In the context of cancer, tumours may have specific
                 disease-defining mutations, but a patient's germline genetic
                 variation will also affect drug response (both efficacy and
                 toxicity), and here we focus on how to study this variation.
                 Advances in sequencing technologies, statistical genetics
                 analysis methods and clinical trial designs have shown promise
                 for the discovery of variants associated with drug response.
                 We discuss the application of germline genetics analysis
                 methods to cancer pharmacogenomics with a focus on the special
                 considerations for study design.",
  journal     = "Nat. Rev. Genet.",
  volume      =  14,
  number      =  1,
  pages       = "23--34",
  month       =  jan,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Li2009-zs,
  title    = "Fast and accurate short read alignment with {Burrows-Wheeler}
              transform",
  author   = "Li, Heng and Durbin, Richard",
  abstract = "MOTIVATION: The enormous amount of short reads generated by the
              new DNA sequencing technologies call for the development of fast
              and accurate read alignment programs. A first generation of hash
              table-based methods has been developed, including MAQ, which is
              accurate, feature rich and fast enough to align short reads from
              a single individual. However, MAQ does not support gapped
              alignment for single-end reads, which makes it unsuitable for
              alignment of longer reads where indels may occur frequently. The
              speed of MAQ is also a concern when the alignment is scaled up to
              the resequencing of hundreds of individuals. RESULTS: We
              implemented Burrows-Wheeler Alignment tool (BWA), a new read
              alignment package that is based on backward search with
              Burrows-Wheeler Transform (BWT), to efficiently align short
              sequencing reads against a large reference sequence such as the
              human genome, allowing mismatches and gaps. BWA supports both
              base space reads, e.g. from Illumina sequencing machines, and
              color space reads from AB SOLiD machines. Evaluations on both
              simulated and real data suggest that BWA is approximately 10-20x
              faster than MAQ, while achieving similar accuracy. In addition,
              BWA outputs alignment in the new standard SAM (Sequence
              Alignment/Map) format. Variant calling and other downstream
              analyses after the alignment can be achieved with the open source
              SAMtools software package. AVAILABILITY:
              http://maq.sourceforge.net.",
  journal  = "Bioinformatics",
  volume   =  25,
  number   =  14,
  pages    = "1754--1760",
  month    =  jul,
  year     =  2009
}

@ARTICLE{Calabrese2009-mi,
  title       = "Functional annotations improve the predictive score of human
                 disease-related mutations in proteins",
  author      = "Calabrese, Remo and Capriotti, Emidio and Fariselli, Piero and
                 Martelli, Pier Luigi and Casadio, Rita",
  affiliation = "Laboratory of Biocomputing, CIRB/Department of Biology,
                 University of Bologna, Bologna 40126, Italy.",
  abstract    = "Single nucleotide polymorphisms (SNPs) are the simplest and
                 most frequent form of human DNA variation, also valuable as
                 genetic markers of disease susceptibility. The most
                 investigated SNPs are missense mutations resulting in residue
                 substitutions in the protein. Here we propose SNPs\&GO, an
                 accurate method that, starting from a protein sequence, can
                 predict whether a mutation is disease related or not by
                 exploiting the protein functional annotation. The scoring
                 efficiency of SNPs\&GO is as high as 82\%, with a Matthews
                 correlation coefficient equal to 0.63 over a wide set of
                 annotated nonsynonymous mutations in proteins, including
                 16,330 disease-related and 17,432 neutral polymorphisms.
                 SNPs\&GO collects in unique framework information derived from
                 protein sequence, evolutionary information, and function as
                 encoded in the Gene Ontology terms, and outperforms other
                 available predictive methods.",
  journal     = "Hum. Mutat.",
  volume      =  30,
  number      =  8,
  pages       = "1237--1244",
  month       =  aug,
  year        =  2009,
  language    = "en"
}

@ARTICLE{Li2008-kx,
  title    = "Mapping short {DNA} sequencing reads and calling variants using
              mapping quality scores",
  author   = "Li, Heng and Ruan, Jue and Durbin, Richard",
  abstract = "New sequencing technologies promise a new era in the use of DNA
              sequence. However, some of these technologies produce very short
              reads, typically of a few tens of base pairs, and to use these
              reads effectively requires new algorithms and software. In
              particular, there is a major issue in efficiently aligning short
              reads to a reference genome and handling ambiguity or lack of
              accuracy in this alignment. Here we introduce the concept of
              mapping quality, a measure of the confidence that a read actually
              comes from the position it is aligned to by the mapping
              algorithm. We describe the software MAQ that can build assemblies
              by mapping shotgun short reads to a reference genome, using
              quality scores to derive genotype calls of the consensus sequence
              of a diploid genome, e.g., from a human sample. MAQ makes full
              use of mate-pair information and estimates the error probability
              of each read alignment. Error probabilities are also derived for
              the final genotype calls, using a Bayesian statistical model that
              incorporates the mapping qualities, error probabilities from the
              raw sequence quality scores, sampling of the two haplotypes, and
              an empirical model for correlated errors at a site. Both read
              mapping and genotype calling are evaluated on simulated data and
              real data. MAQ is accurate, efficient, versatile, and
              user-friendly. It is freely available at
              http://maq.sourceforge.net.",
  journal  = "Genome Res.",
  volume   =  18,
  number   =  11,
  pages    = "1851--1858",
  month    =  nov,
  year     =  2008,
  keywords = "Algorithms; Bacterial; Bacterial: genetics; Bayes Theorem;
              Chromosome Mapping; Chromosome Mapping: statistics \& numerical
              data; Computer Simulation; DNA; DNA: genetics; DNA: statistics \&
              numerical data; Diploidy; Genome; Human; Humans; Polymorphism;
              Reproducibility of Results; Salmonella paratyphi A; Salmonella
              paratyphi A: genetics; Sequence Alignment; Sequence Alignment:
              statistics \& numerical data; Sequence Analysis; Single
              Nucleotide; Software"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Landrum2016-ul,
  title       = "{ClinVar}: public archive of interpretations of clinically
                 relevant variants",
  author      = "Landrum, Melissa J and Lee, Jennifer M and Benson, Mark and
                 Brown, Garth and Chao, Chen and Chitipiralla, Shanmuga and Gu,
                 Baoshan and Hart, Jennifer and Hoffman, Douglas and Hoover,
                 Jeffrey and Jang, Wonhee and Katz, Kenneth and Ovetsky,
                 Michael and Riley, George and Sethi, Amanjeev and Tully, Ray
                 and Villamarin-Salomon, Ricardo and Rubinstein, Wendy and
                 Maglott, Donna R",
  affiliation = "National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA landrum@ncbi.nlm.nih.gov. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, MD 20893, USA.
                 National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA. National Center for Biotechnology Information,
                 National Library of Medicine, National Institutes of Health,
                 Bethesda, MD 20893, USA. National Center for Biotechnology
                 Information, National Library of Medicine, National Institutes
                 of Health, Bethesda, MD 20893, USA. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, MD 20893, USA.
                 National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA. National Center for Biotechnology Information,
                 National Library of Medicine, National Institutes of Health,
                 Bethesda, MD 20893, USA. National Center for Biotechnology
                 Information, National Library of Medicine, National Institutes
                 of Health, Bethesda, MD 20893, USA. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, MD 20893, USA.
                 National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA. National Center for Biotechnology Information,
                 National Library of Medicine, National Institutes of Health,
                 Bethesda, MD 20893, USA. National Center for Biotechnology
                 Information, National Library of Medicine, National Institutes
                 of Health, Bethesda, MD 20893, USA. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, MD 20893, USA.
                 National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA. National Center for Biotechnology Information,
                 National Library of Medicine, National Institutes of Health,
                 Bethesda, MD 20893, USA. National Center for Biotechnology
                 Information, National Library of Medicine, National Institutes
                 of Health, Bethesda, MD 20893, USA. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, MD 20893, USA.
                 National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD 20893, USA.",
  abstract    = "ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) at the
                 National Center for Biotechnology Information (NCBI) is a
                 freely available archive for interpretations of clinical
                 significance of variants for reported conditions. The database
                 includes germline and somatic variants of any size, type or
                 genomic location. Interpretations are submitted by clinical
                 testing laboratories, research laboratories, locus-specific
                 databases, OMIM\textregistered{}, GeneReviews, UniProt,
                 expert panels and practice guidelines. In NCBI's Variation
                 submission portal, submitters upload batch submissions or use
                 the Submission Wizard for single submissions. Each submitted
                 interpretation is assigned an accession number prefixed with
                 SCV. ClinVar staff review validation reports with data types
                 such as HGVS (Human Genome Variation Society) expressions;
                 however, clinical significance is reported directly from
                 submitters. Interpretations are aggregated by
                 variant-condition combination and assigned an accession number
                 prefixed with RCV. Clinical significance is calculated for the
                 aggregate record, indicating consensus or conflict in the
                 submitted interpretations. ClinVar uses data standards, such
                 as HGVS nomenclature for variants and MedGen identifiers for
                 conditions. The data are available on the web as
                 variant-specific views; the entire data set can be downloaded
                 via ftp. Programmatic access for ClinVar records is available
                 through NCBI's E-utilities. Future development includes
                 providing a variant-centric XML archive and a web page for
                 details of SCV submissions.",
  journal     = "Nucleic Acids Res.",
  volume      =  44,
  number      = "D1",
  pages       = "D862--8",
  month       =  "4~" # jan,
  year        =  2016,
  language    = "en"
}

@ARTICLE{Eilbeck2005-js,
  title       = "The Sequence Ontology: a tool for the unification of genome
                 annotations",
  author      = "Eilbeck, Karen and Lewis, Suzanna E and Mungall, Christopher J
                 and Yandell, Mark and Stein, Lincoln and Durbin, Richard and
                 Ashburner, Michael",
  affiliation = "Department of Molecular and Cellular Biology, Life Sciences
                 Addition, University of California, Berkeley, CA 94729-3200,
                 USA. keilbeck@fruitfly.org",
  abstract    = "The Sequence Ontology (SO) is a structured controlled
                 vocabulary for the parts of a genomic annotation. SO provides
                 a common set of terms and definitions that will facilitate the
                 exchange, analysis and management of genomic data. Because SO
                 treats part-whole relationships rigorously, data described
                 with it can become substrates for automated reasoning, and
                 instances of sequence features described by the SO can be
                 subjected to a group of logical operations termed extensional
                 mereology operators.",
  journal     = "Genome Biol.",
  volume      =  6,
  number      =  5,
  pages       = "R44",
  month       =  "29~" # apr,
  year        =  2005,
  language    = "en"
}

@ARTICLE{Bryce2017-ht,
  title       = "Experience with precision genomics and tumor board, indicates
                 frequent target identification, but barriers to delivery",
  author      = "Bryce, Alan H and Egan, Jan B and Borad, Mitesh J and Stewart,
                 A Keith and Nowakowski, Grzegorz S and Chanan-Khan, Asher and
                 Patnaik, Mrinal M and Ansell, Stephen M and Banck, Michaela S
                 and Robinson, Steven I and Mansfield, Aaron S and Klee, Eric W
                 and Oliver, Gavin R and McCormick, Jennifer B and Huneke,
                 Norine E and Tagtow, Colleen M and Jenkins, Robert B and
                 Rumilla, Kandelaria M and Kerr, Sarah E and Kocher,
                 Jean-Pierre A and Beck, Scott A and Fernandez-Zapico, Martin E
                 and Farrugia, Gianrico and Lazaridis, Konstantinos N and
                 McWilliams, Robert R",
  affiliation = "Hematology/Oncology, Mayo Clinic, Phoenix, AZ, U.S.A. Mayo
                 Clinic Cancer Center, Phoenix, AZ, U.S.A. Center for
                 Individualized Medicine, Mayo Clinic, Rochester, MN, U.S.A.
                 Center for Individualized Medicine, Mayo Clinic, Rochester,
                 MN, U.S.A. Hematology/Oncology, Mayo Clinic, Phoenix, AZ,
                 U.S.A. Mayo Clinic Cancer Center, Phoenix, AZ, U.S.A. Center
                 for Individualized Medicine, Mayo Clinic, Rochester, MN,
                 U.S.A. Hematology/Oncology, Mayo Clinic, Phoenix, AZ, U.S.A.
                 Mayo Clinic Cancer Center, Phoenix, AZ, U.S.A. Center for
                 Individualized Medicine, Mayo Clinic, Rochester, MN, U.S.A.
                 Center for Individualized Medicine, Mayo Clinic, Rochester,
                 MN, U.S.A. Hematology, Mayo Clinic, Rochester, MN, U.S.A.
                 Center for Individualized Medicine, Mayo Clinic, Rochester,
                 MN, U.S.A. Hematology/Oncology, Mayo Clinic, Jacksonville, FL,
                 U.S.A. Center for Individualized Medicine, Mayo Clinic,
                 Rochester, MN, U.S.A. Hematology, Mayo Clinic, Rochester, MN,
                 U.S.A. Center for Individualized Medicine, Mayo Clinic,
                 Rochester, MN, U.S.A. Hematology, Mayo Clinic, Rochester, MN,
                 U.S.A. Center for Individualized Medicine, Mayo Clinic,
                 Rochester, MN, U.S.A. Medical Oncology, Mayo Clinic,
                 Rochester, MN, U.S.A. Center for Individualized Medicine, Mayo
                 Clinic, Rochester, MN, U.S.A. Medical Oncology, Mayo Clinic,
                 Rochester, MN, U.S.A. Center for Individualized Medicine, Mayo
                 Clinic, Rochester, MN, U.S.A. Medical Oncology, Mayo Clinic,
                 Rochester, MN, U.S.A. Center for Individualized Medicine, Mayo
                 Clinic, Rochester, MN, U.S.A. Health Sciences Research, Mayo
                 Clinic, Rochester, MN, U.S.A. Center for Individualized
                 Medicine, Mayo Clinic, Rochester, MN, U.S.A. Health Sciences
                 Research, Mayo Clinic, Rochester, MN, U.S.A. Health Sciences
                 Research, Mayo Clinic, Rochester, MN, U.S.A. Center for
                 Individualized Medicine, Mayo Clinic, Rochester, MN, U.S.A.
                 Center for Individualized Medicine, Mayo Clinic, Rochester,
                 MN, U.S.A. Laboratory Medicine and Pathology, Mayo Clinic,
                 Rochester, MN, U.S.A. Laboratory Medicine and Pathology, Mayo
                 Clinic, Rochester, MN, U.S.A. Anatomic Pathology, Mayo Clinic,
                 Rochester, MN, U.S.A. Center for Individualized Medicine, Mayo
                 Clinic, Rochester, MN, U.S.A. Health Sciences Research, Mayo
                 Clinic, Rochester, MN, U.S.A. Center for Individualized
                 Medicine, Mayo Clinic, Rochester, MN, U.S.A. Schulze Center
                 for Novel Therapeutics, Division of Oncology Research, Medical
                 Oncology, Mayo Clinic, Rochester, MN, U.S.A. Center for
                 Individualized Medicine, Mayo Clinic, Rochester, MN, U.S.A.
                 Gastroenterology, Mayo Clinic, Rochester, MN, U.S.A. Center
                 for Individualized Medicine, Mayo Clinic, Rochester, MN,
                 U.S.A. Gastroenterology, Mayo Clinic, Rochester, MN, U.S.A.
                 Center for Individualized Medicine, Mayo Clinic, Rochester,
                 MN, U.S.A. Medical Oncology, Mayo Clinic, Rochester, MN,
                 U.S.A. Mayo Clinic Cancer Center, Rochester, MN, U.S.A.",
  abstract    = "BACKGROUND: The ability to analyze the genomics of
                 malignancies has opened up new possibilities for off-label
                 targeted therapy in cancers that are refractory to standard
                 therapy. At Mayo Clinic these efforts are organized through
                 the Center for Individualized Medicine (CIM). RESULTS: Prior
                 to GTB, datasets were analyzed and integrated by a team of
                 bioinformaticians and cancer biologists. Therapeutically
                 actionable mutations were identified in 65\% (92/141) of the
                 patients tested with 32\% (29/92) receiving genomically
                 targeted therapy with FDA approved drugs or in an independent
                 clinical trial with 45\% (13/29) responding. Standard of care
                 (SOC) options were continued by 15\% (14/92) of patients
                 tested before exhausting SOC options, with 71\% (10/14)
                 responding to treatment. Over 35\% (34/92) of patients with
                 actionable targets were not treated with 65\% (22/34) choosing
                 comfort measures or passing away. MATERIALS AND METHODS:
                 Patients (N = 165) were referred to the CIM Clinic between
                 October 2012 and December 2015. All patients received clinical
                 genomic panel testing with selected subsets receiving array
                 comparative genomic hybridization and clinical whole exome
                 sequencing to complement and validate panel findings. A
                 genomic tumor board (GTB) reviewed results and, when possible,
                 developed treatment recommendations. CONCLUSIONS: Treatment
                 decisions driven by tumor genomic analysis can lead to
                 significant clinical benefit in a minority of patients. The
                 success of genomically driven therapy depends both on access
                 to drugs and robustness of bioinformatics analysis. While
                 novel clinical trial designs are increasing the utility of
                 genomic testing, robust data sharing of outcomes is needed to
                 optimize clinical benefit for all patients.",
  journal     = "Oncotarget",
  volume      =  8,
  number      =  16,
  pages       = "27145--27154",
  month       =  "18~" # apr,
  year        =  2017,
  keywords    = "cancer genomics; genomic tumor board; precision medicine;
                 targeted therapeutics",
  language    = "en"
}

@ARTICLE{Cancer_Genome_Atlas_Research_Network2015-gd,
  title    = "The Molecular Taxonomy of Primary Prostate Cancer",
  author   = "{Cancer Genome Atlas Research Network}",
  abstract = "There is substantial heterogeneity among primary prostate
              cancers, evident in the spectrum of molecular abnormalities and
              its variable clinical course. As part of The Cancer Genome Atlas
              (TCGA), we present a comprehensive molecular analysis of 333
              primary prostate carcinomas. Our results revealed a molecular
              taxonomy in which 74\% of these tumors fell into one of seven
              subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1)
              or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed
              substantial heterogeneity, including an IDH1 mutant subset with a
              methylator phenotype. Androgen receptor (AR) activity varied
              widely and in a subtype-specific manner, with SPOP and FOXA1
              mutant tumors having the highest levels of AR-induced
              transcripts. 25\% of the prostate cancers had a presumed
              actionable lesion in the PI3K or MAPK signaling pathways, and DNA
              repair genes were inactivated in 19\%. Our analysis reveals
              molecular heterogeneity among primary prostate cancers, as well
              as potentially actionable molecular defects.",
  journal  = "Cell",
  volume   =  163,
  number   =  4,
  pages    = "1011--1025",
  month    =  "5~" # nov,
  year     =  2015,
  language = "en"
}

@ARTICLE{Micheel2014-pz,
  title     = "My Cancer Genome",
  author    = "Micheel, Christine M and Lovly, Christine M and Levy, Mia A",
  journal   = "Cancer Genet.",
  publisher = "Elsevier",
  volume    =  207,
  number    =  6,
  pages     = "289",
  month     =  "1~" # jun,
  year      =  2014
}

@ARTICLE{Ashburner2000-gm,
  title     = "Gene Ontology: tool for the unification of biology",
  author    = "Ashburner, Michael and Ball, Catherine A and Blake, Judith A and
               Botstein, David and Butler, Heather and Michael Cherry, J and
               Davis, Allan P and Dolinski, Kara and Dwight, Selina S and
               Eppig, Janan T and Harris, Midori A and Hill, David P and
               Issel-Tarver, Laurie and Kasarskis, Andrew and Lewis, Suzanna
               and Matese, John C and Richardson, Joel E and Ringwald, Martin
               and Rubin, Gerald M and Sherlock, Gavin",
  abstract  = "Genomic sequencing has made it clear that a large fraction of
               the genes specifying the core biological functions are shared by
               all eukaryotes. Knowledge of the biological role of such shared
               proteins in one organism can often be transferred to other
               organisms. The goal of the Gene Ontology Consortium is to
               produce a dynamic, controlled vocabulary that can be applied to
               all eukaryotes even as knowledge of gene and protein roles in
               cells is accumulating and changing. To this end, three
               independent ontologies accessible on the World-Wide Web
               (http://www.geneontology.org) are being constructed: biological
               process, molecular function and cellular component.",
  journal   = "Nat. Genet.",
  publisher = "Nature Publishing Group",
  volume    =  25,
  number    =  1,
  pages     = "25--29",
  month     =  "1~" # may,
  year      =  2000,
  language  = "en"
}

@ARTICLE{Hedley_Carr2016-ul,
  title     = "Defining actionable mutations for oncology therapeutic
               development",
  author    = "Hedley Carr, T and McEwen, Robert and Dougherty, Brian and
               Johnson, Justin H and Dry, Jonathan R and Lai, Zhongwu and
               Ghazoui, Zara and Laing, Naomi M and Hodgson, Darren R and
               Cruzalegui, Francisco and Hollingsworth, Simon J and Carl
               Barrett, J",
  journal   = "Nat. Rev. Cancer",
  publisher = "Nature Research",
  volume    =  16,
  number    =  5,
  pages     = "319--329",
  month     =  "26~" # apr,
  year      =  2016,
  language  = "en"
}

@ARTICLE{Ramos2015-vn,
  title       = "Oncotator: cancer variant annotation tool",
  author      = "Ramos, Alex H and Lichtenstein, Lee and Gupta, Manaswi and
                 Lawrence, Michael S and Pugh, Trevor J and Saksena, Gordon and
                 Meyerson, Matthew and Getz, Gad",
  affiliation = "Cancer Program, Broad Institute, Cambridge, MA 02142, USA;
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, MA 02115, USA; Department of Pathology, Harvard
                 Medical School, Boston, MA 02115, USA; Cancer Center and
                 Department of Pathology, Massachusetts General Hospital,
                 Boston, MA 02114, USA.",
  abstract    = "Oncotator is a tool for annotating genomic point mutations and
                 short nucleotide insertions/deletions (indels) with variant-
                 and gene-centric information relevant to cancer researchers.
                 This information is drawn from 14 different publicly available
                 resources that have been pooled and indexed, and we provide an
                 extensible framework to add additional data sources.
                 Annotations linked to variants range from basic information,
                 such as gene names and functional classification (e.g.
                 missense), to cancer-specific data from resources such as the
                 Catalogue of Somatic Mutations in Cancer (COSMIC), the Cancer
                 Gene Census, and The Cancer Genome Atlas (TCGA). For local
                 use, Oncotator is freely available as a python module hosted
                 on Github (https://github.com/broadinstitute/oncotator).
                 Furthermore, Oncotator is also available as a web service and
                 web application at http://www.broadinstitute.org/oncotator/.",
  journal     = "Hum. Mutat.",
  volume      =  36,
  number      =  4,
  pages       = "E2423--9",
  month       =  apr,
  year        =  2015,
  keywords    = "TCGA; annotation; cancer; database; oncotator",
  language    = "en"
}

@ARTICLE{Sherry2001-li,
  title       = "{dbSNP}: the {NCBI} database of genetic variation",
  author      = "Sherry, S T and Ward, M H and Kholodov, M and Baker, J and
                 Phan, L and Smigielski, E M and Sirotkin, K",
  affiliation = "National Center for Biotechnology Information, National
                 Library of Medicine, National Institutes of Health, Bethesda,
                 MD, 20894, USA. sherry@ncbi.nlm.nih.gov",
  abstract    = "In response to a need for a general catalog of genome
                 variation to address the large-scale sampling designs required
                 by association studies, gene mapping and evolutionary biology,
                 the National Center for Biotechnology Information (NCBI) has
                 established the dbSNP database [S.T.Sherry, M.Ward and K.
                 Sirotkin (1999) Genome Res., 9, 677-679]. Submissions to dbSNP
                 will be integrated with other sources of information at NCBI
                 such as GenBank, PubMed, LocusLink and the Human Genome
                 Project data. The complete contents of dbSNP are available to
                 the public at website: http://www.ncbi.nlm.nih.gov/SNP. The
                 complete contents of dbSNP can also be downloaded in multiple
                 formats via anonymous FTP at ftp://ncbi.nlm.nih.gov/snp/.",
  journal     = "Nucleic Acids Res.",
  volume      =  29,
  number      =  1,
  pages       = "308--311",
  month       =  "1~" # jan,
  year        =  2001,
  language    = "en"
}

@ARTICLE{Sohal2015-bi,
  title       = "Prospective Clinical Study of Precision Oncology in Solid
                 Tumors",
  author      = "Sohal, Davendra P S and Rini, Brian I and Khorana, Alok A and
                 Dreicer, Robert and Abraham, Jame and Procop, Gary W and
                 Saunthararajah, Yogen and Pennell, Nathan A and Stevenson,
                 James P and Pelley, Robert and Estfan, Bassam and Shepard,
                 Dale and Funchain, Pauline and Elson, Paul and Adelstein,
                 David J and Bolwell, Brian J",
  affiliation = "Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
                 (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). sohald@ccf.org. Taussig Cancer
                 Institute, Cleveland Clinic, Cleveland, OH (DPSS, BIR, AAK,
                 RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF, PE, DJA, BJB);
                 University of Virginia School of Medicine, Charlottesville, VA
                 (RD). Taussig Cancer Institute, Cleveland Clinic, Cleveland,
                 OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). Taussig Cancer Institute, Cleveland
                 Clinic, Cleveland, OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP,
                 JPS, RP, BE, DS, PF, PE, DJA, BJB); University of Virginia
                 School of Medicine, Charlottesville, VA (RD). Taussig Cancer
                 Institute, Cleveland Clinic, Cleveland, OH (DPSS, BIR, AAK,
                 RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF, PE, DJA, BJB);
                 University of Virginia School of Medicine, Charlottesville, VA
                 (RD). Taussig Cancer Institute, Cleveland Clinic, Cleveland,
                 OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). Taussig Cancer Institute, Cleveland
                 Clinic, Cleveland, OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP,
                 JPS, RP, BE, DS, PF, PE, DJA, BJB); University of Virginia
                 School of Medicine, Charlottesville, VA (RD). Taussig Cancer
                 Institute, Cleveland Clinic, Cleveland, OH (DPSS, BIR, AAK,
                 RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF, PE, DJA, BJB);
                 University of Virginia School of Medicine, Charlottesville, VA
                 (RD). Taussig Cancer Institute, Cleveland Clinic, Cleveland,
                 OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). Taussig Cancer Institute, Cleveland
                 Clinic, Cleveland, OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP,
                 JPS, RP, BE, DS, PF, PE, DJA, BJB); University of Virginia
                 School of Medicine, Charlottesville, VA (RD). Taussig Cancer
                 Institute, Cleveland Clinic, Cleveland, OH (DPSS, BIR, AAK,
                 RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF, PE, DJA, BJB);
                 University of Virginia School of Medicine, Charlottesville, VA
                 (RD). Taussig Cancer Institute, Cleveland Clinic, Cleveland,
                 OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). Taussig Cancer Institute, Cleveland
                 Clinic, Cleveland, OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP,
                 JPS, RP, BE, DS, PF, PE, DJA, BJB); University of Virginia
                 School of Medicine, Charlottesville, VA (RD). Taussig Cancer
                 Institute, Cleveland Clinic, Cleveland, OH (DPSS, BIR, AAK,
                 RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF, PE, DJA, BJB);
                 University of Virginia School of Medicine, Charlottesville, VA
                 (RD). Taussig Cancer Institute, Cleveland Clinic, Cleveland,
                 OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP, JPS, RP, BE, DS, PF,
                 PE, DJA, BJB); University of Virginia School of Medicine,
                 Charlottesville, VA (RD). Taussig Cancer Institute, Cleveland
                 Clinic, Cleveland, OH (DPSS, BIR, AAK, RD, JA, GWP, YS, NAP,
                 JPS, RP, BE, DS, PF, PE, DJA, BJB); University of Virginia
                 School of Medicine, Charlottesville, VA (RD).",
  abstract    = "Systematic studies evaluating clinical benefit of tumor
                 genomic profiling are lacking. We conducted a prospective
                 study in 250 patients with select solid tumors at the
                 Cleveland Clinic. Eligibility required histopathologic
                 diagnosis, age of 18 years or older, Eastern Cooperative
                 Oncology Group performance status 0-2, and written informed
                 consent. Tumors were sequenced using FoundationOne (Cambridge,
                 MA). Results were reviewed at the Cleveland Clinic Genomics
                 Tumor Board. Outcomes included feasibility and clinical
                 impact. Colorectal (25\%), breast (18\%), lung (13\%), and
                 pancreatobiliary (13\%) cancers were the most common
                 diagnoses. Median time from consent to result was 25 days
                 (range = 3-140). Of 223 evaluable samples, 49\% (n = 109) of
                 patients were recommended a specific therapy, but only 11\% (n
                 = 24) received such therapy: 12 on clinical trials, nine
                 off-label, three on-label. Lack of clinical trial access (n =
                 49) and clinical deterioration (n = 29) were the most common
                 reasons for nonrecommendation/nonreceipt of genomics-driven
                 therapy.",
  journal     = "J. Natl. Cancer Inst.",
  volume      =  108,
  number      =  3,
  month       =  "9~" # nov,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Ng2003-vp,
  title       = "{SIFT}: Predicting amino acid changes that affect protein
                 function",
  author      = "Ng, Pauline C and Henikoff, Steven",
  affiliation = "Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N
                 A1-162, Seattle, WA 98109, USA.",
  abstract    = "Single nucleotide polymorphism (SNP) studies and random
                 mutagenesis projects identify amino acid substitutions in
                 protein-coding regions. Each substitution has the potential to
                 affect protein function. SIFT (Sorting Intolerant From
                 Tolerant) is a program that predicts whether an amino acid
                 substitution affects protein function so that users can
                 prioritize substitutions for further study. We have shown that
                 SIFT can distinguish between functionally neutral and
                 deleterious amino acid changes in mutagenesis studies and on
                 human polymorphisms. SIFT is available at
                 http://blocks.fhcrc.org/sift/SIFT.html.",
  journal     = "Nucleic Acids Res.",
  volume      =  31,
  number      =  13,
  pages       = "3812--3814",
  month       =  "1~" # jul,
  year        =  2003,
  language    = "en"
}

@ARTICLE{Gonzalez-Perez2013-cl,
  title       = "{IntOGen-mutations} identifies cancer drivers across tumor
                 types",
  author      = "Gonzalez-Perez, Abel and Perez-Llamas, Christian and Deu-Pons,
                 Jordi and Tamborero, David and Schroeder, Michael P and
                 Jene-Sanz, Alba and Santos, Alberto and Lopez-Bigas, Nuria",
  affiliation = "Research Unit on Biomedical Informatics, Department of
                 Experimental and Health Sciences, Pompeu Fabra University,
                 Barcelona, Spain.",
  abstract    = "The IntOGen-mutations platform
                 (http://www.intogen.org/mutations/) summarizes somatic
                 mutations, genes and pathways involved in tumorigenesis. It
                 identifies and visualizes cancer drivers, analyzing 4,623
                 exomes from 13 cancer sites. It provides support to cancer
                 researchers, aids the identification of drivers across tumor
                 cohorts and helps rank mutations for better clinical
                 decision-making.",
  journal     = "Nat. Methods",
  volume      =  10,
  number      =  11,
  pages       = "1081--1082",
  month       =  nov,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Pollard2010-of,
  title       = "Detection of nonneutral substitution rates on mammalian
                 phylogenies",
  author      = "Pollard, Katherine S and Hubisz, Melissa J and Rosenbloom,
                 Kate R and Siepel, Adam",
  affiliation = "Gladstone Institutes, University of California, San Francisco,
                 San Francisco, California 94158, USA.
                 kpollard@gladstone.ucsf.edu",
  abstract    = "Methods for detecting nucleotide substitution rates that are
                 faster or slower than expected under neutral drift are widely
                 used to identify candidate functional elements in genomic
                 sequences. However, most existing methods consider either
                 reductions (conservation) or increases (acceleration) in rate
                 but not both, or assume that selection acts uniformly across
                 the branches of a phylogeny. Here we examine the more general
                 problem of detecting departures from the neutral rate of
                 substitution in either direction, possibly in a clade-specific
                 manner. We consider four statistical, phylogenetic tests for
                 addressing this problem: a likelihood ratio test, a score
                 test, a test based on exact distributions of numbers of
                 substitutions, and the genomic evolutionary rate profiling
                 (GERP) test. All four tests have been implemented in a freely
                 available program called phyloP. Based on extensive simulation
                 experiments, these tests are remarkably similar in statistical
                 power. With 36 mammalian species, they all appear to be
                 capable of fairly good sensitivity with low false-positive
                 rates in detecting strong selection at individual nucleotides,
                 moderate selection in 3-bp elements, and weaker or
                 clade-specific selection in longer elements. By applying
                 phyloP to mammalian multiple alignments from the ENCODE
                 project, we shed light on patterns of
                 conservation/acceleration in known and predicted functional
                 elements, approximate fractions of sites subject to
                 constraint, and differences in clade-specific selection in the
                 primate and glires clades. We also describe new
                 ``Conservation'' tracks in the UCSC Genome Browser that
                 display both phyloP and phastCons scores for genome-wide
                 alignments of 44 vertebrate species.",
  journal     = "Genome Res.",
  volume      =  20,
  number      =  1,
  pages       = "110--121",
  month       =  jan,
  year        =  2010,
  language    = "en"
}

@ARTICLE{Grupp2013-nd,
  title     = "Chimeric Antigen {Receptor--Modified} {T} Cells for Acute
               Lymphoid Leukemia",
  author    = "Grupp, Stephan A and Kalos, Michael and Barrett, David and
               Aplenc, Richard and Porter, David L and Rheingold, Susan R and
               Teachey, David T and Chew, Anne and Hauck, Bernd and Wright, J
               Fraser and Milone, Michael C and Levine, Bruce L and June, Carl
               H",
  abstract  = "Patients with relapsed and chemotherapy-refractory pre?B-cell
               ALL have a poor prognosis despite the use of aggressive
               therapies such as allogeneic hematopoietic stem-cell
               transplantation1,2 and bispecific CD19 antibody fragments.3
               Chimeric antigen receptor?modified T cells that target the
               lineage-specific antigens CD19 and CD20 have been reported to be
               effective in adults with CLL and B-cell lymphomas.4?9 However,
               the effects of chimeric antigen receptor T cells on ALL blasts,
               a more immature leukemia that progresses more rapidly, have not
               been fully investigated. In particular, there has been
               uncertainty about whether chimeric antigen receptor T cells
               would expand in vivo in patients . . .",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  368,
  number    =  16,
  pages     = "1509--1518",
  month     =  "25~" # mar,
  year      =  2013
}

@ARTICLE{Rubio-Perez2015-ek,
  title     = "Abstract 2983: In silico prescription of anticancer drugs to
               cohorts of 28 tumor types reveals novel targeting opportunities",
  author    = "Rubio-Perez, Carlota and Tamborero, David and Schroeder, Michael
               P and Antolin, Albert A and Deu-Pons, Jordi and Perez-Llamas,
               Christian and Mestres, Jordi and Gonzalez-Perez, Abel and
               Lopez-Bigas, Nuria",
  abstract  = "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015;
               Philadelphia, PA Recent advances in DNA sequencing technologies
               provide unprecedented capacity to comprehensively identify the
               alterations, genes, and pathways involved in the tumorigenic
               process, raising the hope of extending targeted therapies
               against the drivers of cancer from a few successful examples to
               a broader personalized medicine strategy. However, high
               intertumor heterogeneity is a major obstacle to develop and
               apply therapeutic targeted agents to treat most cancer patient.
               In addition, advances in our ability to precisely assign the
               most effective targeted therapy to each patient based on the
               genome events driving the tumor are urgently needed. The present
               study offers the first comprehensive assessment of the scope of
               targeted drugs in a large pan-cancer cohort. To pursue this
               goal, we developed a three-step in silico drug prescription
               strategy. We first identified the driver genes acting across
               6792 tumor samples from 28 different cancer types via an
               integrated analysis of their mutations, copy number alterations
               and gene fusions. All information pertaining these driver genes
               has been compiled in a publicly available Drivers Database.
               Next, following the rationale that targeted therapies are
               effective only if they are administered to treat tumors driven
               by the alterations they are aimed at, we collected all
               therapeutic agents capable of targeting altered driver genes
               either directly, indirectly or through gene therapies. The
               catalog of available therapeutic agents and ancillary
               information on their application, referred here as Drivers
               Actionability Database, included FDA (Foods and Drugs
               Administration Agency) approved drugs, agents undergoing
               clinical trials, and ligands in pre-clinical stages. Finally,
               based on the driver alterations in each tumor in the cohort and
               the rules in the Drivers Actionability Database, we connected
               each patient to all targeted therapies that could benefit them,
               thus producing the landscape of utility of targeted therapeutic
               agents in the cohort. We found that only a minority of patients
               could benefit from approved targeted therapy interventions
               following clinical guidelines (5.9\%), while up to 40\% could
               benefit from different types of repurposing opportunities of
               approve drugs, and up to 78\% considering treatments currently
               under investigation. In addition, we identified 16
               therapeutically unexploited cancer genes targeted by small
               molecules currently in pre-clinical stages, and 66 others
               structurally suitable for small molecule binding or accessible
               by antibody targeting. These results highlight the current scope
               of targeted anti-cancer therapies and its prospects for growth.
               The application of the strategy to larger cohorts and the
               continuous update of drug-target interactions information, will
               improve the in silico prescription rules contained within the
               two databases, thus enhancing its usefulness within personalized
               cancer medicine. Citation Format: Carlota Rubio-Perez, David
               Tamborero, Michael P. Schroeder, Albert A. Antolin, Jordi
               Deu-Pons, Christian Perez-Llamas, Jordi Mestres, Abel
               Gonzalez-Perez, Nuria Lopez-Bigas. In silico prescription of
               anticancer drugs to cohorts of 28 tumor types reveals novel
               targeting opportunities. [abstract]. In: Proceedings of the
               106th Annual Meeting of the American Association for Cancer
               Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA):
               AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2983.
               doi:10.1158/1538-7445.AM2015-2983",
  journal   = "Cancer Res.",
  publisher = "American Association for Cancer Research",
  volume    =  75,
  number    = "15 Supplement",
  pages     = "2983--2983",
  month     =  "1~" # aug,
  year      =  2015,
  language  = "en"
}

@UNPUBLISHED{Huang2016-zx,
  title    = "The Precision Medicine Knowledge Base: an online application for
              collaborative editing, maintenance and sharing of structured
              clinical-grade cancer mutations interpretations",
  author   = "Huang, Linda and Fernandes, Helen and Zia, Hamid and Tavassoli,
              Peyman and Rennert, Hanna and Pisapia, David and Imielinski,
              Marcin and Sboner, Andrea and Rubin, Mark A and Kluk, Michael and
              Elemento, Olivier",
  abstract = "This paper describes the Precision Medicine Knowledge Base (PMKB;
              https://pmkb.weill.cornell.edu), an interactive online
              application for collaborative editing, maintenance and sharing of
              structured clinical-grade cancer mutations interpretations. PMKB
              was built using the Ruby on Rails Web application framework.
              Leveraging existing standards such as Human Genome Variation
              Society (HGVS) variant description format, we implemented a data
              model that links variants to tumor-specific and tissue-specific
              interpretations. Key features of PMKB include support for all
              major variant types, standardized authentication, distinct user
              roles including high-level approvers, detailed activity history.
              A REpresentational State Transfer (REST) application-programming
              interface (API) was implemented to query the PMKB
              programmatically. At the time of writing, PMKB contains 457
              variant descriptions with 281 clinical-grade interpretations. The
              EGFR, BRAF, KRAS, and KIT genes are associated with the largest
              numbers of interpretable variants. The PMKB interpretations have
              been used in over 1,500 AmpliSeq tests and 750 whole exome
              sequencing tests. The interpretations are accessed either
              directly via the Web interface or programmatically via the
              existing API. An accurate and up-to-date knowledge base of
              genomic alterations of clinical significance is critical to the
              success of precision medicine programs. The open-access,
              programmatically accessible PMKB represents an important attempt
              at creating such a resource in the field of oncology. The PMKB
              was designed to help collect and maintain clinical-grade mutation
              interpretations and facilitates reporting for clinical cancer
              genomic testing. The PMKB was also designed to enable the
              creation of clinical cancer genomics automated reporting
              pipelines via an API.",
  journal  = "bioRxiv",
  pages    = "059824",
  month    =  "19~" # jun,
  year     =  2016,
  language = "en"
}

@ARTICLE{Li2017-aw,
  title     = "Standards and Guidelines for the Interpretation and Reporting of
               Sequence Variants in Cancer",
  author    = "Li, Marilyn M and Datto, Michael and Duncavage, Eric J and
               Kulkarni, Shashikant and Lindeman, Neal I and Roy, Somak and
               Tsimberidou, Apostolia M and Vnencak-Jones, Cindy L and Wolff,
               Daynna J and Younes, Anas and Nikiforova, Marina N",
  abstract  = "Widespread clinical laboratory implementation of next-generation
               sequencing--based cancer testing has highlighted the importance
               and potential benefits of standardizing the interpretation and
               reporting of molecular results among laboratories. A
               multidisciplinary working group tasked to assess the current
               status of next-generation sequencing--based cancer testing and
               establish standardized consensus classification, annotation,
               interpretation, and reporting conventions for somatic sequence
               variants was convened by the Association for Molecular Pathology
               with liaison representation from the American College of Medical
               Genetics and Genomics, American Society of Clinical Oncology,
               and College of American Pathologists. On the basis of the
               results of professional surveys, literature review, and the
               Working Group's subject matter expert consensus, a four-tiered
               system to categorize somatic sequence variations based on their
               clinical significances is proposed: tier I, variants with strong
               clinical significance; tier II, variants with potential clinical
               significance; tier III, variants of unknown clinical
               significance; and tier IV, variants deemed benign or likely
               benign. Cancer genomics is a rapidly evolving field; therefore,
               the clinical significance of any variant in therapy, diagnosis,
               or prognosis should be reevaluated on an ongoing basis.
               Reporting of genomic variants should follow standard
               nomenclature, with testing method and limitations clearly
               described. Clinical recommendations should be concise and
               correlate with histological and clinical findings.",
  journal   = "J. Mol. Diagn.",
  publisher = "Elsevier",
  volume    =  19,
  number    =  1,
  pages     = "4--23",
  month     =  "1~" # jan,
  year      =  2017,
  language  = "en"
}

@UNPUBLISHED{Pejaver2017-lr,
  title    = "{MutPred2}: inferring the molecular and phenotypic impact of
              amino acid variants",
  author   = "Pejaver, Vikas and Urresti, Jorge and Lugo-Martinez, Jose and
              Pagel, Kymberleigh A and Lin, Guan Ning and Nam, Hyun-Jun and
              Mort, Matthew and Cooper, David N and Sebat, Jonathan and
              Iakoucheva, Lilia M and Mooney, Sean D and Radivojac, Predrag",
  abstract = "We introduce MutPred2, a tool that improves the prioritization of
              pathogenic amino acid substitutions, generates molecular
              mechanisms potentially causative of disease, and returns
              interpretable pathogenicity score distributions on individual
              genomes. While its prioritization performance is
              state-of-the-art, a novel and distinguishing feature of MutPred2
              is the probabilistic modeling of variant impact on specific
              aspects of protein structure and function that can serve to guide
              experimental studies of phenotype-altering variants. We
              demonstrate the utility of MutPred2 in the identification of the
              structural and functional mutational signatures relevant to
              Mendelian disorders and the prioritization of de novo mutations
              associated with complex neurodevelopmental disorders. We then
              experimentally validate the functional impact of several variants
              identified in patients with such disorders. We argue that
              mechanism-driven studies of human inherited diseases have the
              potential to significantly accelerate the discovery of clinically
              actionable variants. Availability: http://mutpred.mutdb.org/",
  journal  = "bioRxiv",
  pages    = "134981",
  month    =  "9~" # may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Cheng2015-wh,
  title    = "Memorial Sloan {Kettering-Integrated} Mutation Profiling of
              Actionable Cancer Targets ({MSK-IMPACT)}: A Hybridization
              {Capture-Based} {Next-Generation} Sequencing Clinical Assay for
              Solid Tumor Molecular Oncology",
  author   = "Cheng, Donavan T and Mitchell, Talia N and Zehir, Ahmet and Shah,
              Ronak H and Benayed, Ryma and Syed, Aijazuddin and Chandramohan,
              Raghu and Liu, Zhen Yu and Won, Helen H and Scott, Sasinya N and
              Brannon, A Rose and O'Reilly, Catherine and Sadowska, Justyna and
              Casanova, Jacklyn and Yannes, Angela and Hechtman, Jaclyn F and
              Yao, Jinjuan and Song, Wei and Ross, Dara S and Oultache, Alifya
              and Dogan, Snjezana and Borsu, Laetitia and Hameed, Meera and
              Nafa, Khedoudja and Arcila, Maria E and Ladanyi, Marc and Berger,
              Michael F",
  abstract = "The identification of specific genetic alterations as key
              oncogenic drivers and the development of targeted therapies are
              together transforming clinical oncology and creating a pressing
              need for increased breadth and throughput of clinical genotyping.
              Next-generation sequencing assays allow the efficient and
              unbiased detection of clinically actionable mutations. To enable
              precision oncology in patients with solid tumors, we developed
              Memorial Sloan Kettering-Integrated Mutation Profiling of
              Actionable Cancer Targets (MSK-IMPACT), a hybridization
              capture-based next-generation sequencing assay for targeted deep
              sequencing of all exons and selected introns of 341 key cancer
              genes in formalin-fixed, paraffin-embedded tumors. Barcoded
              libraries from patient-matched tumor and normal samples were
              captured, sequenced, and subjected to a custom analysis pipeline
              to identify somatic mutations. Sensitivity, specificity,
              reproducibility of MSK-IMPACT were assessed through extensive
              analytical validation. We tested 284 tumor samples with
              previously known point mutations and insertions/deletions in 47
              exons of 19 cancer genes. All known variants were accurately
              detected, and there was high reproducibility of inter- and
              intrarun replicates. The detection limit for low-frequency
              variants was approximately 2\% for hotspot mutations and 5\% for
              nonhotspot mutations. Copy number alterations and structural
              rearrangements were also reliably detected. MSK-IMPACT profiles
              oncogenic DNA alterations in clinical solid tumor samples with
              high accuracy and sensitivity. Paired analysis of tumors and
              patient-matched normal samples enables unambiguous detection of
              somatic mutations to guide treatment decisions.",
  journal  = "J. Mol. Diagn.",
  volume   =  17,
  number   =  3,
  pages    = "251--264",
  month    =  may,
  year     =  2015
}

@ARTICLE{Lek2016-bb,
  title       = "Analysis of protein-coding genetic variation in 60,706 humans",
  author      = "Lek, Monkol and Karczewski, Konrad J and Minikel, Eric V and
                 Samocha, Kaitlin E and Banks, Eric and Fennell, Timothy and
                 O'Donnell-Luria, Anne H and Ware, James S and Hill, Andrew J
                 and Cummings, Beryl B and Tukiainen, Taru and Birnbaum, Daniel
                 P and Kosmicki, Jack A and Duncan, Laramie E and Estrada,
                 Karol and Zhao, Fengmei and Zou, James and Pierce-Hoffman,
                 Emma and Berghout, Joanne and Cooper, David N and Deflaux,
                 Nicole and DePristo, Mark and Do, Ron and Flannick, Jason and
                 Fromer, Menachem and Gauthier, Laura and Goldstein, Jackie and
                 Gupta, Namrata and Howrigan, Daniel and Kiezun, Adam and
                 Kurki, Mitja I and Moonshine, Ami Levy and Natarajan, Pradeep
                 and Orozco, Lorena and Peloso, Gina M and Poplin, Ryan and
                 Rivas, Manuel A and Ruano-Rubio, Valentin and Rose, Samuel A
                 and Ruderfer, Douglas M and Shakir, Khalid and Stenson, Peter
                 D and Stevens, Christine and Thomas, Brett P and Tiao, Grace
                 and Tusie-Luna, Maria T and Weisburd, Ben and Won, Hong-Hee
                 and Yu, Dongmei and Altshuler, David M and Ardissino, Diego
                 and Boehnke, Michael and Danesh, John and Donnelly, Stacey and
                 Elosua, Roberto and Florez, Jose C and Gabriel, Stacey B and
                 Getz, Gad and Glatt, Stephen J and Hultman, Christina M and
                 Kathiresan, Sekar and Laakso, Markku and McCarroll, Steven and
                 McCarthy, Mark I and McGovern, Dermot and McPherson, Ruth and
                 Neale, Benjamin M and Palotie, Aarno and Purcell, Shaun M and
                 Saleheen, Danish and Scharf, Jeremiah M and Sklar, Pamela and
                 Sullivan, Patrick F and Tuomilehto, Jaakko and Tsuang, Ming T
                 and Watkins, Hugh C and Wilson, James G and Daly, Mark J and
                 MacArthur, Daniel G and {Exome Aggregation Consortium}",
  affiliation = "Analytic and Translational Genetics Unit, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. School of
                 Paediatrics and Child Health, University of Sydney, Sydney,
                 New South Wales 2145, Australia. Institute for Neuroscience
                 and Muscle Research, Children's Hospital at Westmead, Sydney,
                 New South Wales 2145, Australia. Analytic and Translational
                 Genetics Unit, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Analytic and Translational Genetics
                 Unit, Massachusetts General Hospital, Boston, Massachusetts
                 02114, USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Program in Biological and Biomedical Sciences, Harvard
                 Medical School, Boston, Massachusetts 02115, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Biological and
                 Biomedical Sciences, Harvard Medical School, Boston,
                 Massachusetts 02115, USA. Stanley Center for Psychiatric
                 Research, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Analytic and Translational Genetics
                 Unit, Massachusetts General Hospital, Boston, Massachusetts
                 02114, USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Division of Genetics and Genomics, Boston Children's
                 Hospital, Boston, Massachusetts 02115, USA. Program in Medical
                 and Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Department of Genetics,
                 Harvard Medical School, Boston, Massachusetts 02115, USA.
                 National Heart and Lung Institute, Imperial College London,
                 London SW7 2AZ, UK. NIHR Royal Brompton Cardiovascular
                 Biomedical Research Unit, Royal Brompton Hospital, London SW3
                 6NP, UK. MRC Clinical Sciences Centre, Imperial College
                 London, London SW7 2AZ, UK. Analytic and Translational
                 Genetics Unit, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Genome Sciences, University of
                 Washington, Seattle, Washington 98195, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Biological and
                 Biomedical Sciences, Harvard Medical School, Boston,
                 Massachusetts 02115, USA. Analytic and Translational Genetics
                 Unit, Massachusetts General Hospital, Boston, Massachusetts
                 02114, USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Analytic and Translational Genetics Unit, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Stanley Center
                 for Psychiatric Research, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Bioinformatics
                 and Integrative Genomics, Harvard Medical School, Boston,
                 Massachusetts 02115, USA. Analytic and Translational Genetics
                 Unit, Massachusetts General Hospital, Boston, Massachusetts
                 02114, USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Stanley Center for Psychiatric Research, Broad Institute
                 of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
                 Analytic and Translational Genetics Unit, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Mouse Genome Informatics,
                 Jackson Laboratory, Bar Harbor, Maine 04609, USA. Center for
                 Biomedical Informatics and Biostatistics, University of
                 Arizona, Tucson, Arizona 85721, USA. Institute of Medical
                 Genetics, Cardiff University, Cardiff CF10 3XQ, UK. Google,
                 Mountain View, California 94043, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts 02142, USA. Department
                 of Genetics and Genomic Sciences, Icahn School of Medicine at
                 Mount Sinai, New York, New York 10029, USA. Institute for
                 Genomics and Multiscale Biology, Icahn School of Medicine at
                 Mount Sinai, New York, New York 10029, USA. The Charles
                 Bronfman Institute for Personalized Medicine, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA. The
                 Center for Statistical Genetics, Icahn School of Medicine at
                 Mount Sinai, New York, New York 10029, USA. Program in Medical
                 and Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Department of Molecular
                 Biology, Massachusetts General Hospital, Boston, Massachusetts
                 02114, USA. Analytic and Translational Genetics Unit,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Stanley Center for Psychiatric Research, Broad Institute
                 of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
                 Department of Genetics and Genomic Sciences, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA.
                 Institute for Genomics and Multiscale Biology, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA.
                 Department of Psychiatry, Icahn School of Medicine at Mount
                 Sinai, New York, New York 10029, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts 02142, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Stanley Center for
                 Psychiatric Research, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Stanley Center for
                 Psychiatric Research, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts 02142, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Psychiatric and
                 Neurodevelopmental Genetics Unit, Massachusetts General
                 Hospital, Boston, Massachusetts 02114, USA. Broad Institute of
                 MIT and Harvard, Cambridge, Massachusetts 02142, USA. Program
                 in Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Harvard Medical
                 School, Boston, Massachusetts 02115, USA. Center for Human
                 Genetic Research, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Cardiovascular Research Center,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Immunogenomics and Metabolic Disease Laboratory,
                 Instituto Nacional de Medicina Gen{\'o}mica, Mexico City
                 14610, Mexico. Program in Medical and Population Genetics,
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts
                 02142, USA. Center for Human Genetic Research, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA.
                 Cardiovascular Research Center, Massachusetts General
                 Hospital, Boston, Massachusetts 02114, USA. Broad Institute of
                 MIT and Harvard, Cambridge, Massachusetts 02142, USA. Program
                 in Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Broad Institute
                 of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
                 Stanley Center for Psychiatric Research, Broad Institute of
                 MIT and Harvard, Cambridge, Massachusetts 02142, USA.
                 Department of Genetics and Genomic Sciences, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA.
                 Institute for Genomics and Multiscale Biology, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA.
                 Department of Psychiatry, Icahn School of Medicine at Mount
                 Sinai, New York, New York 10029, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts 02142, USA. Institute of
                 Medical Genetics, Cardiff University, Cardiff CF10 3XQ, UK.
                 Program in Medical and Population Genetics, Broad Institute of
                 MIT and Harvard, Cambridge, Massachusetts 02142, USA. Analytic
                 and Translational Genetics Unit, Massachusetts General
                 Hospital, Boston, Massachusetts 02114, USA. Program in Medical
                 and Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts 02142, USA. Molecular
                 Biology and Genomic Medicine Unit, Instituto Nacional de
                 Ciencias M{\'e}dicas y Nutrici{\'o}n, Mexico City 14080,
                 Mexico. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Samsung Advanced Institute for Health Sciences and
                 Technology (SAIHST), Sungkyunkwan University, Samsung Medical
                 Center, Seoul, South Korea. Stanley Center for Psychiatric
                 Research, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Psychiatric and Neurodevelopmental
                 Genetics Unit, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Center for Human Genetic Research,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Department of Neurology, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Vertex Pharmaceuticals,
                 Boston, Massachusetts 02210, USA. Department of Cardiology,
                 University Hospital, 43100 Parma, Italy. Department of
                 Biostatistics and Center for Statistical Genetics, University
                 of Michigan, Ann Arbor, Michigan 48109, USA. Department of
                 Public Health and Primary Care, Strangeways Research
                 Laboratory, Cambridge CB1 8RN, UK. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Cardiovascular
                 Epidemiology and Genetics, Hospital del Mar Medical Research
                 Institute, 08003 Barcelona, Spain. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Harvard Medical School,
                 Boston, Massachusetts 02115, USA. Center for Human Genetic
                 Research, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Harvard Medical School,
                 Boston, Massachusetts 02115, USA. Department of Pathology and
                 Cancer Center, Massachusetts General Hospital, Boston,
                 Massachusetts, 02114 USA. Psychiatric Genetic Epidemiology
                 \&Neurobiology Laboratory, State University of New York,
                 Upstate Medical University, Syracuse, New York 13210, USA.
                 Department of Psychiatry and Behavioral Sciences, State
                 University of New York, Upstate Medical University, Syracuse,
                 New York 13210, USA. Department of Neuroscience and
                 Physiology, State University of New York, Upstate Medical
                 University, Syracuse, New York 13210, USA. Department of
                 Medical Epidemiology and Biostatistics, Karolinska Institutet,
                 SE-171 77 Stockholm, Sweden. Program in Medical and Population
                 Genetics, Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts 02142, USA. Harvard Medical School, Boston,
                 Massachusetts 02115, USA. Center for Human Genetic Research,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Cardiovascular Research Center, Massachusetts General
                 Hospital, Boston, Massachusetts 02114, USA. Department of
                 Medicine, University of Eastern Finland and Kuopio University
                 Hospital, 70211 Kuopio, Finland. Stanley Center for
                 Psychiatric Research, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Department of Genetics,
                 Harvard Medical School, Boston, Massachusetts 02115, USA.
                 Wellcome Trust Centre for Human Genetics, University of
                 Oxford, Oxford OX1 2JD, UK. Oxford Centre for Diabetes,
                 Endocrinology and Metabolism, University of Oxford, Oxford OX1
                 2JD, UK. Oxford NIHR Biomedical Research Centre, Oxford
                 University Hospitals Foundation Trust, Oxford OX1 2JD, UK.
                 Inflammatory Bowel Disease and Immunobiology Research
                 Institute, Cedars-Sinai Medical Center, Los Angeles,
                 California 90048, USA. Atherogenomics Laboratory, University
                 of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada.
                 Analytic and Translational Genetics Unit, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA. Stanley Center
                 for Psychiatric Research, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Analytic and
                 Translational Genetics Unit, Massachusetts General Hospital,
                 Boston, Massachusetts 02114, USA. Program in Medical and
                 Population Genetics, Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts 02142, USA. Program in Biological and
                 Biomedical Sciences, Harvard Medical School, Boston,
                 Massachusetts 02115, USA. Institute for Molecular Medicine
                 Finland (FIMM), University of Helsinki, 00100 Helsinki,
                 Finland. Department of Genetics and Genomic Sciences, Icahn
                 School of Medicine at Mount Sinai, New York, New York 10029,
                 USA. Institute for Genomics and Multiscale Biology, Icahn
                 School of Medicine at Mount Sinai, New York, New York 10029,
                 USA. Department of Psychiatry, Icahn School of Medicine at
                 Mount Sinai, New York, New York 10029, USA. Department of
                 Biostatistics and Epidemiology, Perelman School of Medicine at
                 the University of Pennsylvania, Philadelphia, Pennsylvania
                 19104, USA. Department of Medicine, Perelman School of
                 Medicine at the University of Pennsylvania, Philadelphia,
                 Pennsylvania 19104, USA. Center for Non-Communicable Diseases,
                 Karachi, Pakistan. Program in Medical and Population Genetics,
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts
                 02142, USA. Stanley Center for Psychiatric Research, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Psychiatric and Neurodevelopmental Genetics Unit,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Center for Human Genetic Research, Massachusetts General
                 Hospital, Boston, Massachusetts 02114, USA. Department of
                 Neurology, Massachusetts General Hospital, Boston,
                 Massachusetts 02114, USA. Department of Genetics and Genomic
                 Sciences, Icahn School of Medicine at Mount Sinai, New York,
                 New York 10029, USA. Institute for Genomics and Multiscale
                 Biology, Icahn School of Medicine at Mount Sinai, New York,
                 New York 10029, USA. Department of Psychiatry, Icahn School of
                 Medicine at Mount Sinai, New York, New York 10029, USA.
                 Friedman Brain Institute, Icahn School of Medicine at Mount
                 Sinai, New York, New York 10029, USA. Department of
                 Neuroscience, Icahn School of Medicine at Mount Sinai, New
                 York, New York 10029, USA. Department of Genetics, University
                 of North Carolina, Chapel Hill, North Carolina 27599, USA.
                 Department of Medical Epidemiology and Biostatistics,
                 Karolinska Institutet SE-171 77 Stockholm, Sweden. Department
                 of Public Health, University of Helsinki, 00100 Helsinki,
                 Finland. Department of Psychiatry, University of California,
                 San Diego, California 92093, USA. Wellcome Trust Centre for
                 Human Genetics, University of Oxford, Oxford OX1 2JD, UK.
                 Radcliffe Department of Medicine, University of Oxford, Oxford
                 OX1 2JD, UK. Department of Physiology and Biophysics,
                 University of Mississippi Medical Center, Jackson, Mississippi
                 39216, USA. Analytic and Translational Genetics Unit,
                 Massachusetts General Hospital, Boston, Massachusetts 02114,
                 USA. Program in Medical and Population Genetics, Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts 02142,
                 USA. Stanley Center for Psychiatric Research, Broad Institute
                 of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
                 Analytic and Translational Genetics Unit, Massachusetts
                 General Hospital, Boston, Massachusetts 02114, USA. Program in
                 Medical and Population Genetics, Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts 02142, USA.",
  abstract    = "Large-scale reference data sets of human genetic variation are
                 critical for the medical and functional interpretation of DNA
                 sequence changes. Here we describe the aggregation and
                 analysis of high-quality exome (protein-coding region) DNA
                 sequence data for 60,706 individuals of diverse ancestries
                 generated as part of the Exome Aggregation Consortium (ExAC).
                 This catalogue of human genetic diversity contains an average
                 of one variant every eight bases of the exome, and provides
                 direct evidence for the presence of widespread mutational
                 recurrence. We have used this catalogue to calculate objective
                 metrics of pathogenicity for sequence variants, and to
                 identify genes subject to strong selection against various
                 classes of mutation; identifying 3,230 genes with
                 near-complete depletion of predicted protein-truncating
                 variants, with 72\% of these genes having no currently
                 established human disease phenotype. Finally, we demonstrate
                 that these data can be used for the efficient filtering of
                 candidate disease-causing variants, and for the discovery of
                 human 'knockout' variants in protein-coding genes.",
  journal     = "Nature",
  volume      =  536,
  number      =  7616,
  pages       = "285--291",
  month       =  "18~" # aug,
  year        =  2016,
  language    = "en"
}

@ARTICLE{Knepper2017-no,
  title       = "Key Lessons Learned from Moffitt's Molecular Tumor Board: The
                 Clinical Genomics Action Committee Experience",
  author      = "Knepper, Todd C and Bell, Gillian C and Hicks, J Kevin and
                 Padron, Eric and Teer, Jamie K and Vo, Teresa T and Gillis,
                 Nancy K and Mason, Neil T and McLeod, Howard L and Walko,
                 Christine M",
  affiliation = "DeBartolo Family Personalized Medicine Institute, H. Lee
                 Moffitt Cancer Center and Research Institute, Tampa, Florida,
                 USA. Department of Cancer Epidemiology, H. Lee Moffitt Cancer
                 Center and Research Institute, Tampa, Florida, USA.
                 Personalized Medicine Program, Mission Health, Asheville,
                 North Carolina, USA. DeBartolo Family Personalized Medicine
                 Institute, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Cancer
                 Epidemiology, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Hematologic
                 Malignancies, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Biostatistics
                 and Bioinformatics, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Pharmacy
                 Practice, University of South Florida College of Pharmacy,
                 Tampa, Florida, USA. DeBartolo Family Personalized Medicine
                 Institute, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Cancer
                 Epidemiology, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Center for Pharmacogenomics
                 and Individualized Therapy, University of North Carolina
                 Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
                 DeBartolo Family Personalized Medicine Institute, H. Lee
                 Moffitt Cancer Center and Research Institute, Tampa, Florida,
                 USA. Department of Cancer Epidemiology, H. Lee Moffitt Cancer
                 Center and Research Institute, Tampa, Florida, USA. DeBartolo
                 Family Personalized Medicine Institute, H. Lee Moffitt Cancer
                 Center and Research Institute, Tampa, Florida, USA
                 Howard.McLeod@Moffitt.org. Department of Cancer Epidemiology,
                 H. Lee Moffitt Cancer Center and Research Institute, Tampa,
                 Florida, USA. DeBartolo Family Personalized Medicine
                 Institute, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA. Department of Cancer
                 Epidemiology, H. Lee Moffitt Cancer Center and Research
                 Institute, Tampa, Florida, USA.",
  abstract    = "BACKGROUND: The increasing practicality of genomic sequencing
                 technology has led to its incorporation into routine clinical
                 practice. Successful identification and targeting of driver
                 genomic alterations that provide proliferative and survival
                 advantages to tumor cells have led to approval and ongoing
                 development of several targeted cancer therapies. Within many
                 major cancer centers, molecular tumor boards are constituted
                 to shepherd precision medicine into clinical practice.
                 MATERIALS AND METHODS: In July 2014, the Clinical Genomics
                 Action Committee (CGAC) was established as the molecular tumor
                 board companion to the Personalized Medicine Clinical Service
                 (PMCS) at Moffitt Cancer Center in Tampa, Florida. The
                 processes and outcomes of the program were assessed in order
                 to help others move into the practice of precision medicine.
                 RESULTS: Through the establishment and initial 1,400 patients
                 of the PMCS and its associated molecular tumor board at a
                 major cancer center, five practical lessons of broad
                 applicability have been learned: transdisciplinary engagement,
                 the use of the molecular report as an aid to clinical
                 management, clinical actionability, getting therapeutic
                 options to patients, and financial considerations. Value to
                 patients includes access to cutting-edge practice merged with
                 individualized preferences in treatment and care. CONCLUSIONS:
                 Genomic-driven cancer medicine is increasingly becoming a part
                 of routine clinical practice. For successful implementation of
                 precision cancer medicine, strategically organized molecular
                 tumor boards are critical to provide objective evidence-based
                 translation of observed molecular alterations into
                 patient-centered clinical action. Molecular tumor board
                 implementation models along with clinical and economic
                 outcomes will define future treatment standards. The
                 Oncologist 2017;22:144-151Implications for Practice: It is
                 clear that the increasing practicality of genetic tumor
                 sequencing technology has led to its incorporation as part of
                 routine clinical practice. Subsequently, many cancer centers
                 are seeking to develop a personalized medicine services and/or
                 molecular tumor board to shepherd precision medicine into
                 clinical practice. This article discusses the key lessons
                 learned through the establishment and development of a
                 molecular tumor board and personalized medicine clinical
                 service. This article highlights practical issues and can
                 serve as an important guide to other centers as they conceive
                 and develop their own personalized medicine services and
                 molecular tumor boards.",
  journal     = "Oncologist",
  volume      =  22,
  number      =  2,
  pages       = "144--151",
  month       =  feb,
  year        =  2017,
  keywords    = "Cancer; Lessons learned; Molecular tumor board; Personalized
                 medicine; Precision medicine",
  language    = "en"
}

@ARTICLE{Griffith2013-uv,
  title       = "{DGIdb}: mining the druggable genome",
  author      = "Griffith, Malachi and Griffith, Obi L and Coffman, Adam C and
                 Weible, James V and McMichael, Josh F and Spies, Nicholas C
                 and Koval, James and Das, Indraniel and Callaway, Matthew B
                 and Eldred, James M and Miller, Christopher A and Subramanian,
                 Janakiraman and Govindan, Ramaswamy and Kumar, Runjun D and
                 Bose, Ron and Ding, Li and Walker, Jason R and Larson, David E
                 and Dooling, David J and Smith, Scott M and Ley, Timothy J and
                 Mardis, Elaine R and Wilson, Richard K",
  affiliation = "1] The Genome Institute, Washington University School of
                 Medicine, St. Louis, Missouri, USA. [2] Department of
                 Genetics, Washington University School of Medicine, St. Louis,
                 Missouri, USA. [3].",
  abstract    = "The Drug-Gene Interaction database (DGIdb) mines existing
                 resources that generate hypotheses about how mutated genes
                 might be targeted therapeutically or prioritized for drug
                 development. It provides an interface for searching lists of
                 genes against a compendium of drug-gene interactions and
                 potentially 'druggable' genes. DGIdb can be accessed at
                 http://dgidb.org/.",
  journal     = "Nat. Methods",
  volume      =  10,
  number      =  12,
  pages       = "1209--1210",
  month       =  dec,
  year        =  2013,
  language    = "en"
}

@PHDTHESIS{Addepalli2014-oa,
  title  = "Models Predicting Effects of Missense Mutations in Oncogenesis",
  author = "Addepalli, Kanakadurga",
  year   =  2014,
  school = "George Mason University"
}

@MISC{noauthor_undated-da,
  title        = "{NCI-MATCH} Trial (Molecular Analysis for Therapy Choice)",
  booktitle    = "National Cancer Institute",
  abstract     = "Information about the NCI-MATCH precision medicine trial, in
                  which patients with advanced solid tumors and lymphomas are
                  assigned to treatment arms based on the molecular profiles of
                  their disease.",
  howpublished = "\url{https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match}",
  note         = "Accessed: 2017-5-31"
}

@ARTICLE{Wagner2016-fs,
  title       = "{DGIdb} 2.0: mining clinically relevant drug-gene interactions",
  author      = "Wagner, Alex H and Coffman, Adam C and Ainscough, Benjamin J
                 and Spies, Nicholas C and Skidmore, Zachary L and Campbell,
                 Katie M and Krysiak, Kilannin and Pan, Deng and McMichael,
                 Joshua F and Eldred, James M and Walker, Jason R and Wilson,
                 Richard K and Mardis, Elaine R and Griffith, Malachi and
                 Griffith, Obi L",
  affiliation = "McDonnell Genome Institute, Washington University School of
                 Medicine, St. Louis, MO 63108, USA. McDonnell Genome
                 Institute, Washington University School of Medicine, St.
                 Louis, MO 63108, USA. McDonnell Genome Institute, Washington
                 University School of Medicine, St. Louis, MO 63108, USA
                 Siteman Cancer Center, Washington University School of
                 Medicine, St. Louis, MO 63110, USA. McDonnell Genome
                 Institute, Washington University School of Medicine, St.
                 Louis, MO 63108, USA. McDonnell Genome Institute, Washington
                 University School of Medicine, St. Louis, MO 63108, USA.
                 McDonnell Genome Institute, Washington University School of
                 Medicine, St. Louis, MO 63108, USA. McDonnell Genome
                 Institute, Washington University School of Medicine, St.
                 Louis, MO 63108, USA. Department of Medicine, Washington
                 University School of Medicine, St. Louis, MO 63110, USA.
                 McDonnell Genome Institute, Washington University School of
                 Medicine, St. Louis, MO 63108, USA. McDonnell Genome
                 Institute, Washington University School of Medicine, St.
                 Louis, MO 63108, USA. McDonnell Genome Institute, Washington
                 University School of Medicine, St. Louis, MO 63108, USA.
                 McDonnell Genome Institute, Washington University School of
                 Medicine, St. Louis, MO 63108, USA Siteman Cancer Center,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA Department of Medicine, Washington University School of
                 Medicine, St. Louis, MO 63110, USA Department of Genetics,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA. McDonnell Genome Institute, Washington University School
                 of Medicine, St. Louis, MO 63108, USA Siteman Cancer Center,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA Department of Medicine, Washington University School of
                 Medicine, St. Louis, MO 63110, USA Department of Genetics,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA. McDonnell Genome Institute, Washington University School
                 of Medicine, St. Louis, MO 63108, USA Siteman Cancer Center,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA Department of Genetics, Washington University School of
                 Medicine, St. Louis, MO 63110, USA mgriffit@genome.wustl.edu.
                 McDonnell Genome Institute, Washington University School of
                 Medicine, St. Louis, MO 63108, USA Siteman Cancer Center,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA Department of Medicine, Washington University School of
                 Medicine, St. Louis, MO 63110, USA Department of Genetics,
                 Washington University School of Medicine, St. Louis, MO 63110,
                 USA ogriffit@genome.wustl.edu.",
  abstract    = "The Drug-Gene Interaction Database (DGIdb, www.dgidb.org) is a
                 web resource that consolidates disparate data sources
                 describing drug-gene interactions and gene druggability. It
                 provides an intuitive graphical user interface and a
                 documented application programming interface (API) for
                 querying these data. DGIdb was assembled through an extensive
                 manual curation effort, reflecting the combined information of
                 twenty-seven sources. For DGIdb 2.0, substantial updates have
                 been made to increase content and improve its usefulness as a
                 resource for mining clinically actionable drug targets.
                 Specifically, nine new sources of drug-gene interactions have
                 been added, including seven resources specifically focused on
                 interactions linked to clinical trials. These additions have
                 more than doubled the overall count of drug-gene interactions.
                 The total number of druggable gene claims has also increased
                 by 30\%. Importantly, a majority of the unrestricted,
                 publicly-accessible sources used in DGIdb are now
                 automatically updated on a weekly basis, providing the most
                 current information for these sources. Finally, a new web view
                 and API have been developed to allow searching for
                 interactions by drug identifiers to complement existing
                 gene-based search functionality. With these updates, DGIdb
                 represents a comprehensive and user friendly tool for mining
                 the druggable genome for precision medicine hypothesis
                 generation.",
  journal     = "Nucleic Acids Res.",
  volume      =  44,
  number      = "D1",
  pages       = "D1036--44",
  month       =  "4~" # jan,
  year        =  2016,
  language    = "en"
}

@ARTICLE{Thomas2003-rj,
  title       = "{PANTHER}: a library of protein families and subfamilies
                 indexed by function",
  author      = "Thomas, Paul D and Campbell, Michael J and Kejariwal, Anish
                 and Mi, Huaiyu and Karlak, Brian and Daverman, Robin and
                 Diemer, Karen and Muruganujan, Anushya and Narechania, Apurva",
  affiliation = "Protein Informatics, Celera Genomics, Foster City, California
                 94404, USA. paul.thomas@fc.celera.com",
  abstract    = "In the genomic era, one of the fundamental goals is to
                 characterize the function of proteins on a large scale. We
                 describe a method, PANTHER, for relating protein sequence
                 relationships to function relationships in a robust and
                 accurate way. PANTHER is composed of two main components: the
                 PANTHER library (PANTHER/LIB) and the PANTHER index
                 (PANTHER/X). PANTHER/LIB is a collection of ``books,'' each
                 representing a protein family as a multiple sequence
                 alignment, a Hidden Markov Model (HMM), and a family tree.
                 Functional divergence within the family is represented by
                 dividing the tree into subtrees based on shared function, and
                 by subtree HMMs. PANTHER/X is an abbreviated ontology for
                 summarizing and navigating molecular functions and biological
                 processes associated with the families and subfamilies. We
                 apply PANTHER to three areas of active research. First, we
                 report the size and sequence diversity of the families and
                 subfamilies, characterizing the relationship between sequence
                 divergence and functional divergence across a wide range of
                 protein families. Second, we use the PANTHER/X ontology to
                 give a high-level representation of gene function across the
                 human and mouse genomes. Third, we use the family HMMs to rank
                 missense single nucleotide polymorphisms (SNPs), on a
                 database-wide scale, according to their likelihood of
                 affecting protein function.",
  journal     = "Genome Res.",
  volume      =  13,
  number      =  9,
  pages       = "2129--2141",
  month       =  sep,
  year        =  2003,
  language    = "en"
}

@ARTICLE{Yang2015-bg,
  title       = "Genomic variant annotation and prioritization with {ANNOVAR}
                 and {wANNOVAR}",
  author      = "Yang, Hui and Wang, Kai",
  affiliation = "Zilkha Neurogenetic Institute, University of Southern
                 California, Los Angeles, California, USA. Neuroscience
                 Graduate Program, University of Southern California, Los
                 Angeles, California, USA. Zilkha Neurogenetic Institute,
                 University of Southern California, Los Angeles, California,
                 USA. Department of Psychiatry, University of Southern
                 California, Los Angeles, California, USA. Department of
                 Preventive Medicine, Division of Bioinformatics, University of
                 Southern California, Los Angeles, California, USA.",
  abstract    = "Recent developments in sequencing techniques have enabled
                 rapid and high-throughput generation of sequence data,
                 democratizing the ability to compile information on large
                 amounts of genetic variations in individual laboratories.
                 However, there is a growing gap between the generation of raw
                 sequencing data and the extraction of meaningful biological
                 information. Here, we describe a protocol to use the ANNOVAR
                 (ANNOtate VARiation) software to facilitate fast and easy
                 variant annotations, including gene-based, region-based and
                 filter-based annotations on a variant call format (VCF) file
                 generated from human genomes. We further describe a protocol
                 for gene-based annotation of a newly sequenced nonhuman
                 species. Finally, we describe how to use a user-friendly and
                 easily accessible web server called wANNOVAR to prioritize
                 candidate genes for a Mendelian disease. The variant
                 annotation protocols take 5-30 min of computer time, depending
                 on the size of the variant file, and 5-10 min of hands-on
                 time. In summary, through the command-line tool and the web
                 server, these protocols provide a convenient means to analyze
                 genetic variants generated in humans and other species.",
  journal     = "Nat. Protoc.",
  volume      =  10,
  number      =  10,
  pages       = "1556--1566",
  month       =  oct,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Kircher2014-im,
  title       = "A general framework for estimating the relative pathogenicity
                 of human genetic variants",
  author      = "Kircher, Martin and Witten, Daniela M and Jain, Preti and
                 O'Roak, Brian J and Cooper, Gregory M and Shendure, Jay",
  affiliation = "1] Department of Genome Sciences, University of Washington,
                 Seattle, Washington, USA. [2]. 1] Department of Biostatistics,
                 University of Washington, Seattle, Washington, USA. [2]. 1]
                 HudsonAlpha Institute for Biotechnology, Huntsville, Alabama,
                 USA. [2]. 1] Department of Genome Sciences, University of
                 Washington, Seattle, Washington, USA. [2]. HudsonAlpha
                 Institute for Biotechnology, Huntsville, Alabama, USA.
                 Department of Genome Sciences, University of Washington,
                 Seattle, Washington, USA.",
  abstract    = "Current methods for annotating and interpreting human genetic
                 variation tend to exploit a single information type (for
                 example, conservation) and/or are restricted in scope (for
                 example, to missense changes). Here we describe Combined
                 Annotation-Dependent Depletion (CADD), a method for
                 objectively integrating many diverse annotations into a single
                 measure (C score) for each variant. We implement CADD as a
                 support vector machine trained to differentiate 14.7 million
                 high-frequency human-derived alleles from 14.7 million
                 simulated variants. We precompute C scores for all 8.6 billion
                 possible human single-nucleotide variants and enable scoring
                 of short insertions-deletions. C scores correlate with allelic
                 diversity, annotations of functionality, pathogenicity,
                 disease severity, experimentally measured regulatory effects
                 and complex trait associations, and they highly rank known
                 pathogenic variants within individual genomes. The ability of
                 CADD to prioritize functional, deleterious and pathogenic
                 variants across many functional categories, effect sizes and
                 genetic architectures is unmatched by any current
                 single-annotation method.",
  journal     = "Nat. Genet.",
  volume      =  46,
  number      =  3,
  pages       = "310--315",
  month       =  mar,
  year        =  2014,
  language    = "en"
}

@ARTICLE{Drmanac2010-od,
  title       = "Human genome sequencing using unchained base reads on
                 self-assembling {DNA} nanoarrays",
  author      = "Drmanac, Radoje and Sparks, Andrew B and Callow, Matthew J and
                 Halpern, Aaron L and Burns, Norman L and Kermani, Bahram G and
                 Carnevali, Paolo and Nazarenko, Igor and Nilsen, Geoffrey B
                 and Yeung, George and Dahl, Fredrik and Fernandez, Andres and
                 Staker, Bryan and Pant, Krishna P and Baccash, Jonathan and
                 Borcherding, Adam P and Brownley, Anushka and Cedeno, Ryan and
                 Chen, Linsu and Chernikoff, Dan and Cheung, Alex and Chirita,
                 Razvan and Curson, Benjamin and Ebert, Jessica C and Hacker,
                 Coleen R and Hartlage, Robert and Hauser, Brian and Huang,
                 Steve and Jiang, Yuan and Karpinchyk, Vitali and Koenig, Mark
                 and Kong, Calvin and Landers, Tom and Le, Catherine and Liu,
                 Jia and McBride, Celeste E and Morenzoni, Matt and Morey,
                 Robert E and Mutch, Karl and Perazich, Helena and Perry,
                 Kimberly and Peters, Brock A and Peterson, Joe and
                 Pethiyagoda, Charit L and Pothuraju, Kaliprasad and Richter,
                 Claudia and Rosenbaum, Abraham M and Roy, Shaunak and Shafto,
                 Jay and Sharanhovich, Uladzislau and Shannon, Karen W and
                 Sheppy, Conrad G and Sun, Michel and Thakuria, Joseph V and
                 Tran, Anne and Vu, Dylan and Zaranek, Alexander Wait and Wu,
                 Xiaodi and Drmanac, Snezana and Oliphant, Arnold R and Banyai,
                 William C and Martin, Bruce and Ballinger, Dennis G and
                 Church, George M and Reid, Clifford A",
  affiliation = "Complete Genomics, Inc., 2071 Stierlin Court, Mountain View,
                 CA 94043, USA. rdrmanac@completegenomics.com",
  abstract    = "Genome sequencing of large numbers of individuals promises to
                 advance the understanding, treatment, and prevention of human
                 diseases, among other applications. We describe a genome
                 sequencing platform that achieves efficient imaging and low
                 reagent consumption with combinatorial probe anchor ligation
                 chemistry to independently assay each base from patterned
                 nanoarrays of self-assembling DNA nanoballs. We sequenced
                 three human genomes with this platform, generating an average
                 of 45- to 87-fold coverage per genome and identifying 3.2 to
                 4.5 million sequence variants per genome. Validation of one
                 genome data set demonstrates a sequence accuracy of about 1
                 false variant per 100 kilobases. The high accuracy, affordable
                 cost of \$4400 for sequencing consumables, and scalability of
                 this platform enable complete human genome sequencing for the
                 detection of rare variants in large-scale genetic studies.",
  journal     = "Science",
  volume      =  327,
  number      =  5961,
  pages       = "78--81",
  month       =  "1~" # jan,
  year        =  2010,
  language    = "en"
}

@ARTICLE{Relling2015-ie,
  title       = "Pharmacogenomics in the clinic",
  author      = "Relling, Mary V and Evans, William E",
  affiliation = "Department of Pharmaceutical Sciences, St. Jude Children's
                 Research Hospital, Memphis, Tennessee 38105-2794, USA.
                 Department of Pharmaceutical Sciences, St. Jude Children's
                 Research Hospital, Memphis, Tennessee 38105-2794, USA.",
  abstract    = "After decades of discovery, inherited variations have been
                 identified in approximately 20 genes that affect about 80
                 medications and are actionable in the clinic. And some
                 somatically acquired genetic variants direct the choice of
                 'targeted' anticancer drugs for individual patients. Current
                 efforts that focus on the processes required to appropriately
                 act on pharmacogenomic variability in the clinic are moving
                 away from discovery and towards implementation of an
                 evidenced-based strategy for improving the use of medications,
                 thereby providing a cornerstone for precision medicine.",
  journal     = "Nature",
  volume      =  526,
  number      =  7573,
  pages       = "343--350",
  month       =  "15~" # oct,
  year        =  2015,
  language    = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Wang2010-bt,
  title       = "{ANNOVAR}: functional annotation of genetic variants from
                 high-throughput sequencing data",
  author      = "Wang, Kai and Li, Mingyao and Hakonarson, Hakon",
  affiliation = "Center for Applied Genomics, Children's Hospital of
                 Philadelphia, PA 19104, USA. kai@openbioinformatics.org",
  abstract    = "High-throughput sequencing platforms are generating massive
                 amounts of genetic variation data for diverse genomes, but it
                 remains a challenge to pinpoint a small subset of functionally
                 important variants. To fill these unmet needs, we developed
                 the ANNOVAR tool to annotate single nucleotide variants (SNVs)
                 and insertions/deletions, such as examining their functional
                 consequence on genes, inferring cytogenetic bands, reporting
                 functional importance scores, finding variants in conserved
                 regions, or identifying variants reported in the 1000 Genomes
                 Project and dbSNP. ANNOVAR can utilize annotation databases
                 from the UCSC Genome Browser or any annotation data set
                 conforming to Generic Feature Format version 3 (GFF3). We also
                 illustrate a 'variants reduction' protocol on 4.7 million SNVs
                 and indels from a human genome, including two causal mutations
                 for Miller syndrome, a rare recessive disease. Through a
                 stepwise procedure, we excluded variants that are unlikely to
                 be causal, and identified 20 candidate genes including the
                 causal gene. Using a desktop computer, ANNOVAR requires 4 min
                 to perform gene-based annotation and 15 min to perform
                 variants reduction on 4.7 million variants, making it
                 practical to handle hundreds of human genomes in a day.
                 ANNOVAR is freely available at
                 http://www.openbioinformatics.org/annovar/.",
  journal     = "Nucleic Acids Res.",
  volume      =  38,
  number      =  16,
  pages       = "e164",
  month       =  sep,
  year        =  2010,
  language    = "en"
}

@ARTICLE{Hewett2002-yu,
  title       = "{PharmGKB}: the Pharmacogenetics Knowledge Base",
  author      = "Hewett, Micheal and Oliver, Diane E and Rubin, Daniel L and
                 Easton, Katrina L and Stuart, Joshua M and Altman, Russ B and
                 Klein, Teri E",
  affiliation = "Stanford Medical Informatics, 251 Campus Drive, MSOB X-215,
                 Stanford, CA 94305-5479, USA. hewett@smi.stanford.edu",
  abstract    = "The Pharmacogenetics Knowledge Base (PharmGKB;
                 http://www.pharmgkb.org/) contains genomic, phenotype and
                 clinical information collected from ongoing pharmacogenetic
                 studies. Tools to browse, query, download, submit, edit and
                 process the information are available to registered research
                 network members. A subset of the tools is publicly available.
                 PharmGKB currently contains over 150 genes under study, 14
                 Coriell populations and a large ontology of pharmacogenetics
                 concepts. The pharmacogenetic concepts and the experimental
                 data are interconnected by a set of relations to form a
                 knowledge base of information for pharmacogenetic researchers.
                 The information in PharmGKB, and its associated tools for
                 processing that information, are tailored for leading-edge
                 pharmacogenetics research. The PharmGKB project was initiated
                 in April 2000 and the first version of the knowledge base went
                 online in February 2001.",
  journal     = "Nucleic Acids Res.",
  volume      =  30,
  number      =  1,
  pages       = "163--165",
  month       =  "1~" # jan,
  year        =  2002,
  language    = "en"
}

@ARTICLE{Den_Dunnen2016-gw,
  title       = "{HGVS} Recommendations for the Description of Sequence
                 Variants: 2016 Update",
  author      = "den Dunnen, Johan T and Dalgleish, Raymond and Maglott, Donna
                 R and Hart, Reece K and Greenblatt, Marc S and McGowan-Jordan,
                 Jean and Roux, Anne-Francoise and Smith, Timothy and
                 Antonarakis, Stylianos E and Taschner, Peter E M",
  affiliation = "Human Genetics \& Clinical Genetics, Leiden University Medical
                 Center, Leiden, Nederland. Department of Genetics, University
                 of Leicester, Leicester, United Kingdom. National Center for
                 Biotechnology Information, National Library of Medicine,
                 National Institutes of Health, Bethesda, Maryland. Invitae,
                 Inc, San Francisco, California. University of Vermont College
                 of Medicine, Burlington, Vermont. Children's Hospital of
                 Eastern Ontario and University of Ottawa, Ottawa, Ontario,
                 Canada. Laboratoire de G{\'e}n{\'e}tique Mol{\'e}culaire, CHRU
                 Montpellier, Montpellier, France. Human Variome Project
                 International Coordinating Office, Melbourne, Australia.
                 Department of Genetic Medicine, University of Geneva Medical
                 School, Geneva, Switzerland. Generade Centre of Expertise
                 Genomics and University of Applied Sciences Leiden, Leiden,
                 The Netherlands.",
  abstract    = "The consistent and unambiguous description of sequence
                 variants is essential to report and exchange information on
                 the analysis of a genome. In particular, DNA diagnostics
                 critically depends on accurate and standardized description
                 and sharing of the variants detected. The sequence variant
                 nomenclature system proposed in 2000 by the Human Genome
                 Variation Society has been widely adopted and has developed
                 into an internationally accepted standard. The recommendations
                 are currently commissioned through a Sequence Variant
                 Description Working Group (SVD-WG) operating under the
                 auspices of three international organizations: the Human
                 Genome Variation Society (HGVS), the Human Variome Project
                 (HVP), and the Human Genome Organization (HUGO). Requests for
                 modifications and extensions go through the SVD-WG following a
                 standard procedure including a community consultation step.
                 Version numbers are assigned to the nomenclature system to
                 allow users to specify the version used in their variant
                 descriptions. Here, we present the current recommendations,
                 HGVS version 15.11, and briefly summarize the changes that
                 were made since the 2000 publication. Most focus has been on
                 removing inconsistencies and tightening definitions allowing
                 automatic data processing. An extensive version of the
                 recommendations is available online, at
                 http://www.HGVS.org/varnomen.",
  journal     = "Hum. Mutat.",
  volume      =  37,
  number      =  6,
  pages       = "564--569",
  month       =  jun,
  year        =  2016,
  keywords    = "database; mutation; nomenclature; sequence variation;
                 standards",
  language    = "en"
}

@ARTICLE{Davydov2010-ui,
  title       = "Identifying a high fraction of the human genome to be under
                 selective constraint using {GERP++}",
  author      = "Davydov, Eugene V and Goode, David L and Sirota, Marina and
                 Cooper, Gregory M and Sidow, Arend and Batzoglou, Serafim",
  affiliation = "Department of Computer Science, Stanford University, Stanford,
                 California, United States of America.",
  abstract    = "Computational efforts to identify functional elements within
                 genomes leverage comparative sequence information by looking
                 for regions that exhibit evidence of selective constraint. One
                 way of detecting constrained elements is to follow a bottom-up
                 approach by computing constraint scores for individual
                 positions of a multiple alignment and then defining
                 constrained elements as segments of contiguous, highly scoring
                 nucleotide positions. Here we present GERP++, a new tool that
                 uses maximum likelihood evolutionary rate estimation for
                 position-specific scoring and, in contrast to previous
                 bottom-up methods, a novel dynamic programming approach to
                 subsequently define constrained elements. GERP++ evaluates a
                 richer set of candidate element breakpoints and ranks them
                 based on statistical significance, eliminating the need for
                 biased heuristic extension techniques. Using GERP++ we
                 identify over 1.3 million constrained elements spanning over
                 7\% of the human genome. We predict a higher fraction than
                 earlier estimates largely due to the annotation of longer
                 constrained elements, which improves one to one correspondence
                 between predicted elements with known functional sequences.
                 GERP++ is an efficient and effective tool to provide both
                 nucleotide- and element-level constraint scores within deep
                 multiple sequence alignments.",
  journal     = "PLoS Comput. Biol.",
  volume      =  6,
  number      =  12,
  pages       = "e1001025",
  month       =  "2~" # dec,
  year        =  2010,
  language    = "en"
}

@ARTICLE{Masso2010-gf,
  title       = "{AUTO-MUTE}: web-based tools for predicting stability changes
                 in proteins due to single amino acid replacements",
  author      = "Masso, Majid and Vaisman, Iosif I",
  affiliation = "Laboratory for Structural Bioinformatics, Department of
                 Bioinformatics and Computational Biology, George Mason
                 University, 10900 University Blvd. MS 5B3, Manassas, VA 20110,
                 USA. mmasso@gmu.edu",
  abstract    = "Utilizing cutting-edge supervised classification and
                 regression algorithms, three web-based tools have been
                 developed for predicting stability changes upon single residue
                 substitutions in proteins with known native structures.
                 Trained models classify independent mutant test sets with
                 accuracies ranging from 87 to 94\%. Attributes representing
                 each mutant protein are based on a computational mutagenesis
                 methodology relying on a four-body statistical potential,
                 illustrating a novel integration of both energy-based and
                 machine learning approaches. The servers are written in PHP
                 and hosted on a Linux platform, and they can be freely
                 accessed online along with detailed data sets, documentation
                 and performance results at http://proteins.gmu.edu/automute.",
  journal     = "Protein Eng. Des. Sel.",
  volume      =  23,
  number      =  8,
  pages       = "683--687",
  month       =  aug,
  year        =  2010,
  language    = "en"
}

@ARTICLE{Cancer_Genome_Atlas_Research_Network2013-gt,
  title       = "The Cancer Genome Atlas {Pan-Cancer} analysis project",
  author      = "{Cancer Genome Atlas Research Network} and Weinstein, John N
                 and Collisson, Eric A and Mills, Gordon B and Shaw, Kenna R
                 Mills and Ozenberger, Brad A and Ellrott, Kyle and Shmulevich,
                 Ilya and Sander, Chris and Stuart, Joshua M",
  affiliation = "Human Genome Sequencing Center, Baylor College of Medicine,
                 Houston, Texas, USA.",
  abstract    = "The Cancer Genome Atlas (TCGA) Research Network has profiled
                 and analyzed large numbers of human tumors to discover
                 molecular aberrations at the DNA, RNA, protein and epigenetic
                 levels. The resulting rich data provide a major opportunity to
                 develop an integrated picture of commonalities, differences
                 and emergent themes across tumor lineages. The Pan-Cancer
                 initiative compares the first 12 tumor types profiled by TCGA.
                 Analysis of the molecular aberrations and their functional
                 roles across tumor types will teach us how to extend therapies
                 effective in one cancer type to others with a similar genomic
                 profile.",
  journal     = "Nat. Genet.",
  volume      =  45,
  number      =  10,
  pages       = "1113--1120",
  month       =  oct,
  year        =  2013,
  language    = "en"
}

@UNPUBLISHED{Griffith2016-sy,
  title    = "{CIViC}: A knowledgebase for expert-crowdsourcing the clinical
              interpretation of variants in cancer",
  author   = "Griffith, Malachi and Spies, Nicholas C and Krysiak, Kilannin and
              Coffman, Adam C and McMichael, Joshua F and Ainscough, Benjamin J
              and Rieke, Damian T and Danos, Arpad M and Kujan, Lynzey and
              Ramirez, Cody A and Wagner, Alex H and Skidmore, Zachary L and
              Liu, Connor J and Jones, Martin R and Bilski, Rachel L and
              Lesurf, Robert and Barnell, Erica K and Shah, Nakul M and
              Bonakdar, Melika and Trani, Lee and Matlock, Matthew and Ramu,
              Avinash and Campbell, Katie M and Spies, Gregory C and Graubert,
              Aaron P and Gangavarapu, Karthik and Eldred, James M and Larson,
              David E and Walker, Jason R and Good, Benjamin M and Wu, Chunlei
              and Su, Andrew I and Dienstmann, Rodrigo and Jones, Steven J M
              and Bose, Ron and Spencer, David H and Wartman, Lukas D and
              Wilson, Richard K and Mardis, Elaine R and Griffith, Obi L",
  abstract = "CIViC is an expert crowdsourced knowledgebase for Clinical
              Interpretation of Variants in Cancer (www.civicdb.org) describing
              the therapeutic, prognostic, and diagnostic relevance of
              inherited and somatic variants of all types. CIViC is committed
              to open source code, open access content, public application
              programming interfaces (APIs), and provenance of supporting
              evidence to allow for the transparent creation of current and
              accurate variant interpretations for use in cancer precision
              medicine.",
  journal  = "bioRxiv",
  pages    = "072892",
  month    =  "1~" # sep,
  year     =  2016,
  language = "en"
}

@ARTICLE{Kohler2017-wn,
  title       = "The Human Phenotype Ontology in 2017",
  author      = "K{\"o}hler, Sebastian and Vasilevsky, Nicole A and Engelstad,
                 Mark and Foster, Erin and McMurry, Julie and Aym{\'e},
                 S{\'e}gol{\`e}ne and Baynam, Gareth and Bello, Susan M and
                 Boerkoel, Cornelius F and Boycott, Kym M and Brudno, Michael
                 and Buske, Orion J and Chinnery, Patrick F and Cipriani,
                 Valentina and Connell, Laureen E and Dawkins, Hugh J S and
                 DeMare, Laura E and Devereau, Andrew D and de Vries, Bert B A
                 and Firth, Helen V and Freson, Kathleen and Greene, Daniel and
                 Hamosh, Ada and Helbig, Ingo and Hum, Courtney and J{\"a}hn,
                 Johanna A and James, Roger and Krause, Roland and F
                 Laulederkind, Stanley J and Lochm{\"u}ller, Hanns and Lyon,
                 Gholson J and Ogishima, Soichi and Olry, Annie and Ouwehand,
                 Willem H and Pontikos, Nikolas and Rath, Ana and Schaefer,
                 Franz and Scott, Richard H and Segal, Michael and
                 Sergouniotis, Panagiotis I and Sever, Richard and Smith,
                 Cynthia L and Straub, Volker and Thompson, Rachel and Turner,
                 Catherine and Turro, Ernest and Veltman, Marijcke W M and
                 Vulliamy, Tom and Yu, Jing and von Ziegenweidt, Julie and
                 Zankl, Andreas and Z{\"u}chner, Stephan and Zemojtel, Tomasz
                 and Jacobsen, Julius O B and Groza, Tudor and Smedley, Damian
                 and Mungall, Christopher J and Haendel, Melissa and Robinson,
                 Peter N",
  affiliation = "Institute for Medical Genetics and Human Genetics,
                 Charit{\'e}-Universit{\"a}tsmedizin Berlin, Augustenburger
                 Platz 1, 13353 Berlin, Germany dr.sebastian.koehler@gmail.com.
                 Library and Department of Medical Informatics and Clinical
                 Epidemiology, Oregon Health \& Science University, Portland,
                 OR 97239, USA. Library and Department of Medical Informatics
                 and Clinical Epidemiology, Oregon Health \& Science
                 University, Portland, OR 97239, USA. Library and Department of
                 Medical Informatics and Clinical Epidemiology, Oregon Health
                 \& Science University, Portland, OR 97239, USA. Library and
                 Department of Medical Informatics and Clinical Epidemiology,
                 Oregon Health \& Science University, Portland, OR 97239, USA.
                 Institut du Cerveau et de la Moelle {\'e}pini{\`e}re-ICM, CNRS
                 UMR 7225-Inserm U 1127-UPMC-P6 UMR S 1127, H{\^o}pital
                 Piti{\'e}-Salp{\^e}tri{\`e}re, 47, bd de l'H{\^o}pital, 75013
                 Paris, France. Western Australian Register of Developmental
                 Anomalies and Genetic Services of Western Australia, King
                 Edward Memorial Hospital Department of Health, Government of
                 Western Australia, Perth, WA 6008, Australia. School of
                 Paediatrics and Child Health, University of Western Australia,
                 Perth, WA 6008, Australia. The Jackson Laboratory, 600 Main
                 St, Bar Harbor, ME 04609, USA. Imagenetics Research, Sanford
                 Health, PO Box 5039, Route 5001, Sioux Falls, SD 57117-5039,
                 USA. Children's Hospital of Eastern Ontario Research
                 Institute, University of Ottawa, Ottawa, Ontario, Canada.
                 Department of Computer Science, University of Toronto,
                 Toronto, ON M5S 2E4, Canada Centre for Computational Medicine,
                 Hospital for Sick Children, Toronto, ON M5G 1L7, Canada.
                 Department of Computer Science, University of Toronto,
                 Toronto, ON M5S 2E4, Canada Centre for Computational Medicine,
                 Hospital for Sick Children, Toronto, ON M5G 1L7, Canada.
                 Department of Clinical Neurosciences, School of Clinical
                 Medicine, University of Cambridge, Cambridge CB2 0QQ, UK. NIHR
                 Rare Diseases Translational Research Collaboration, Cambridge
                 Biomedical Campus, Cambridge CB2 0QQ, UK. UCL Institute of
                 Ophthalmology, Department of Ocular Biology and Therapeutics,
                 11-43 Bath Street, London EC1V 9EL, UK. UCL Genetics
                 Institute, University College London, London WC1E 6BT, UK.
                 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,
                 USA. Office of Population Health Genomics, Public Health
                 Division, Health Department of Western Australia, 189 Royal
                 Street, Perth, WA, 6004 Australia. Cold Spring Harbor
                 Laboratory Press, Cold Spring Harbor, NY, USA. Genomics
                 England, Queen Mary University of London, Dawson Hall,
                 Charterhouse Square, London EC1M 6BQ, UK. Department of Human
                 Genetics, Radboud University, University Medical Centre,
                 Nijmegen, The Netherlands. Wellcome Trust Sanger Institute,
                 Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
                 Department of Cardiovascular Sciences, Center for Molecular
                 and Vascular Biology, University of Leuven, Leuven, Belgium.
                 Department of Haematology, University of Cambridge, NHS Blood
                 and Transplant Centre, Long Road, Cambridge CB2 0PT, UK.
                 Medical Research Council Biostatistics Unit, Cambridge
                 Institute of Public Health, Cambridge Biomedical Campus,
                 Cambridge, UK. McKusick-Nathans Institute of Genetic Medicine,
                 Department of Pediatrics, Johns Hopkins University School of
                 Medicine, Baltimore, MD, USA. Division of Neurology, The
                 Children's Hospital of Philadelphia, 3501 Civic Center Blvd,
                 Philadelphia, PA 19104, USA. Department of Neuropediatrics,
                 University Medical Center Schleswig-Holstein (UKSH), Kiel,
                 Germany. Centre for Computational Medicine, The Hospital for
                 Sick Children, Toronto, ON M5G 1H3, Canada. Department of
                 Neuropediatrics, University Medical Center Schleswig-Holstein
                 (UKSH), Kiel, Germany. NIHR Rare Diseases Translational
                 Research Collaboration, Cambridge Biomedical Campus, Cambridge
                 CB2 0QQ, UK. Medical Research Council Biostatistics Unit,
                 Cambridge Institute of Public Health, Cambridge Biomedical
                 Campus, Cambridge, UK. LuxembourgCentre for Systems
                 Biomedicine, University of Luxembourg, 7, avenue des
                 Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg. Human
                 and Molecular Genetics Center, Medical College of Wisconsin,
                 USA. John Walton Muscular Dystrophy Research Centre, MRC
                 Centre for Neuromuscular Diseases, Institute of Genetic
                 Medicine, University of Newcastle, Newcastle upon Tyne, UK.
                 Stanley Institute for Cognitive Genomics, Cold Spring Harbor
                 Laboratory, New York, NY 11797, USA. Dept of Bioclinical
                 Informatics, Tohoku Medical Megabank Organization, Tohoku
                 University, Tohoku Medical Megabank Organization Bldg 7F room
                 \#741,736, Seiryo 2-1, Aoba-ku, Sendai Miyagi 980-8573 Japan.
                 Orphanet-INSERM, US14, Plateforme Maladies Rares, 96 rue
                 Didot, 75014 Paris, France. Medical Research Council
                 Biostatistics Unit, Cambridge Institute of Public Health,
                 Cambridge Biomedical Campus, Cambridge, UK. UCL Institute of
                 Ophthalmology, Department of Ocular Biology and Therapeutics,
                 11-43 Bath Street, London EC1V 9EL, UK. UCL Genetics
                 Institute, University College London, London WC1E 6BT, UK.
                 Orphanet-INSERM, US14, Plateforme Maladies Rares, 96 rue
                 Didot, 75014 Paris, France. Division of Pediatric Nephrology
                 and KFH Children's Kidney Center, Center for Pediatrics and
                 Adolescent Medicine, 69120 Heidelberg, Germany. Genomics
                 England, Queen Mary University of London, Dawson Hall,
                 Charterhouse Square, London EC1M 6BQ, UK. SimulConsult Inc.,
                 27 Crafts Road, Chestnut Hill, MA 02467, USA. Manchester Royal
                 Eye Hospital \& University of Manchester, Manchester M13 9WL,
                 UK. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
                 NY, USA. The Jackson Laboratory, 600 Main St, Bar Harbor, ME
                 04609, USA. John Walton Muscular Dystrophy Research Centre,
                 MRC Centre for Neuromuscular Diseases, Institute of Genetic
                 Medicine, University of Newcastle, Newcastle upon Tyne, UK.
                 John Walton Muscular Dystrophy Research Centre, MRC Centre for
                 Neuromuscular Diseases, Institute of Genetic Medicine,
                 University of Newcastle, Newcastle upon Tyne, UK. John Walton
                 Muscular Dystrophy Research Centre, MRC Centre for
                 Neuromuscular Diseases, Institute of Genetic Medicine,
                 University of Newcastle, Newcastle upon Tyne, UK. Department
                 of Haematology, University of Cambridge, NHS Blood and
                 Transplant Centre, Long Road, Cambridge CB2 0PT, UK. Medical
                 Research Council Biostatistics Unit, Cambridge Institute of
                 Public Health, Cambridge Biomedical Campus, Cambridge, UK.
                 NIHR Rare Diseases Translational Research Collaboration,
                 Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. Blizard
                 Institute, Barts and The London School of Medicine and
                 Dentistry, Queen Mary University of London, London E1 2AT, UK.
                 Nuffield Department of Clinical Neurosciences, University of
                 Oxford, Level 6, West Wing, John Radcliffe Hospital, Oxford
                 OX3 9DU, UK. Department of Haematology, University of
                 Cambridge, NHS Blood and Transplant Centre, Long Road,
                 Cambridge CB2 0PT, UK. Discipline of Genetic Medicine, Sydney
                 Medical School, The University of Sydney, Australia. Academic
                 Department of Medical Genetics, Sydney Childrens Hospitals
                 Network (Westmead), Australia. JD McDonald Department of Human
                 Genetics and Hussman Institute for Human Genomics, University
                 of Miami, Miami, FL, USA. Institute for Medical Genetics and
                 Human Genetics, Charit{\'e}-Universit{\"a}tsmedizin Berlin,
                 Augustenburger Platz 1, 13353 Berlin, Germany. Genomics
                 England, Queen Mary University of London, Dawson Hall,
                 Charterhouse Square, London EC1M 6BQ, UK. Garvan Institute of
                 Medical Research, Darlinghurst, Sydney, NSW 2010, Australia.
                 St Vincent's Clinical School, Faculty of Medicine, UNSW
                 Australia. Genomics England, Queen Mary University of London,
                 Dawson Hall, Charterhouse Square, London EC1M 6BQ, UK.
                 Environmental Genomics and Systems Biology Division, Lawrence
                 Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA
                 94720, USA. Library and Department of Medical Informatics and
                 Clinical Epidemiology, Oregon Health \& Science University,
                 Portland, OR 97239, USA. The Jackson Laboratory for Genomic
                 Medicine, 10 Discovery Drive, Farmington, CT 06032, USA
                 peter.robinson@jax.org. Institute for Systems Genomics,
                 University of Connecticut, Farmington, CT 06032, USA.",
  abstract    = "Deep phenotyping has been defined as the precise and
                 comprehensive analysis of phenotypic abnormalities in which
                 the individual components of the phenotype are observed and
                 described. The three components of the Human Phenotype
                 Ontology (HPO; www.human-phenotype-ontology.org) project are
                 the phenotype vocabulary, disease-phenotype annotations and
                 the algorithms that operate on these. These components are
                 being used for computational deep phenotyping and precision
                 medicine as well as integration of clinical data into
                 translational research. The HPO is being increasingly adopted
                 as a standard for phenotypic abnormalities by diverse groups
                 such as international rare disease organizations, registries,
                 clinical labs, biomedical resources, and clinical software
                 tools and will thereby contribute toward nascent efforts at
                 global data exchange for identifying disease etiologies. This
                 update article reviews the progress of the HPO project since
                 the debut Nucleic Acids Research database article in 2014,
                 including specific areas of expansion such as common (complex)
                 disease, new algorithms for phenotype driven genomic discovery
                 and diagnostics, integration of cross-species mapping efforts
                 with the Mammalian Phenotype Ontology, an improved quality
                 control pipeline, and the addition of patient-friendly
                 terminology.",
  journal     = "Nucleic Acids Res.",
  volume      =  45,
  number      = "D1",
  pages       = "D865--D876",
  month       =  "4~" # jan,
  year        =  2017,
  language    = "en"
}

@ARTICLE{Langmead2009-pw,
  title    = "Ultrafast and memory-efficient alignment of short {DNA} sequences
              to the human genome",
  author   = "Langmead, Ben and Trapnell, Cole and Pop, Mihai and Salzberg,
              Steven L",
  abstract = "Bowtie is an ultrafast, memory-efficient alignment program for
              aligning short DNA sequence reads to large genomes. For the human
              genome, Burrows-Wheeler indexing allows Bowtie to align more than
              25 million reads per CPU hour with a memory footprint of
              approximately 1.3 gigabytes. Bowtie extends previous
              Burrows-Wheeler techniques with a novel quality-aware
              backtracking algorithm that permits mismatches. Multiple
              processor cores can be used simultaneously to achieve even
              greater alignment speeds. Bowtie is open source
              http://bowtie.cbcb.umd.edu .",
  journal  = "Genome Biol.",
  volume   =  10,
  number   =  3,
  pages    = "R25",
  year     =  2009
}

@ARTICLE{Chakravarty2017-gx,
  title     = "{OncoKB}: A Precision Oncology Knowledge Base",
  author    = "Chakravarty, Debyani and Gao, Jianjiong and Phillips, Sarah and
               Kundra, Ritika and Zhang, Hongxin and Wang, Jiaojiao and
               Rudolph, Julia E and Yaeger, Rona and Soumerai, Tara and Nissan,
               Moriah H and Chang, Matthew T and Chandarlapaty, Sarat and
               Traina, Tiffany A and Paik, Paul K and Ho, Alan L and Hantash,
               Feras M and Grupe, Andrew and Baxi, Shrujal S and Callahan,
               Margaret K and Snyder, Alexandra and Chi, Ping and Danila,
               Daniel C and Gounder, Mrinal and Harding, James J and Hellmann,
               Matthew D and Iyer, Gopa and Janjigian, Yelena Y and Kaley,
               Thomas and Levine, Douglas A and Lowery, Maeve and Omuro,
               Antonio and Postow, Michael A and Rathkopf, Dana and Shoushtari,
               Alexander N and Shukla, Neerav and Voss, Martin H and Paraiso,
               Ederlinda and Zehir, Ahmet and Berger, Michael F and Taylor,
               Barry S and Saltz, Leonard B and Riely, Gregory J and Ladanyi,
               Marc and Hyman, David M and Baselga, Jos{\'e} and Sabbatini,
               Paul and Solit, David B and Schultz, Nikolaus",
  abstract  = "PurposeWith prospective clinical sequencing of tumors emerging
               as a mainstay in cancer care, an urgent need exists for a
               clinical support tool that distills the clinical implications
               associated with specific mutation events into a standardized and
               easily interpretable format. To this end, we developed OncoKB,
               an expert-guided precision oncology knowledge base.MethodsOncoKB
               annotates the biologic and oncogenic effects and prognostic and
               predictive significance of somatic molecular alterations.
               Potential treatment implications are stratified by the level of
               evidence that a specific molecular alteration is predictive of
               drug response on the basis of US Food and Drug Administration
               labeling, National Comprehensive Cancer Network guidelines,
               disease-focused expert group recommendations, and scientific
               literature.ResultsTo date, > 3,000 unique mutations, fusions,
               and copy number alterations in 418 cancer-associated genes have
               been annotated. To test the utility of OncoKB, we annotated all
               genomic events in 5,983 primary tumor samples in 19 cancer
               types. Forty-one percent of samples harbored at least one
               potentially actionable alteration, of which 7.5\% were
               predictive of clinical benefit from a standard treatment. OncoKB
               annotations are available through a public Web resource
               (http://oncokb.org) and are incorporated into the cBioPortal for
               Cancer Genomics to facilitate the interpretation of genomic
               alterations by physicians and researchers.ConclusionOncoKB, a
               comprehensive and curated precision oncology knowledge base,
               offers oncologists detailed, evidence-based information about
               individual somatic mutations and structural alterations present
               in patient tumors with the goal of supporting optimal treatment
               decisions.",
  journal   = "JCO Precision Oncology",
  publisher = "American Society of Clinical Oncology",
  number    =  1,
  pages     = "1--16",
  month     =  "1~" # may,
  year      =  2017
}

@ARTICLE{Bouaoun2016-yy,
  title       = "{TP53} Variations in Human Cancers: New Lessons from the
                 {IARC} {TP53} Database and Genomics Data",
  author      = "Bouaoun, Liacine and Sonkin, Dmitriy and Ardin, Maude and
                 Hollstein, Monica and Byrnes, Graham and Zavadil, Jiri and
                 Olivier, Magali",
  affiliation = "Group of Biostatistics, International Agency for Research on
                 Cancer, Lyon Cedex 08, 69372, France. Division of Cancer
                 Treatment and Diagnosis, Biometric Research Program, National
                 Cancer Institute, Rockville, 9609, Maryland. Group of
                 Molecular Mechanisms and Biomarkers, International Agency for
                 Research on Cancer, Lyon Cedex 08, 69372, France. Group of
                 Molecular Mechanisms and Biomarkers, International Agency for
                 Research on Cancer, Lyon Cedex 08, 69372, France. Faculty of
                 Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
                 Group of Biostatistics, International Agency for Research on
                 Cancer, Lyon Cedex 08, 69372, France. Group of Molecular
                 Mechanisms and Biomarkers, International Agency for Research
                 on Cancer, Lyon Cedex 08, 69372, France. Group of Molecular
                 Mechanisms and Biomarkers, International Agency for Research
                 on Cancer, Lyon Cedex 08, 69372, France.",
  abstract    = "TP53 gene mutations are one of the most frequent somatic
                 events in cancer. The IARC TP53 Database (http://p53.iarc.fr)
                 is a popular resource that compiles occurrence and phenotype
                 data on TP53 germline and somatic variations linked to human
                 cancer. The deluge of data coming from cancer genomic studies
                 generates new data on TP53 variations and attracts a growing
                 number of database users for the interpretation of TP53
                 variants. Here, we present the current contents and
                 functionalities of the IARC TP53 Database and perform a
                 systematic analysis of TP53 somatic mutation data extracted
                 from this database and from genomic data repositories. This
                 analysis showed that IARC has more TP53 somatic mutation data
                 than genomic repositories (29,000 vs. 4,000). However, the
                 more complete screening achieved by genomic studies
                 highlighted some overlooked facts about TP53 mutations, such
                 as the presence of a significant number of mutations occurring
                 outside the DNA-binding domain in specific cancer types. We
                 also provide an update on TP53 inherited variants including
                 the ones that should be considered as neutral frequent
                 variations. We thus provide an update of current knowledge on
                 TP53 variations in human cancer as well as inform users on the
                 efficient use of the IARC TP53 Database.",
  journal     = "Hum. Mutat.",
  volume      =  37,
  number      =  9,
  pages       = "865--876",
  month       =  sep,
  year        =  2016,
  keywords    = "TP53; annotations; cancer; germline variations; locus-specific
                 database; mutation hotspots; somatic mutations",
  language    = "en"
}

@ARTICLE{Bao2005-jn,
  title       = "{nsSNPAnalyzer}: identifying disease-associated nonsynonymous
                 single nucleotide polymorphisms",
  author      = "Bao, Lei and Zhou, Mi and Cui, Yan",
  affiliation = "Department of Molecular Sciences, Center of Genomics and
                 Bioinformatics, University of Tennessee Health Science Center,
                 858 Madison Avenue, Memphis, TN 38163, USA.",
  abstract    = "Nonsynonymous single nucleotide polymorphisms (nsSNPs) are
                 prevalent in genomes and are closely associated with inherited
                 diseases. To facilitate identifying disease-associated nsSNPs
                 from a large number of neutral nsSNPs, it is important to
                 develop computational tools to predict the nsSNP's phenotypic
                 effect (disease-associated versus neutral). nsSNPAnalyzer, a
                 web-based software developed for this purpose, extracts
                 structural and evolutionary information from a query nsSNP and
                 uses a machine learning method called Random Forest to predict
                 the nsSNP's phenotypic effect. nsSNPAnalyzer server is
                 available at http://snpanalyzer.utmem.edu/.",
  journal     = "Nucleic Acids Res.",
  volume      =  33,
  number      = "Web Server issue",
  pages       = "W480--2",
  month       =  "1~" # jul,
  year        =  2005,
  language    = "en"
}

@ARTICLE{Ai2014-nf,
  title       = "Practical management of patients with chronic myeloid leukemia
                 who develop tyrosine kinase inhibitor-resistant {BCR-ABL1}
                 mutations",
  author      = "Ai, Jing and Tiu, Ramon V",
  affiliation = "Cleveland Clinic, Cleveland, OH, USA. Translational Hematology
                 and Oncology Research, Cleveland Clinic, Mail Code R40, 9500
                 Euclid Avenue, Cleveland, OH 44195, USA.",
  abstract    = "Five BCR-ABL1 tyrosine kinase inhibitors (TKIs), imatinib,
                 nilotinib, dasatinib, bosutinib, and ponatinib, are currently
                 approved for the treatment of chronic myeloid leukemia (CML).
                 Standard treatment of CML with TKIs is highly effective in
                 reducing disease burden, delaying disease progression, and
                 prolonging overall survival of patients; however, resistance
                 to TKI treatment has become an increasingly important cause of
                 treatment failure. The emergence of mutations in the BCR-ABL1
                 kinase domain is a common mechanism of TKI resistance, and
                 laboratory testing to detect these mutations is currently
                 available for clinical use. Patients who do not respond or
                 have lost their response to TKI therapy should be considered
                 for mutational testing. Despite clinical practice guidelines
                 that recommend testing for BCR-ABL1 mutations in patients with
                 clinical signs of TKI resistance, many oncologists and
                 hematologists managing patients with CML do not perform such
                 testing. This review addresses outstanding questions related
                 to when testing should be conducted, what type of testing
                 should be done, and how testing results should be applied to
                 subsequent therapeutic decisions. It describes how BCR-ABL1
                 kinase domain mutations confer resistance, outlines the
                 prevalence of mutations in patients with resistance to TKIs,
                 summarizes the common and investigational methods used in
                 mutational testing, and presents an algorithm reflecting a
                 clinical perspective on how and when to conduct mutational
                 testing, and what to do with test results.",
  journal     = "Ther. Adv. Hematol.",
  volume      =  5,
  number      =  4,
  pages       = "107--120",
  month       =  aug,
  year        =  2014,
  keywords    = "BCR-ABL1; DNA mutational analysis; chronic myeloid leukemia;
                 drug resistance; missense mutation",
  language    = "en"
}

@ARTICLE{Tang2016-ot,
  title       = "Evaluation of Bioinformatic Programmes for the Analysis of
                 Variants within Splice Site Consensus Regions",
  author      = "Tang, Rongying and Prosser, Debra O and Love, Donald R",
  affiliation = "Diagnostic Genetics, LabPLUS, Auckland City Hospital, P.O. Box
                 110031, Auckland 1148, New Zealand. Diagnostic Genetics,
                 LabPLUS, Auckland City Hospital, P.O. Box 110031, Auckland
                 1148, New Zealand. Diagnostic Genetics, LabPLUS, Auckland City
                 Hospital, P.O. Box 110031, Auckland 1148, New Zealand.",
  abstract    = "The increasing diagnostic use of gene sequencing has led to an
                 expanding dataset of novel variants that lie within consensus
                 splice junctions. The challenge for diagnostic laboratories is
                 the evaluation of these variants in order to determine if they
                 affect splicing or are merely benign. A common evaluation
                 strategy is to use in silico analysis, and it is here that a
                 number of programmes are available online; however, currently,
                 there are no consensus guidelines on the selection of
                 programmes or protocols to interpret the prediction results.
                 Using a collection of 222 pathogenic mutations and 50 benign
                 polymorphisms, we evaluated the sensitivity and specificity of
                 four in silico programmes in predicting the effect of each
                 variant on splicing. The programmes comprised Human Splice
                 Finder (HSF), Max Entropy Scan (MES), NNSplice, and ASSP. The
                 MES and ASSP programmes gave the highest performance based on
                 Receiver Operator Curve analysis, with an optimal cut-off of
                 score reduction of 10\%. The study also showed that the
                 sensitivity of prediction is affected by the level of
                 conservation of individual positions, with in silico
                 predictions for variants at positions -4 and +7 within
                 consensus splice sites being largely uninformative.",
  journal     = "Adv. Bioinformatics",
  volume      =  2016,
  pages       = "5614058",
  month       =  "24~" # may,
  year        =  2016,
  language    = "en"
}

@ARTICLE{Bateman2004-da,
  title       = "The Pfam protein families database",
  author      = "Bateman, Alex and Coin, Lachlan and Durbin, Richard and Finn,
                 Robert D and Hollich, Volker and Griffiths-Jones, Sam and
                 Khanna, Ajay and Marshall, Mhairi and Moxon, Simon and
                 Sonnhammer, Erik L L and Studholme, David J and Yeats, Corin
                 and Eddy, Sean R",
  affiliation = "Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
                 Hinxton, Cambridge CB10 1SA, UK. agb@sanger.ac.uk",
  abstract    = "Pfam is a large collection of protein families and domains.
                 Over the past 2 years the number of families in Pfam has
                 doubled and now stands at 6190 (version 10.0). Methodology
                 improvements for searching the Pfam collection locally as well
                 as via the web are described. Other recent innovations include
                 modelling of discontinuous domains allowing Pfam domain
                 definitions to be closer to those found in structure
                 databases. Pfam is available on the web in the UK
                 (http://www.sanger.ac.uk/Software/Pfam/), the USA
                 (http://pfam.wustl.edu/), France (http://pfam.jouy.inra.fr/)
                 and Sweden (http://Pfam.cgb.ki.se/).",
  journal     = "Nucleic Acids Res.",
  publisher   = "Oxford Univ Press",
  volume      =  32,
  number      = "Database issue",
  pages       = "D138--41",
  month       =  "1~" # jan,
  year        =  2004,
  language    = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Choi2012-tk,
  title       = "Predicting the functional effect of amino acid substitutions
                 and indels",
  author      = "Choi, Yongwook and Sims, Gregory E and Murphy, Sean and
                 Miller, Jason R and Chan, Agnes P",
  affiliation = "The J. Craig Venter Institute, Rockville, Maryland, United
                 States of America.",
  abstract    = "As next-generation sequencing projects generate massive
                 genome-wide sequence variation data, bioinformatics tools are
                 being developed to provide computational predictions on the
                 functional effects of sequence variations and narrow down the
                 search of casual variants for disease phenotypes. Different
                 classes of sequence variations at the nucleotide level are
                 involved in human diseases, including substitutions,
                 insertions, deletions, frameshifts, and non-sense mutations.
                 Frameshifts and non-sense mutations are likely to cause a
                 negative effect on protein function. Existing prediction tools
                 primarily focus on studying the deleterious effects of single
                 amino acid substitutions through examining amino acid
                 conservation at the position of interest among related
                 sequences, an approach that is not directly applicable to
                 insertions or deletions. Here, we introduce a versatile
                 alignment-based score as a new metric to predict the damaging
                 effects of variations not limited to single amino acid
                 substitutions but also in-frame insertions, deletions, and
                 multiple amino acid substitutions. This alignment-based score
                 measures the change in sequence similarity of a query sequence
                 to a protein sequence homolog before and after the
                 introduction of an amino acid variation to the query sequence.
                 Our results showed that the scoring scheme performs well in
                 separating disease-associated variants (n = 21,662) from
                 common polymorphisms (n = 37,022) for UniProt human protein
                 variations, and also in separating deleterious variants (n =
                 15,179) from neutral variants (n = 17,891) for UniProt
                 non-human protein variations. In our approach, the area under
                 the receiver operating characteristic curve (AUC) for the
                 human and non-human protein variation datasets is 0.85. We
                 also observed that the alignment-based score correlates with
                 the deleteriousness of a sequence variation. In summary, we
                 have developed a new algorithm, PROVEAN (Protein Variation
                 Effect Analyzer), which provides a generalized approach to
                 predict the functional effects of protein sequence variations
                 including single or multiple amino acid substitutions, and
                 in-frame insertions and deletions. The PROVEAN tool is
                 available online at http://provean.jcvi.org.",
  journal     = "PLoS One",
  volume      =  7,
  number      =  10,
  pages       = "e46688",
  month       =  "8~" # oct,
  year        =  2012,
  language    = "en"
}

@ARTICLE{Beltran2015-pz,
  title       = "{Whole-Exome} Sequencing of Metastatic Cancer and Biomarkers
                 of Treatment Response",
  author      = "Beltran, Himisha and Eng, Kenneth and Mosquera, Juan Miguel
                 and Sigaras, Alexandros and Romanel, Alessandro and Rennert,
                 Hanna and Kossai, Myriam and Pauli, Chantal and Faltas, Bishoy
                 and Fontugne, Jacqueline and Park, Kyung and Banfelder, Jason
                 and Prandi, Davide and Madhukar, Neel and Zhang, Tuo and
                 Padilla, Jessica and Greco, Noah and McNary, Terra J and
                 Herrscher, Erick and Wilkes, David and MacDonald, Theresa Y
                 and Xue, Hui and Vacic, Vladimir and Emde, Anne-Katrin and
                 Oschwald, Dayna and Tan, Adrian Y and Chen, Zhengming and
                 Collins, Colin and Gleave, Martin E and Wang, Yuzhuo and
                 Chakravarty, Dimple and Schiffman, Marc and Kim, Robert and
                 Campagne, Fabien and Robinson, Brian D and Nanus, David M and
                 Tagawa, Scott T and Xiang, Jenny Z and Smogorzewska, Agata and
                 Demichelis, Francesca and Rickman, David S and Sboner, Andrea
                 and Elemento, Olivier and Rubin, Mark A",
  affiliation = "Institute for Precision Medicine, New York Presbyterian
                 Hospital-Weill Cornell Medical College, New York, New
                 York2Division of Hematology and Medical Oncology, Weill
                 Cornell Medical College, New York, New York3Department of
                 Medicine, Weill Cornell Medical. Institute for Precision
                 Medicine, New York Presbyterian Hospital-Weill Cornell Medical
                 College, New York, New York4Institute for Computational
                 Biomedicine, Weill Cornell Medical College, New York, New
                 York. Institute for Precision Medicine, New York Presbyterian
                 Hospital-Weill Cornell Medical College, New York, New
                 York5Department of Pathology and Laboratory Medicine, Weill
                 Cornell Medical College, New York, New York. Institute for
                 Precision Medicine, New York Presbyterian Hospital-Weill
                 Cornell Medical College, New York, New York. Centre of
                 Integrative Biology, University of Trento, Trento, Italy.
                 Department of Pathology and Laboratory Medicine, Weill Cornell
                 Medical College, New York, New York. Institute for Precision
                 Medicine, New York Presbyterian Hospital-Weill Cornell Medical
                 College, New York, New York5Department of Pathology and
                 Laboratory Medicine, Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York5Department of Pathology and Laboratory Medicine,
                 Weill Cornell Medical College, New York, New York. Division of
                 Hematology and Medical Oncology, Weill Cornell Medical
                 College, New York, New York. Institute for Precision Medicine,
                 New York Presbyterian Hospital-Weill Cornell Medical College,
                 New York, New York5Department of Pathology and Laboratory
                 Medicine, Weill Cornell Medical College, New York, New York.
                 Department of Pathology and Laboratory Medicine, Weill Cornell
                 Medical College, New York, New York. Institute for Precision
                 Medicine, New York Presbyterian Hospital-Weill Cornell Medical
                 College, New York, New York4Institute for Computational
                 Biomedicine, Weill Cornell Medical College, New York, New
                 York. Centre of Integrative Biology, University of Trento,
                 Trento, Italy. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York4Institute for Computational Biomedicine, Weill
                 Cornell Medical College, New York, New York. Institute for
                 Precision Medicine, New York Presbyterian Hospital-Weill
                 Cornell Medical College, New York, New York4Institute for
                 Computational Biomedicine, Weill Cornell Medical College, New
                 York, New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Department of Pathology and Laboratory Medicine,
                 Weill Cornell Medical College, New York, New York. Vancouver
                 Prostate Centre, University of British Columbia, Vancouver,
                 Canada. New York Genome Center, New York, New York. New York
                 Genome Center, New York, New York. New York Genome Center, New
                 York, New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Department of Biostatistics and Epidemiology, Weill
                 Cornell Medical College, New York, New York. Centre of
                 Integrative Biology, University of Trento, Trento, Italy.
                 Centre of Integrative Biology, University of Trento, Trento,
                 Italy. Centre of Integrative Biology, University of Trento,
                 Trento, Italy. Department of Pathology and Laboratory
                 Medicine, Weill Cornell Medical College, New York, New York.
                 Department of Radiology, Weill Cornell Medical College, New
                 York, New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York4Institute for Computational Biomedicine, Weill
                 Cornell Medical College, New York, New York. Institute for
                 Computational Biomedicine, Weill Cornell Medical College, New
                 York, New York11Department of Physiology and Biophysics, Weill
                 Cornell Medical College, New York, New York. Institute for
                 Precision Medicine, New York Presbyterian Hospital-Weill
                 Cornell Medical College, New York, New York6Centre of
                 Integrative Biology, University of Trento, Trento, Italy.
                 Division of Hematology and Medical Oncology, Weill Cornell
                 Medical College, New York, New York. Division of Hematology
                 and Medical Oncology, Weill Cornell Medical College, New York,
                 New York. Institute for Precision Medicine, New York
                 Presbyterian Hospital-Weill Cornell Medical College, New York,
                 New York. Rockefeller University, New York, New York.
                 Department of Pathology and Laboratory Medicine, Weill Cornell
                 Medical College, New York, New York6Centre of Integrative
                 Biology, University of Trento, Trento, Italy. Institute for
                 Precision Medicine, New York Presbyterian Hospital-Weill
                 Cornell Medical College, New York, New York5Department of
                 Pathology and Laboratory Medicine, Weill Cornell Medical
                 College, New York, New York. Institute for Precision Medicine,
                 New York Presbyterian Hospital-Weill Cornell Medical College,
                 New York, New York4Institute for Computational Biomedicine,
                 Weill Cornell Medical College, New York, New York5Department
                 of Pathology and Laboratory Medicine. Institute for Precision
                 Medicine, New York Presbyterian Hospital-Weill Cornell Medical
                 College, New York, New York4Institute for Computational
                 Biomedicine, Weill Cornell Medical College, New York, New
                 York. Institute for Precision Medicine, New York Presbyterian
                 Hospital-Weill Cornell Medical College, New York, New
                 York5Department of Pathology and Laboratory Medicine, Weill
                 Cornell Medical College, New York, New York.",
  abstract    = "IMPORTANCE: Understanding molecular mechanisms of response and
                 resistance to anticancer therapies requires prospective
                 patient follow-up and clinical and functional validation of
                 both common and low-frequency mutations. We describe a
                 whole-exome sequencing (WES) precision medicine trial focused
                 on patients with advanced cancer. OBJECTIVE: To understand how
                 WES data affect therapeutic decision making in patients with
                 advanced cancer and to identify novel biomarkers of response.
                 DESIGN, SETTING, AND PATIENTS: Patients with metastatic and
                 treatment-resistant cancer were prospectively enrolled at a
                 single academic center for paired metastatic tumor and normal
                 tissue WES during a 19-month period (February 2013 through
                 September 2014). A comprehensive computational pipeline was
                 used to detect point mutations, indels, and copy number
                 alterations. Mutations were categorized as category 1, 2, or 3
                 on the basis of actionability; clinical reports were generated
                 and discussed in precision tumor board. Patients were observed
                 for 7 to 25 months for correlation of molecular information
                 with clinical response. MAIN OUTCOMES AND MEASURES:
                 Feasibility, use of WES for decision making, and
                 identification of novel biomarkers. RESULTS: A total of 154
                 tumor-normal pairs from 97 patients with a range of metastatic
                 cancers were sequenced, with a mean coverage of 95X and 16
                 somatic alterations detected per patient. In total, 16
                 mutations were category 1 (targeted therapy available), 98
                 were category 2 (biologically relevant), and 1474 were
                 category 3 (unknown significance). Overall, WES provided
                 informative results in 91 cases (94\%), including alterations
                 for which there is an approved drug, there are therapies in
                 clinical or preclinical development, or they are considered
                 drivers and potentially actionable (category 1-2); however,
                 treatment was guided in only 5 patients (5\%) on the basis of
                 these recommendations because of access to clinical trials
                 and/or off-label use of drugs. Among unexpected findings, a
                 patient with prostate cancer with exceptional response to
                 treatment was identified who harbored a somatic hemizygous
                 deletion of the DNA repair gene FANCA and putative partial
                 loss of function of the second allele through germline
                 missense variant. Follow-up experiments established that loss
                 of FANCA function was associated with platinum
                 hypersensitivity both in vitro and in patient-derived
                 xenografts, thus providing biologic rationale and functional
                 evidence for his extreme clinical response. CONCLUSIONS AND
                 RELEVANCE: The majority of advanced, treatment-resistant
                 tumors across tumor types harbor biologically informative
                 alterations. The establishment of a clinical trial for WES of
                 metastatic tumors with prospective follow-up of patients can
                 help identify candidate predictive biomarkers of response.",
  journal     = "JAMA Oncol",
  volume      =  1,
  number      =  4,
  pages       = "466--474",
  month       =  jul,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Ghazani2017-oo,
  title       = "Assigning clinical meaning to somatic and germ-line
                 whole-exome sequencing data in a prospective cancer precision
                 medicine study",
  author      = "Ghazani, Arezou A and Oliver, Nelly M and St Pierre, Joseph P
                 and Garofalo, Andrea and Rainville, Irene R and Hiller, Elaine
                 and Treacy, Daniel J and Rojas-Rudilla, Vanesa and Wood, Sam
                 and Bair, Elizabeth and Parello, Michael and Huang, Franklin
                 and Giannakis, Marios and Wilson, Frederick H and Stover,
                 Elizabeth H and Corsello, Steven M and Nguyen, Tom and Rana,
                 Huma Q and Church, Alanna J and Lowenstein, Carol and
                 Cibulskis, Carrie and Amin-Mansour, Ali and Heng, Jennifer and
                 Brais, Lauren and Santos, Abigail and Bauer, Patrick and
                 Waldron, Amanda and Lo, Peter and Gorman, Megan and Lydon,
                 Christine A and Welch, Marisa and McNamara, Philip and
                 Gabriel, Stacey and Sholl, Lynette M and Lindeman, Neal I and
                 Garber, Judy E and Joffe, Steven and Van Allen, Eliezer M and
                 Gray, Stacy W and Ja Nne, Pasi A and Garraway, Levi A and
                 Wagle, Nikhil",
  affiliation = "Center for Cancer Precision Medicine, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Department of Medical
                 Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
                 USA. Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA. Center for Cancer Precision Medicine,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts,
                 USA. Department of Medical Oncology, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Center for Cancer
                 Genetics and Prevention, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Center for Cancer Genetics and Prevention, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Center for Cancer
                 Precision Medicine, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Pathology, Brigham and Women's Hospital, Boston,
                 Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts, USA. Department of Medical
                 Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
                 USA. Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts,
                 USA. Department of Medical Oncology, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts, USA. Department of
                 Medical Oncology, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Center for Cancer Genetics and
                 Prevention, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Department of Pathology, Boston Children's
                 Hospital, Boston, Massachusetts, USA. Department of Medical
                 Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
                 USA. Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA. Broad Institute of MIT and Harvard,
                 Cambridge, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts, USA. Department of
                 Pathology, Brigham and Women's Hospital, Boston,
                 Massachusetts, USA. Department of Pathology, Brigham and
                 Women's Hospital, Boston, Massachusetts, USA. Department of
                 Medical Oncology, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Center for Cancer Genetics and Prevention,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Ethics and Health Policy, University of
                 Pennsylvania Perelman School of Medicine, Philadelphia,
                 Pennsylvania, USA. Center for Cancer Precision Medicine,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Department of Medical Oncology, Dana-Farber Cancer Institute,
                 Boston, Massachusetts, USA. Broad Institute of MIT and
                 Harvard, Cambridge, Massachusetts, USA. Department of Medical
                 Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
                 USA. Department of Medical Oncology, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Center for Cancer
                 Precision Medicine, Dana-Farber Cancer Institute, Boston,
                 Massachusetts, USA. Department of Medical Oncology,
                 Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts,
                 USA. Center for Cancer Precision Medicine, Dana-Farber Cancer
                 Institute, Boston, Massachusetts, USA. Department of Medical
                 Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,
                 USA. Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA.",
  abstract    = "PURPOSE: Implementing cancer precision medicine in the clinic
                 requires assessing the therapeutic relevance of genomic
                 alterations. A main challenge is the systematic interpretation
                 of whole-exome sequencing (WES) data for clinical care.
                 METHODS: One hundred sixty-five adults with metastatic
                 colorectal and lung adenocarcinomas were prospectively
                 enrolled in the CanSeq study. WES was performed on DNA
                 extracted from formalin-fixed paraffin-embedded tumor biopsy
                 samples and matched blood samples. Somatic and germ-line
                 alterations were ranked according to therapeutic or clinical
                 relevance. Results were interpreted using an integrated
                 somatic and germ-line framework and returned in accordance
                 with patient preferences. RESULTS: At the time of this
                 analysis, WES had been performed and results returned to the
                 clinical team for 165 participants. Of 768 curated somatic
                 alterations, only 31\% were associated with clinical evidence
                 and 69\% with preclinical or inferential evidence. Of 806
                 curated germ-line variants, 5\% were clinically relevant and
                 56\% were classified as variants of unknown significance. The
                 variant review and decision-making processes were effective
                 when the process was changed from that of a Molecular Tumor
                 Board to a protocol-based approach. CONCLUSION: The
                 development of novel interpretive and decision-support tools
                 that draw from scientific and clinical evidence will be
                 crucial for the success of cancer precision medicine in WES
                 studies.Genet Med advance online publication 26 January
                 2017Genetics in Medicine (2017); doi:10.1038/gim.2016.191.",
  journal     = "Genet. Med.",
  month       =  "26~" # jan,
  year        =  2017,
  language    = "en"
}

@MISC{Cingolani2012-pt,
  title  = "snpEff: Variant effect prediction",
  author = "Cingolani, Pablo",
  year   =  2012
}

@ARTICLE{Forbes2015-jj,
  title       = "{COSMIC}: exploring the world's knowledge of somatic mutations
                 in human cancer",
  author      = "Forbes, Simon A and Beare, David and Gunasekaran, Prasad and
                 Leung, Kenric and Bindal, Nidhi and Boutselakis, Harry and
                 Ding, Minjie and Bamford, Sally and Cole, Charlotte and Ward,
                 Sari and Kok, Chai Yin and Jia, Mingming and De, Tisham and
                 Teague, Jon W and Stratton, Michael R and McDermott, Ultan and
                 Campbell, Peter J",
  affiliation = "Cancer Genome Project, Wellcome Trust Sanger Institute,
                 Wellcome Trust Genome Campus, Hinxton, Cambridge, UK, CB10
                 1SA. saf@sanger.ac.uk. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA. Cancer Genome Project, Wellcome Trust
                 Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
                 Cambridge, UK, CB10 1SA.",
  abstract    = "COSMIC, the Catalogue Of Somatic Mutations In Cancer
                 (http://cancer.sanger.ac.uk) is the world's largest and most
                 comprehensive resource for exploring the impact of somatic
                 mutations in human cancer. Our latest release (v70; Aug 2014)
                 describes 2 002 811 coding point mutations in over one million
                 tumor samples and across most human genes. To emphasize depth
                 of knowledge on known cancer genes, mutation information is
                 curated manually from the scientific literature, allowing very
                 precise definitions of disease types and patient details.
                 Combination of almost 20,000 published studies gives
                 substantial resolution of how mutations and phenotypes relate
                 in human cancer, providing insights into the stratification of
                 mutations and biomarkers across cancer patient populations.
                 Conversely, our curation of cancer genomes (over 12,000)
                 emphasizes knowledge breadth, driving discovery of
                 unrecognized cancer-driving hotspots and molecular targets.
                 Our high-resolution curation approach is globally unique,
                 giving substantial insight into molecular biomarkers in human
                 oncology. In addition, COSMIC also details more than six
                 million noncoding mutations, 10,534 gene fusions, 61,299
                 genome rearrangements, 695,504 abnormal copy number segments
                 and 60,119,787 abnormal expression variants. All these types
                 of somatic mutation are annotated to both the human genome and
                 each affected coding gene, then correlated across disease and
                 mutation types.",
  journal     = "Nucleic Acids Res.",
  volume      =  43,
  number      = "Database issue",
  pages       = "D805--11",
  month       =  jan,
  year        =  2015,
  language    = "en"
}

@ARTICLE{Yen2017-lq,
  title       = "A variant by any name: quantifying annotation discordance
                 across tools and clinical databases",
  author      = "Yen, Jennifer L and Garcia, Sarah and Montana, Aldrin and
                 Harris, Jason and Chervitz, Stephen and Morra, Massimo and
                 West, John and Chen, Richard and Church, Deanna M",
  affiliation = "Personalis, 1330 O'Brien Drive, Menlo, Park, CA, 94025, USA.
                 jennifer.yen@personalis.com. Personalis, 1330 O'Brien Drive,
                 Menlo, Park, CA, 94025, USA. 10X Genomics, 7068 Koll Center
                 Pkwy \#401, Pleasanton, CA, 94566, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. Personalis, 1330
                 O'Brien Drive, Menlo, Park, CA, 94025, USA. 10X Genomics, 7068
                 Koll Center Pkwy \#401, Pleasanton, CA, 94566, USA.",
  abstract    = "BACKGROUND: Clinical genomic testing is dependent on the
                 robust identification and reporting of variant-level
                 information in relation to disease. With the shift to
                 high-throughput sequencing, a major challenge for clinical
                 diagnostics is the cross-identification of variants called on
                 their genomic position to resources that rely on transcript-
                 or protein-based descriptions. METHODS: We evaluated the
                 accuracy of three tools (SnpEff, Variant Effect Predictor, and
                 Variation Reporter) that generate transcript and protein-based
                 variant nomenclature from genomic coordinates according to
                 guidelines by the Human Genome Variation Society (HGVS). Our
                 evaluation was based on transcript-controlled comparisons to a
                 manually curated set of 126 test variants of various types
                 drawn from data sources, each with HGVS-compliant transcript
                 and protein descriptors. We further evaluated the concordance
                 between annotations generated by Snpeff and Variant Effect
                 Predictor and those in major germline and cancer databases:
                 ClinVar and COSMIC, respectively. RESULTS: We find that there
                 is substantial discordance between the annotation tools and
                 databases in the description of insertions and/or deletions.
                 Using our ground truth set of variants, constructed
                 specifically to identify challenging events, accuracy was
                 between 80 and 90\% for coding and 50 and 70\% for protein
                 changes for 114 to 126 variants. Exact concordance for SNV
                 syntax was over 99.5\% between ClinVar and Variant Effect
                 Predictor and SnpEff, but less than 90\% for non-SNV variants.
                 For COSMIC, exact concordance for coding and protein SNVs was
                 between 65 and 88\% and less than 15\% for insertions. Across
                 the tools and datasets, there was a wide range of different
                 but equivalent expressions describing protein variants.
                 CONCLUSIONS: Our results reveal significant inconsistency in
                 variant representation across tools and databases. While some
                 of these syntax differences may be clear to a clinician, they
                 can confound variant matching, an important step in variant
                 classification. These results highlight the urgent need for
                 the adoption and adherence to uniform standards in variant
                 annotation, with consistent reporting on the genomic
                 reference, to enable accurate and efficient data-driven
                 clinical care.",
  journal     = "Genome Med.",
  volume      =  9,
  number      =  1,
  pages       = "7",
  month       =  "26~" # jan,
  year        =  2017,
  keywords    = "Annotation; Clinical testing; Genomics; HGVS; Precision
                 medicine; Sequencing; Syntax; Variant",
  language    = "en"
}

@ARTICLE{Prawira2017-gv,
  title       = "Data resources for the identification and interpretation of
                 actionable mutations by clinicians",
  author      = "Prawira, A and Pugh, T J and Stockley, T L and Siu, L L",
  affiliation = "Division of Medical Oncology and Hematology. Cancer Genomics
                 Program, Princess Margaret Cancer Centre, University Health
                 Network, Toronto. Cancer Genomics Program, Princess Margaret
                 Cancer Centre, University Health Network, Toronto. Department
                 of Medical Biophysics, University of Toronto, Toronto. Cancer
                 Genomics Program, Princess Margaret Cancer Centre, University
                 Health Network, Toronto. Laboratory Medicine Program,
                 University Health Network, Toronto. Department of Laboratory
                 Medicine and Pathobiology, University of Toronto, Toronto,
                 Canada. Division of Medical Oncology and Hematology. Cancer
                 Genomics Program, Princess Margaret Cancer Centre, University
                 Health Network, Toronto.",
  abstract    = "Following initial characterization of the reference human
                 genome, initiatives have evolved worldwide to identify genomic
                 aberrations in cancer with the aim of deriving diagnostic,
                 prognostic and predictive information. However, the functional
                 and clinical relevance of many somatic variants in cancer are
                 presently unknown and there is no consensus definition of
                 'actionability' for genomic aberrancies. Therefore, while
                 robust detection of a variety of genetic aberrations in
                 clinical specimens remains a technical hurdle, the greater
                 challenge lies in the interpretation of these alterations.
                 Critical evaluation of genomic variation in cancer requires
                 the integration of available clinical and preclinical evidence
                 related to their frequencies, functions and roles as
                 therapeutic targets. Many publicly accessible data resources
                 have compiled such evidence to facilitate the understanding of
                 genomic results and ultimately translating results to clinical
                 action. Information for these data resources is derived from
                 various sources including large population genomic datasets,
                 curation of published literature, and data sharing by the
                 scientific community. Currently, there is no widely accepted
                 guidance to definitively assess and integrate the diagnostic,
                 prognostic and predictive information of somatic variants
                 using these knowledge databases. This review will describe
                 data resources pertinent to the identification and
                 interpretation of actionable genomic aberrations by
                 clinicians, and highlight relevant issues in the clinical
                 application of tumor molecular profiling results.",
  journal     = "Ann. Oncol.",
  volume      =  28,
  number      =  5,
  pages       = "946--957",
  month       =  "1~" # may,
  year        =  2017,
  keywords    = "actionable mutations; data resources; next-generation
                 sequencing; somatic variants",
  language    = "en"
}

@ARTICLE{Downing2012-do,
  title       = "The Pediatric Cancer Genome Project",
  author      = "Downing, James R and Wilson, Richard K and Zhang, Jinghui and
                 Mardis, Elaine R and Pui, Ching-Hon and Ding, Li and Ley,
                 Timothy J and Evans, William E",
  affiliation = "St. Jude Children's Research Hospital-Washington University
                 Pediatric Cancer Genome Project, Memphis, Tennessee, USA.
                 james.downing@stjude.org",
  journal     = "Nat. Genet.",
  volume      =  44,
  number      =  6,
  pages       = "619--622",
  month       =  "29~" # may,
  year        =  2012,
  language    = "en"
}

@MISC{Fda2016-kx,
  title  = "Draft Guidance for Stakeholders and Food and Drug Administration
            Staff",
  author = "{FDA}",
  month  =  "8~" # jul,
  year   =  2016
}
